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ABSTRACT
Allergic airways disease is mediated by a variety of cells, inflammatory mediators and 
cytokines, particularly TH2 cells, and their secreted cytokines, IL-4 and IL-5, and 
eosinophils. Active intervention to down regulate the activity of these cells and molecules 
may represent an effective treatment. The work described in this thesis was performed in 
order to study the inhibitory activity of IL-12 in suppressing allergic airways disease and 
to examine the potential of vector-mediated delivery of this factor as a basis for novel 
vaccination and therapeutic strategies. The role of inducible nitric oxide in regulating 
allergic airways disease was also studied using mice deficient for the production of nitric 
oxide synthase.
Initially, a murine model of allergic airways disease was established in which TH2-driven 
pulmonary eosinophilic inflammation was known to be a critical mediator of the disease 
state, symptoms of which include airways inflammation, airways hyperreactivity and 
lung damage. The local administration of DN A vaccines or fowlpoxvirus (FPV) vectors 
encoding IL-12 to sensitized C57BL/6 mice immediately prior to their exposure to 
allergen was shown to protect these animals from each of the above mentioned 
manifestations of disease. IL-12 gene transfer via these vectors also mediated longer- 
term protective effects, for at least four weeks after inoculation, and in both cases the 
suppression of disease correlated with increased local T cell production of IFNy with 
concomitant inhibition of IL-5 secretion.
A DNA vaccine encoding IL-12 together with the allergen, ovalbumin, was also 
examined as a neonatal vaccination strategy against allergic airways disease. It was 
initially found that the vaccine was highly immunogenic for humoral and cell-mediated 
responses in both C57BL/6 and BALB/c neonates. It was also shown that both strains 
were fully protected against the development of eosinophilic inflammation and lung
iv
damage following sensitization and allergen challenge in adult life if they had been given 
systemic inocula of the OVA/IL-12 DNA vaccine as neonates.
Suppression of allergic disease in mice given vector-encoded IL-12 correlated with 
reduced levels of IL-5 secretion and increased IFNy production. Whether this change in 
cytokine profile fully accounts for the protective efficacy of these constructs remains to be 
determined. However, the possibility that IL-12 may down regulate allergic responses 
via suppression of inflammatory cell hematopoiesis was studied using bone marrow 
progenitor cells in colony formation assays. Initially, it was shown that IL-12 selectively 
inhibited eosinophil hematopoiesis when administered either in vitro or in vivo using 
cells from mice which had not been treated with allergen. Eosinophilopoiesis was also 
inhibited in bone marrow progenitors from allergen-treated mice which had been 
protected from the development of disease by vector-encoded IL-12. The use of cells 
from mice deficient for IFNy activity (IFNyR-/- mice) in each of these experiments 
demonstrated that IL-12 could suppress eosinophil development independently of this 
factor.
Nitric oxide (NO) is a molecule thought to be involved in the pathogenesis of allergic 
disease. Mice rendered deficient for NOS2 activity, the enzyme which catalyses 
inducible NO production, exhibited markedly less severe allergic airways disease 
compared to wild-type animals, correlating with pronounced increases in the capacity of 
their cultured T cells to secrete IFNy upon restimulation in vitro. The high levels of IFNy 
found in allergen-treated NOS2 mutant mice were apparently responsible for the 
suppression of eosinophilia and lung damage associated with allergic airways disease, as 
in vivo depletion of this factor restored allergic pathology in these animals.
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Chapter 1
General Introduction and Review of Literature
1.1 Introduction
The immune system consists of a variety of different cell types and soluble factors 
which mediate both innate and adaptive responses against a great range of 
environmental antigens, both infectious and inert. This system has evolved to protect 
the host against invasion by a multitude of infectious organisms or against 
physiological aberrations, such as tumors, but occasionally, and particularly in pre­
disposed individuals, it over reacts to otherwise innocuous environmental antigens 
giving rise to chronic inflammatory conditions, such as allergic asthma.
This literature review will cover the regulation of adaptive immune responses, 
particularly the roles of antigen-presenting cells, T cells, B cells and their secreted 
factors, or cytokines. Characteristics of the mucosal immune system, especially in the 
lung, and the neonatal immune system, will also be discussed. Finally the regulation 
of allergic airways disease, and the development of prophylactic and therapeutic 
strategies will be reviewed.
1.2 The mammalian immune system
The mammalian immune system is a highly complex physiological system which has 
evolved to combat a great variety of antigens present in the environment. It comprises 
a variety of cells and soluble mediators and can mount both innate and adaptive 
responses. Innate immunity is predominant in the earliest stages of responsiveness and 
is mediated largely by phagocytic cells and natural killer cells. The recognition system 
in innate immunity is non-specific (Brown et al., 1994), however, the adaptive immune 
response, which is elicited later, is characterised by specificity and memory and is 
usually mediated through the induction of humoral and cell-mediated immunity.
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Innate immunity is the ability of a host to immediately identify and limit potentially 
noxious antigens. A number of non-specific anti-microbial mechanisms function 
during the first encounter with foreign antigens. The first lines of defence are the skin 
and mucosal epithelia. Intact skin is impermeable to most infectious agents and many 
micro-organisms cannot survive in the low pH environment created by skin secretions 
(Janeway, 1989). Mucus secreted at the mucosal membranes which cover the internal 
surfaces of the body represents a further protective barrier. Phagocytosis of antigen by 
macrophages and neutrophils is another innate antimicrobial mechanism, by which 
large particles, including infectious agents, senescent cells and cellular debris which 
have penetrated epithelia, may be cleared (Rabinovitch, 1995). Macrophages recognize 
the diverse array of antigens which they constantly encounter via the interaction of 
specific receptors on their surface with ligands on the invading particles (Allen and 
Aderem, 1996). Certain receptors, such as the macrophage scavenger receptor 
(Pearson, 1996), CD 14, integrins and the mannose receptor (Epstein et al, 1996), may 
either recognize particular patterns on the surfaces of microbes or may recognize 
antigens directly. Macrophages also have receptors for lipopolysaccharide (LPS), the 
binding of which signals the presence of foreign antigens and stimulates the synthesis 
of cytokines, such as interleukin-1 (IL-1), IL-6, IL-12 and tumor necrosis factor 
(TNF), and other mediators, which may induce acute phase responses, enhance 
microbicidal activity and promote the development of helper T cells (Ulevitch and 
Tobias, 1995). Many natural killer cells also have lectin-like membrane receptors 
which are involved in the recognition of target cells destined for cytolysis (Yokoyama 
and Seaman, 1993). The major soluble protein effector system of innate immunity is 
the complement system, which is activated by the binding of collectin to certain 
carbohydrates and functions by attracting phagocytic cells to microbes (Fearon and 
Locksley et al,  1996). Complement also mediates acute inflammatory reactions 
characterized by capillary dilatation, exudation of plasma proteins and accumulation of 
neutrophils (Fearon and Locksley et al, 1996). In addition to these functions, the
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innate immune system may play a role in guiding the selection of antigen by B and T 
cells, and in the secretion, by T helper cells, of cytokines which promote appropriate 
immune responses to different antigens (Fearon and Locksley et ai, 1996). The 
mammalian innate immune system, therefore, appears not only to be an evolutionarily 
ancient anti-microbial system, but one that may also influence the expression of 
adaptive immune responses.
1.3 The adaptive immune response
Innate immune responses alone are not sufficient to defend the body against the wide 
range of micro-organisms which may be encountered. Specific immune defences are 
needed and are known collectively as adaptive or acquired immunity. Lymphocytes 
play a central role in all adaptive immune responses. B lymphocytes respond to 
extracellular invaders through their production of antibodies. T lymphocytes either 
provide help for B cells (helper T cells), mediate delayed-type hypersensitivity (DTH) 
reactions, or recognise and kill intracellular pathogens (cytotoxic T cells). T helper 
(TH) cells recognize peptide fragments of antigens, generated by antigen processing, in 
association with major histocompatibility complex (MHC) class II molecules, whereas 
cytotoxic T cells recognize antigenic peptides in association with MHC class I 
molecules on the cell surface (reviewed in Germain, 1994). Antigen recognition by T 
cells is mediated through the T cell receptor (TCR), a single receptor which recognizes 
the complex of peptide and MHC molecule. In addition to these interactions between 
the TCR and peptide-MHC complex, costimulatory signals are needed for T cell 
activation and these are usually provided by accessory molecules and soluble factors 
such as cytokines (Kuchroo et al., 1995) as discussed below.
Although the immune system is generally remarkably effective against foreign 
invaders, it may also give rise to undesirable consequences which sometimes result in
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disease. Reactivity following recognition of self antigens causes autoimmunity, 
whereas an ineffective immune response may result in immunodeficiency. In contrast, 
an overactive immune response to otherwise innocuous antigens may give rise to 
hypersensitivity reactions which underlie conditions such as allergic airways disease.
1.4 Major cell types of the adaptive immune response
1.4.1 B lymphocytes
B lymphocytes are derived from the bone marrow in mammals and are characterized by 
surface immunoglobulins (Ig) which act as specific antigen receptors. There are five 
classes of Ig molecules in most mammals, namely IgM, IgD, IgG, IgE and IgA. These 
glycoproteins are carried on the B cell as surface molecules or are secreted and circulate 
in the blood and lymph as antibodies.
The activation of naive B cells require two signals: (i) antigen signalling directly 
through Ig (reviewed by Reth, 1992), and (ii) costimulation by CD4+ TH cells 
(Parker, 1993). Surface Ig molecules mediate the internalization of antigen which is 
subsequently degraded and presented in association with class II MHC molecules on 
the B cell surface (Lanzavecchia, 1990; Hodgkin and Basten, 1995). During T-B 
lymphocyte interaction, the TH cells recognise antigenic peptide-class II MHC 
molecules on B lymphocytes and, through their production of a variety of cytokines, 
induce these cells to proliferation, differentiation and antibody secretion. IL-4 and IL-5 
appear to be the major factors provided by CD4+ T cells to enhance the growth and 
differentiation of activated B cells (Coffman et al., 1988), whilst these and other 
cytokines which they secrete have profound effects on the isotype of antibody which is 
ultimately produced (detailed in Section 1.5.1). The T-B lymphocyte interaction also 
involves binding between co-stimulatory receptors, particularly CD40 (Armitage et al.,
4
1992a; Noelle et ai ,  1992) on B lymphocytes and CD40 ligand (CD40L) on T 
lymphocytes (Cronin et al , 1995). These interactions activate B lymphocytes to 
respond to cytokines secreted by the T cells. CD8+ T lymphocytes have also been 
shown to provide "help" for antibody secretion by B lymphocytes (Paganelli et al., 
1995). The role of B cells in allergic immune responses is discussed in more detail in 
Section 1.8.2.1.
1.4.2 T lymphocytes - antigen presentation and activation
T lymphocytes are derived from bone marrow stem cells and develop in the thymus, 
with T cell antigen receptors (TCR) as lineage markers. These receptors are similar in 
structure to the Fab portion of the antibody molecule and recognize specific antigens 
(reviewed in Whitton, 1998). T cells are divided into two subclasses, aß T cells and yb 
T cells, based on the nature of their TCR. The aß T cells are subdivided further into 
two non-overlaping populations, CD4+ and CD8+ T cells, which differ in their 
functions and in the nature of the antigens which they recognize (Littman, 1987).
T cells recognize antigen in association with MHC molecules, of which the most 
important, MHC class I and class II molecules, differ in several respects including 
structure, composition and the nature of the antigenic peptides which they bind 
(Cresswell, 1994). Class I MHC molecules are found on all nucleated cells, whereas 
only certain cell types express class II molecules, including macrophages, dendritic 
cells and B lymphocytes (Harding et al., 1991). The recent elucidation of the three 
dimensional structures of MHC class I (Zhang et al,  1992) and class II molecules 
(Brown et al,  1993) has led to further insights into the mechanisms of antigen­
processing and presentation. The general structure of MHC-peptide complexes are 
similar for both class I and class II insofar as both molecules contain a groove in which 
a peptide is bound and thereby "presented" to T cells (Brown et al., 1993). When
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different classes of T cells distinguish between a class I complex (generally CD8+ T 
cells) or a class II complex (generally CD4+ T cells), they are discriminating between 
intracellular (endogenous) and soluble (extracellular) antigens. Endogenous antigens, 
such as viral proteins, are broken down by a cytosolic organelle, the proteasome, and 
the peptides thereby derived, typically but not exclusively of nine amino acids, are 
transported to the endoplasmic reticulum (ER) by the transporter associated with 
antigen processing (TAP) (reviewed in Heemels and Ploegh, 1995; York and Rock, 
1996; Whitton, 1998). In the ER, peptides bind newly synthesized dimers of MHC 
class I heavy chain and ß2-microglobulin, to form a peptide-MHC complex which is 
transported to the cell surface for presentation to CD8+ cytotoxic T cells. For MHC 
class II antigen presentation, exogenous protein taken up by cells via endocytosis or 
phagocytosis is degraded into peptides by lysosomal proteases. These peptides bind to 
class II molecules to form a class II peptide-MHC complex which appears on the cell 
surface for presentation to T helper cells (reviewed in Cresswell, 1994; Neefjes and 
Momburg, 1993; Nordeng et al., 1998). There are exceptions to the "class 
I/endogenous, class II/exogenous" rule; it appears that some specialized cells (perhaps 
macrophages) can take up exogenous proteins and introduce them into the class I 
antigen processing pathway (Rock, 1996)
The binding of the TCR to the peptide-MHC complex delivers the first activating signal 
to naive T cells by TCR dimerization and consequent signal transduction into the 
nucleus via a phosphokinase cascade (Daser et al., 1995). Both ligand density and 
binding affinity between the peptide-MHC complex and the TCR can affect the type of 
response which is induced. Indeed, changes in ligand structure may result in 
quantitative variations in ligand density which lead to further qualitative differences in T 
cell responses (Racioppi et al., 1993).
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Interaction between the TCR and processed antigen is crucial but not sufficient for the 
production of an immune response. A second costimulatory signal between APC and 
T cells is also needed for T cell activation (Bretscher and Cohn, 1970; Lafferty et al., 
1975). Costimulatory factors include accessory molecules, such as B7.1, B7.2, 
CD30L, and soluble factors, such as cytokines (reviewed by Croft, 1994). These 
molecules appear to induce different types of T cell responses, as discussed below, 
however, the absence of costimulatory signals may result in the induction of T cell 
tolerance (Seder and Paul, 1994).
1.4.2.1 CD4+ T lymphocytes
CD4+ T cells normally "help" or "induce" immune responses and are thus called T 
helper cells. These cells may provide help for both humoral and cell-mediated immune 
responses and are essential for the switch from IgM production. Indeed, their 
depletion, using anti-L3T4 antibodies, greatly suppresses IgG production in the case of 
virus infection (Leist, et al , 1987). The effects of CD4+ T cells on antibody 
production are mediated largely via their expression of surface molecules, such as 
CD40L (Cronin et a l , 1995), and by their production of cytokines, such as IL-4, IL-5, 
IL-6, IL-10 and IFNy. These factors induce the switching of B cells from IgM 
production to the production of other subclasses (Armitage et a l , 1992). For example, 
IFNy favours, but is not essential for, the production of IgG2a antibodies, whilst IL-4 
induces IgGl and IgE production (Snapper and Paul, 1987). CD4+ T cells are also 
thought to provide "help" for CD8+ T cell activation through their production of IL-2 
(Glasebrook and Fitch, 1979), although it has been shown that they are not essential 
for CD8+ T cell activity (Buller et al., 1987).
TH cells have been divided into at least three subclasses, THO, TH1 and TH2 cells, 
based on the profile of cytokines which they secrete, as discussed in Section 1.4.3.
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The balance between TH1 and TH2 subsets is thought to be crucial in determining the 
outcome of immune responses, including autoimmune responses, allergic responses 
and those mounted against infectious antigens (Romagnani, 1994; Abbas et al., 1996).
1.4.2.2 CD8+ T lymphocytes
CD8+ T cells are usually regarded as cytotoxic effector cells, restricted by MHC class I 
antigen presentation, and are thus also termed cytotoxic T lymphocytes (CTL). 
Recovery from most virus infections is critically dependent on CTL. Several 
mechanisms appear to underlie their antiviral activity. Firstly, cytotoxicity may be 
mediated by exocytosis of toxic substances by these killer cells. Perforin appears to be 
the major cytolytic molecule in this respect (reviewed in Liu et al., 1995) and is 
produced by cytolytic lymphocytes and natural killer (NK) cells (Lowrey et al., 1989), 
Perforin is activated in response to elevated Ca 2+ levels and may insert into the target 
cell plasma membrane and cause lysis (Liu et a l, 1995). Alternatively, contact- 
mediated transmembrane signaling involving the surface molecule Fas/Apo-1 on targets 
and its ligand on CTL can mediate target cell lysis (reviewed in Squier and Cohen, 
1994). It has also recently been proposed that the production of cytokines such as 
IFNy and TNFa is an important antiviral effector function of CD8+ CTL (Ramshaw et 
al., 1991; Ramsay et al., 1993). Indeed, IFNy is regarded as a major antiviral cytokine 
(Ramsay et al., 1993).
Recent studies suggest that CD8+ T cells may also play a role in regulating immune 
responses through their production of both type 1 (Fong and Mosmann, 1990) and 
type 2 cytokines (Croft et al., 1994; Sad et al., 1995). As with CD4+ T cell regulation, 
CD8+ T cell subset development also appears to be tightly regulated by cytokines. 
Development in the presence of IL-4 may promote type 2 CD8+ cell development, 
whilst IFNy and IL-12 favour type 1 CD8+ T cells (Sad et al., 1995; Noble et al.,
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1995; Seder and Le Gros, 1995). CD8+ T cells activated in the presence of IL-4 have 
been designated TC2 cells, whilst those activated in its absence, and which develop 
into classical cytolytic CTL, have been designated TCI cells (Sad and Mosmann, 
1995). Some authors have reported that TCI and TC2 cells retain cytotoxicity when 
stimulated in vitro (Sad et a l, 1995; Croft et a l, 1994), the cytotoxic mechanism of 
TC2 cells appearing to be restricted to the perforin pathway, whereas TCI cells can act 
through both perforin- and Fas-mediated cytotoxicity (Carter and Dutton, 1995). Other 
studies have indicated that CD8+ T cells activated in the presence of EL-4 may lose their 
cytotoxic capacity (Erard et al, 1993). In addition, TC2-type cells may have the ability 
to suppress proliferation of TH1 cells (Salgame et al., 1991), raising the possibility of 
a role for CD8+ T cells in the development of TH2 cell-mediated allergic responses. 
This is discussed in detail in Section 1.8.1.1.
1.4.3 The TH1/TH2 concept
In the 1970's, Parish and Liew observed that cell-mediated and humoral immunity may 
alternate in reciprocal dominance over each other (Parish and Liew, 1972). This led 
them to suggest that antigen-mediated cell-cell interactions between B cells and T cells 
may result in the induction of antibodies with the suppression of cell-mediated 
immunity. It was further postulated, by Bretscher (1970), that different cell types 
might regulate humoral and cell-mediated immune responses. A decade later, 
Mosmann and Coffman (1989) identified two types of TH cells in long-term clones of 
murine CD4+ T cells, defined by the different patterns of cytokines which they 
secreted, the so-called TH1 and TH2 T cells, which appeared to provide a rational basis 
for the earlier observations. TH1 and TH2 cells appear to provide "help" for the 
different arms of the immune response and to have counter-regulatory effects on each 
others activity (Mosmann and Coffman, 1989). Thereafter, in vivo correlates for the 
activity of TH1 and TH2 helper cells were soon found, eg. in mouse models of
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Leishmaniasis (Scott et a l , 1988; Heinzei et al., 1989), in human leprosy (Salgame et 
al., 1991) and in atopic allergic disease (Romagnani, 1991). However, more recent 
evidence suggests that simple classification of TH cells into TH1/TH2 may be an over­
simplification. In vitro-primed short-term cultured cells from mice were shown to 
display neither TH1 nor TH2 profiles (Kelso and Gough, 1988; Firestein et al., 1989), 
whilst T cell clones were found to display a random distribution of TH1- and TH2-type 
cytokine production (Kelso, 1995). Moreover, T cells were isolated which expressed 
both TH1 and TH2 cytokines (Firestein et al., 1989) and these have been termed THO 
cells (Mosmann and Coffman, 1989).
Both TH1 and TH2 cells may derive from a common IL-2-secreting precursor cell. 
Upon initial antigen stimulation, naive CD4+ T cells produce IL-2 and may 
subsequently differentiate into populations that secrete either TH1 or TH2 cytokines 
(Mosmann and Coffman, 1989). This phenomenon was also observed in studies using 
a single precursor T cell population from naive TCR transgenic mice, which produced 
either THl-type or TH2-type cells under appropriate stimulation (Constant and 
Bottomly, 1997).
Factors which influence the development of TH1 or TH2 cells include 
microenvironmental signals and the genetic background of the individual (Seder and 
Paul, 1994). Microenvironmental factors, including antigen presentation, the nature of 
any adjuvant, antigen dose, peptide density, hormones, antigen-presenting cells, 
costimulatory molecules, the physical form of the immunogen and cytokines, may each 
be important determinants of the development of TH1 or TH2 cells (Romagnani, 
1994). Among these factors, cytokines are the most clearly defined TH cell 
differentiation factors, for example, IFNy, TGF-ß and IL-12 favor the induction of 
TH1 cell development, whilst IL-4 stimulates TH2 cell differentiation (this will be 
discussed in more detail in Section 1.5.1). IL-6 derived from APCs has also been
shown to polarize the development of naive TH cells to TH2 cells, by inducing the 
production of IL-4 (Rincon et al., 1997). Prostaglandin E2 may also promote TH2 cell 
development by suppressing IL-12 and IFNy production (Hilkens et al., 1996).
Recent studies have demonstrated that cytokines may also possess the capacity to 
reverse the polarity of an ongoing response. Indeed, IL-4 may switch the polarity of 
TH cell populations obtained from mice infected with L.major from TH1 towards TH2 
(Mocci and Coffman, 1995). IL-12 has also been shown, in mice, to switch an 
ongoing TH2 response against L. major towards a "healing" TH1 response (Nabors et 
al., 1995), and may also reverse TH2-driven allergic responses to TH1 -dominant 
responses and abolish disease (Gavett et al., 1995; Kips et al., 1996; Hogan et al., 
1998). Whether these data actually represent a switch in the polarity of an ongoing 
response or rather the development of new TH cell populations of a different phenotype 
from those driving the original response, remains to be clarified. However, cultured 
TH2 cells appear to be resistant to changes in polarity in the presence of IL-12 (Szabo 
et al., 1995). This may be explained by the observation that TH2 cells functionally 
extinguish the IL-12 receptor signalling pathway within 3 days of primary activation 
(Szabo et al., 1995). Indeed, the polarity of TH1 and TH2 cells does not appear to be 
reversible following long-term stimulation in vitro (Murphy et al., 1997).
Other factors may also contribute to the regulation of TH1/TH2 development. 
Adjuvants such as complete Freund's adjuvant (CFA) induce TH1 cell development, 
whereas alum preferentially induces TH2 cell responses (Romagnani, 1997). In 
addition, the MHC binding affinity of antigenic determinants may be crucial for the 
development of TH cells, with high affinity MHC class II ligand binding apparently 
promoting TH1 cell proliferation, whilst lower affinity ligand binding appears to 
promote TH2 cell development (Kumar et al., 1995). Moreover, APC vary in their 
ability to induce TH1 versus TH2 responses; there is some evidence that macrophages
tend to induce the former, whereas B cells preferentially induce the latter (Schmitz et 
al., 1993; Gajewski et al., 1991).
Until recently, the only means of discriminating between TH1 and TH2 cells was 
through analyses of cytokine secretion. However, cell surface markers have also 
recently been shown to be characteristic of TH1 or TH2 populations (Szabo et al., 
1997). Indeed, it appears that the ß2 chain of the IL-12 receptor is expressed only on 
TH1 cells (i.e. not on TH2 cells) following their stimulation. This finding provides a 
possible explanation for the observation that IL-12 selectively promotes TH1 cell 
development, because the ß2 chain is the signal-transducing component of IL-12 
(Presky et al., 1996) and induces phosphorylation of the signal transducers and 
activators of transcription (STAT) 4 in TH1 cells but not in TH2 cells (Szabo et al., 
1995). Another cell surface marker which may distinguish TH1 from TH2 cells was 
recently found by Xu et al. (1998). This membrane-bound molecule, originally 
designated ST2L (Tominaga, 1989), appears to be expressed constitutively and stably 
on murine TH2 cells, but not on TH1 cells, after exposure to a variety of 
immunological stimuli. Such findings may be of great significance for the development 
of clinical therapies for conditions such as autoimmune disease and allergy.
The balance between TH1 and TH2 cell development appears to be a major determinant 
of whether an immune response is "physiological" or "pathological". For example, 
allergic responses are regarded as TH2-dominant responses (Wierenga, et a l , 1990). 
In an atopic disease state, allergen-specific TH2-like cells preferentially proliferate and 
accumulate in target organs and local activation and recruitment of allergen-specific 
TH2 cells follows (Romagnani, 1995) with the resultant secretion of TH2 type 
cytokines, such as IL-4 and IL-5 (Romagnani, 1997). The initiation of allergic 
immune responses will be discussed in more detail in Section 1.8.
1.5 Immunoregulatory molecules
1.5.1 Cytokines
Cytokines are glycoproteins of low molecular weight and most are pleiotropic, having 
multiple biological activities (Arai, 1986). They form an immuno-regulatory network 
with lymphoid cells, endothelial cells and hematopoietic cells, and also act as important 
immune effector molecules. Based on their functions, cytokines have been divided into 
two groups. Factors such as IL-2, TGFß, IFNy and IL-12, associated with TH1 type 
responses and CMI, are designated "type 1" cytokines, whilst cytokines such as IL-4, 
IL-5, IL-6, IL-10 and IL-13, associated with TH2 responses, are designated "type 2" 
cytokines.
1.5.1.1 Some important type 1 cytokines 
(a) Interleukin-12 (IL-12)
IL-12 is a heterodimeric cytokine first discovered and purified from supernatants 
overlying Epstein-Barr virus (EBV)-transformed human lymphoblastoid B cell lines 
(Kobayashi et al. 1989). The heterodimer of 70 kDa (p70) consists of two covalently- 
linked chains, the heavy chain termed p40 and the light chain, p35 (Kobayashi et al. 
1989). Transfection of COS cells or CHO cells with either p40 or p35 cDNA induced 
secretion of the respective IL-12 chains, but co-transfection of both p40 and p35 in the 
same cell was needed in order to induce the biologically active forms of IL-12, the p70 
heterodimer (Wolf et al., 1991). Transcripts of the p35 gene, but not the protein, are 
constitutively expressed at low levels in many cell types (D'Andrea et al., 1992; Wolf 
et al., 1992). Normally, very low concentrations of p35 are produced by transfected 
cells and the p35 chain can be efficiently secreted only when associated with p40 chain
to form a p70 heterodimer (Trinchieri, 1995). Expression of the p40 gene is apparently 
restricted to cells which can produce biologically active IL-12 (D'Andrea et a l 1992; 
Wolf et al., 1992). The p40 subunit of IL-12 has been shown to specifically 
antagonize the effect of the IL-12 heterodimer as an endogenous inhibitor (Trinchieri, 
1995). Human IL-12 is not active in murine lymphocytes, however murine IL-12 is 
active on both murine and human cells (Schoenhaut et a l, 1992). Interspecies 
heterodimers are active on both human and murine cells when p35 is of murine origin, 
but active only on human lymphocytes when the p35 is of human origin (Schoenhaut et 
al, 1992).
Cells which produce IL-12 can be divided into two overlapping groups. The first 
comprises those which mediate innate immune responses, such as phagocytic cells and 
mast cells. Human peripheral blood mononuclear cells produce low levels of IL-12 
and this production is enhanced following stimulation by bacteria or their products, 
such as LPS (D'Andrea et al., 1992). Murine mast cells express IL-12 p40 and p35 
mRNA after stimulation with mast-cell growth factor (Smith et al., 1994). The second 
group of cells are B cells and "professional" APC, including monocytes/macrophages 
and dendritic cells. EBV-transformed human B cell lines also constitutively secrete IL- 
12 (D'Andrea et al., 1992; Wolf et al., 1992) although it appears that macrophages are 
the major producers of this factor (Wysocka et al., 1995).
Responses to IL-12 are determined by expression of the IL-12 receptor (IL-12R) and 
/or the nature of the link between the receptor and signal transduction pathways in 
target cells. To date, two subunits of the IL-12R, ßl and ß2, have been identified 
(Chua et al, 1994; Presky et al., 1996). The ß2 subunit is the signalling component of 
the IL-12R and contains tyrosine residues which are phosphorylated upon receptor 
activation (Greenlund et al., 1994). Early studies showed that IL-12 receptors were 
expressed on activated NK cells and T cells (Desai et al., 1992; Chua et al., 1994). It
now appears that IL-12R ßl transcripts are expressed by both TH1 and TH2 cells, 
however the IL-12R ß2 subunit is selectively expressed on TH1 cells (Rogge et al., 
1997). The IL-12 signalling pathway involves the Janus kinases, Tyk2 and Jak2, 
(Bacon et al., 1995a) and STAT 4 (Bacon et al., 1995b). IL-12 induces tyrosine 
phosphorylation of STAT 4 and Jak2 in TH1 cells but not in TH2 cells (Rogge et al., 
1997).
Thus, heterodimeric IL-12 has a unique molecular characterisation among cytokines 
and mediates a wide variety of biological activities. IL-12 acts as a growth factor for, 
and induces production of, IFNy by NK cells and T cells (Gately et al., 1991; Perussia 
et al., 1992), enhances the cytotoxic activity of NK cells (Kobayashi, et al., 1989), and 
favours cytotoxic T cell generation (Gately et al., 1992; Bloom and Horvath, 1994). 
IL-12 also appears to be a key cytokine for TH1 cell activation. TH1 cell development 
is enhanced when naive T cells are activated in the presence of this factor (Hsieh et al., 
1993; Manetti et al., 1993), whilst the use of anti-IL-12 antibodies ablates induction of 
TH1 responses following antigen stimulation (Manetti et al., 1993). In allergic 
models, stimulation of peripheral blood lymphocytes from atopic patients with 
allergen, such as Dermatophagoides pteronyssinus (Der p i ) ,  together with IL-12, 
induces TH1 type cells specific for the allergen, whereas stimulation with allergen 
alone generates specific TH2 cells (Manetti et al., 1993). There is some controversy, 
however, surrounding the mechanism by which IL-12 induces TH1 cell responses. 
Induction has been reported to be both dependent on IFNy production (Macatonia et 
al., 1993) and to occur independently of this factor (Seder et al., 1992). In addition, 
further cells and molecules, such as costimulatory molecules, are required for the full 
expression of IL-12 activity on TH1 cell development (Kubin et al. 1994; Romagnani, 
1994). For example, IL-12 synergizes with the costimulatory molecule B7, which 
interacts with its T cell ligand, CD28, to induce efficient proliferation and IFNy 
production in T cells (Kubin et al., 1994).
IL-12 has also been shown to exert hematopoietic activity. In combination with 
hematopoietic growth factors and cytokines such as steel factor (SF), IL-3, IL-11, 
granulocyte colony-stimulating factor (G-CSF) or CSF-1, IL-12 synergistically 
enhances the proliferation of bone marrow progenitor cells as well as peripheral 
hematopoiesis in vitro (Hirayama et al., 1994; Ploemacher et al., 1993; Fardoun- 
Joalland et al, 1995; Ikebuchi and Clark, 1988; Jackson et al., 1995). However, in 
vivo, IL-12 appears to inhibit, rather than enhance, bone marrow hematopoiesis, most 
likely through the induction of IFNy (Eng et al., 1995; Quesniaux and Ryffel, 1996). 
No detailed studies of the effects of IL-12 on the development of different cell lineages 
have yet been reported.
(b) Interferon-gamma (IFNy)
IFNy is secreted by both CD4+ and CD8+ T cells and NK cells (Mosmann et al., 1986; 
Mosmarm and Coffman, 1989). It was originally described as a factor having antiviral 
activity and differs from other members of the interferon family by its ability to survive 
exposure to extreme temperature and pH. In addition to possessing antiviral activity, 
IFNy, like IL-12, appears to play a key role in TH1 cell development. IFNy was 
reported to promote the development of TH1 cell clones (Gajewski and Fitch, 1988), 
whilst neutralising anti-IFNy antibodies abolished the development of TH 1 responses 
in vivo (Belosevic et al., 1989). However, the direct addition of IFNy had no 
enhancing effect on TH1 cell proliferation (Schmitt et al., 1997). It is now clear that 
IFNy acts as an important co-factor for TH1 cell development in response to IL-12 
(Rogge and Sinigaglia, 1997).
IFNy also has immunoregulatory effects, including up-regulation of MHC class I and 
class II molecule expression and enhancement of expression of cytokine receptors,
including those for IL-1, IL-8, TNFß and IL-12, on target cells (Billiau et al., 1990; 
Szabo et al., 1997) as well as for IFNy itself (Hardy and Sawada, 1989).
IFNy also appears to play an important role in modulating antibody responses. It may 
act to suppress in vitro production of the IgE and IgGl subclasses, but favours the 
production of IgG2a antibodies (Snapper and Paul, 1987). Indeed, mice lacking a 
functional IFNy system developed higher levels of IgE and IgGl antibodies, but lower 
levels of IgG2a following immunization with OVA in alum (Coyle et al., 1996b).
1.5.1.2 Some important type 2 cytokines
(a) lnterleukin-4 (IL-4)
IL-4 was initially described as a growth factor for murine B cells, however subsequent 
studies have shown that its actions are not restricted to these cells, indeed, it appears to 
be a key cytokine initiating TH2 responses. The presence of IL-4 during primary 
stimulation of naive CD4+ T cells with mitogens (Swain et al., 1990; Le Gros et al., 
1990), or specific antigen (Hsieh et al., 1992; Seder et al., 1992) results in the 
development of TH2 cell populations, and this may occur independently of the type of 
APC involved (Hsieh et al., 1992; Seder et al., 1992). In vivo, TH2-type responses 
are abolished in IL-4 gene knockout mice infected with Nippostrongylus brasiliensis 
(Kopf et al., 1993), and the importance of this factor in the induction of TH2 responses 
has also been reported in other infectious disease models (Kopf et al, 1993) and in 
models of allergic disease (Bruselle et al., 1994).
In vitro, the ability of IL-4 to induce TH2 responses has been reported to dominate the 
counter-acting TH1-inducing capacity of IL-12. When naive CD4+ T cells were 
stimulated in the presence of both IL-12 and IL-4 at similar concentrations, the effects
of IL-12 were greatly inhibited by IL-4 (Schmitt et al., 1997). In contrast, when naive 
CD4+ T cells were stimulated in the presence of IL-4, the addition of IL-12 failed to 
inhibit IL-4-induced TH2 development (Schmitt et al., 1994b; Romani et al., 1994; 
Wynn et al., 1995).
The primary source of IL-4 for induction of TH2 responses is uncertain at present. It 
has been suggested that cross-linking of the FceRI receptor enables mast cells and 
basophils to produce IL-4 and that these cells may provide an initial source of this 
factor (Punnonen et al., 1993). In addition, NK1.1+ T cells can produce IL-4 mRNA 
in vivo after activation, suggesting that these cells might also provide an early source of 
IL-4 to prime naive CD4+ T cells to the TH2 phenotype (Punnonen et al., 1993).
Recently, the molecular mechanisms by which IL-4 delivers signals to T cells have 
been clarified. IL-4 appears to act directly on T cells through the activation of ST AT 6 
to induce TH2 phenotype development (Le Gros et al., 1990; Swain, 1991; Hsieh et 
al., 1992; Kaplan et al. 1996; Kopf et al., 1993)
(b) Interleukin-5 (IL-5)
IL-5 is produced by CD4+ T cells (Mosmann and Coffman, 1989), eosinophils and 
mast cells (Desreumaux et al., 1992), and was initially described as B cell growth 
factor II (Takatsu et al., 1980). IL-5 is now known to be the major cytokine 
controlling eosinophil development (Lopez et al., 1986; Yamaguchi et al., 1988a; 
Campbell et al., 1987). Also formerly known as eosinophil differentiation factor 
(Sanderson et al., 1986), IL-5 selectively stimulates the clonal proliferation and 
differentiation of murine and human eosinophil progenitors and also plays a role in 
eosinophil mobilization and Chemotaxis (Schweizer et al., 1994; Broide et al., 1992). 
In vivo, administration of anti-IL-5 antibodies abrogated eosinophilia both in a mouse
allergic model (Kung et a l, 1995) and in a helminth infection model (Limaye et al., 
1990). Furthermore, mice deficient in IL-5 production (IL-5-/-) did not develop blood 
and tissue eosinophilia when infected with the helminth Mesocestoides corti (Kopf et 
al., 1996), whilst IL-5 ß chain receptor-deficient mice did not show eosinophilia in 
response to nematode infection (Nishinakamura et al., 1995). In addition, the 
pronounced eosinophilia normally seen during the development of allergic airways 
disease was abolished in IL-5-/- mice, but was restored following the administration of 
recombinant vaccinia virus vectors encoding this factor (Foster et al., 1996). Together, 
these data demonstrate a central role for IL-5 in eosinophil development. In addition, 
IL-5 has the capacity to enhance IL-4-induced IgE synthesis and CD23 expression on 
B cell cultures at suboptimal IL-4 concentrations (Coffman et al., 1988; Pene, et al., 
1988).
1.5.2 The cytokine network
Cytokines generally perform their functions through networks involving hematopoietic 
cells and immunocompetent cells (Arai, 1986). Multi-potential stem cells in the bone 
marrow give rise to a variety of myeloid cells, T cells and B cells. The maturation of 
committed stem cells is, to a large extent, under the control of cytokines such as IL-3, 
GM-CSF, IL-5, IL-6 and IL-7. Immune responses mediated by mature 
immunocompetent cells are also regulated within a cytokine network. Most cytokines 
perform their functions at a local site as paracrine or autocrine mediators, but also at 
distant sites as endocrine factors (Arai, 1986). The results of these functional linkages 
are the production of a wide variety of biological responses.
1.5.2.1 The cytokine network in immune class regulation
IL-4 and IL-12 were initially shown to be the two major cytokines regulating TH2 and 
TH1 responses, respectively (Swain et a l, 1990; Le Gros et a l, 1990; Hseih et al., 
1993; Manetti et al., 1993). Several studies have since shown that these factors, 
together with other cytokines, form networks which are major determinants of the 
types of immune responses generated against antigens.
IL-12 and IFNy may act in synergy to induce optimal TH1 responses (Schmitt, 1997). 
Indeed, IFNy alone, or IL-12 without IFNy, appears to induce relatively weak TH1 
responses. However, IL-12, in the presence of IFNy, induces strong TH1 responses, 
whereas priming with IL-12 in combination with anti-IFNymAb greatly reduces their 
magnitude (Schmitt, 1997). In IL-12p40 gene knock out (gko) mice, TH1 cell 
development is markedly diminished and the residual TH1 response is dependent on 
IFNy. Thus, at least in terms of TH1 cell development, the activity of IL-12 may be, at 
least partially, mediated by IFNy. IL-12 and IFNy also appear to be involved in a 
feedback mechanism, with IL-12 up-regulating the production of IFNy by T and NK 
cells, whilst IFNy promotes APC to produce IL-12 (Schmitt, 1997).
In contrast to IFNy, TGFß acts as a negative regulator of TH1 cell development. The 
addition of IL-12 to naive CD4+ T cells, together with TGFß, substantially reduced the 
level of TH1 cell development compared to that induced by IL-12 alone (Schmitt, 
1994). These suppressive effects may be mediated either directly, or indirectly, via a 
reduction in endogenous IFNy production (Schmitt, 1994b; Wu et al., 1993). IL-4, 
which promotes TH2 cell development, also affects the capacity of IL-12 to induce 
TH1 cell responses. As mentioned previously, TH1 cell differentiation is inhibited 
when naive CD4+ T cells are stimulated with IL-12 in the presence of comparable 
concentrations of IL-4 (Szabo et al., 1995).
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1.5.2.2 The cytokine network in regulation of hematopoiesis
Regulation of hematopoiesis is normally achieved by two interacting control systems 
which have been extensively reviewed (Metcalf, 1991). Stem cells in the bone marrow 
are usually in the resting G state and may be stimulated into a proliferative state in the 
absence of immunological stimuli, termed "constitutive hematopoiesis" (Metcalf, 
1991). The mechanisms controlling this process remain undefined, although some 
authors have suggested that stromal cell-derived cytokines, such as CSF and GM-CSF, 
may contribute to "constitutive hematopoiesis" (Manos, 1988; Malone et al., 1988). In 
contrast, "inducible hematopoiesis" is associated with host defence and inflammatory 
responses and is apparently mediated by factors produced by T cells and macrophages 
(Arai, 1986; Nakayama et al., 1989). Helper T cells produce IL-3 and GM-CSF to 
stimulate early hematopoietic progenitor cells, whilst macrophages produce IL-6, G- 
CSF and M-CSF, which may directly induce hematopoiesis.
Cytokines not only affect the proliferation, but also the differentiation, of bone marrow 
progenitor cells, for example, IL-5, produced by T cells, is an eosinophil 
differentiation and maturation factor and selectively induces eosinophil hematopoiesis 
as discussed earlier (Yamaguchi et al, 1988a). In addition, IL-4 may synergize with 
EL-6 to induce the differentiation of cells of the erythroid lineage (Rennick et al., 1989), 
whilst IL-6, combined with IL-3, IL-4, GM-CSF, M-CSF or G-CSF, induces 
megakaryocyte progenitor differentiation (Rennick et al., 1989).
In summary, the proliferation and differentiation of hematopoietic cells may be 
triggered and regulated by a variety of growth factors and cytokines in response to a 
wide range of environmental stimuli.
1.5.3 Nitric Oxide
Nitric oxide or NO, a lipid- and water-soluble radical gas, is synthesized from L- 
arginine by the NO synthases (NOS). It possesses diverse biological activities and is 
considered to play an important role in many physiological functions and pathological 
conditions. NO also exerts important immunoregulatory activities (Moncada et al., 
1991; Barnes, 1995). NO is produced by most cell types in the body, either 
constitutively or in response to external stimuli (MacMicking et al., 1997). There are, 
to date, three forms of NOS: neuronal NOS (nNOS) or NOS1; endothelial NOS 
(eNOS) or NOS3; and inducible NOS (iNOS) or NOS2.
NOS1 and NOS3 are constitutive forms of NOS in mammals and are dependent on 
elevated intracellular Ca2+ levels for their activity. NO is generated at low levels by 
these constitutive forms (generally picomolar) and acts as a signalling molecule in a 
number of physiological processes, including neurotransmission and vascular 
relaxation in the cardiovascular system (reviewed in Moncada et al., 1991; Nathan and 
Xie, 1994). In contrast, NOS2, which catalyses the production of much higher, 
usually micromolar, levels of NO, is inducible and is independent of Ca2+ for its 
activities. NOS2 may be induced by bacterial LPS (endotoxin), cytokines and growth 
factors, including IFNy, TNFa and IL-1 (Nathan et al., 1994a; Koide et al., 1993; 
Kunz et al., 1994; Taylor-Robinson et al., 1994). Many cell types can express NOS2, 
including macrophages, endothelial cells, smooth muscle cells, fibroblasts, retinal 
epithelium and possibly T cells (Kilbourn et al., 1990; Barnes, 1995). NOS2 has been 
shown to be the major source of NO during inflammatory responses and is thought to 
be an important mediator in allergic responses (Liew and Barnes, 1995). This will be 
further discussed in Section 1.8.
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1.6 The mucosal immune system
The mucous membranes cover the internal surfaces of the body and serve as a first line 
of defence against foreign invaders. They are associated with a large and specialised 
immune system - the mucosal immune system, which is highly compartmentalised and 
functions somewhat independently of systemic immunity (Mestecky and McGhee, 
1987; Czerkinsky and Holmgren, 1995). The mucosal immune system has several 
features distingushing it from systemic immunity: (i) the major humoral response of the 
mucosal immune system is mediated by secretory immunoglobulin A (slgA), as 
opposed to IgG as in the systemic immune response, and antibody-producing cells 
function in mucosal effector tissues rather than systemic lymphoid tissues, (ii) mucosal 
immune responses are initiated in mucosa-associated lymphoid tissues (MALT), such 
as the Peyer’s patches of the gut and similar tissues in the respiratory tract (the 
bronchus-associated lymphoid tissues or BALT) and, possibly, the uro-genital tract 
(inductive sites) and are expressed at mucosal epithelia (effector sites) (Miller et al., 
1992), (iii) in addition to mucosal immune responses, peripheral tolerance or oral 
tolerance may be easily induced by antigenic stimulation of the mucosal immune system 
(Elson and Zivny, 1996).
The development and regulation of mucosal immune responses have been extensively 
reviewed elsewhere (Mestecky and McGhee, 1987; Brandtzaeg, 1989; Miller et al., 
1992; Czerkinsky and Holmgren, 1995). This discussion will focus briefly on matters 
of relevance to allergic disease, in particular mucosal immunity in the lung and the 
phenomenon of mucosal tolerance.
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The epithelial surfaces of the respiratory tract represent a fragile interface between the 
immune system and the outside environment. The adaptive immune system 
continuously discriminates between innocous antigens, which are ubiquitous in the 
atmosphere, and antigens associated with microbial pathogens. Any breakdown in this 
process can lead to chronic inflammatory disease, such as asthma. A range of airborne 
proteins (environmental allergens) may trigger inappropriate or exaggerated adaptive 
immune responses, such as allergic responses, and these include grasses, pollen and 
house dust mites. T cell immunity against these allergens in atopic asthmatics is 
associated with TH2 cell activation and the secretion of IL-4 and EL-5 (Wierenga et al, 
1990), whereas in normal individuals, these antigens usually give rise to specific TH1 
clones which secrete IL-2 and IFNy. Allergen-specific TH2 cells in atopic individuals 
provide help, initially for IgE production, and, upon subsequent exposure to the 
allergen, drive later stage airways inflammation resulting in the clinical symptoms 
associated with atopy, as described in Section 1.8. Thus, immunological interventions 
which regulate T cell phenotypes, and the intensity and duration of local T cell 
responses may potentially provide efficient control of atopic diseases, including 
asthma.
1.6.2 Mucosal tolerance
In contrast to elicting antibody and CMI responses, mucosal delivery of antigen via the 
oral, respiratory or nasal mucosa may induce a state of immunological 
unresponsiveness which has been termed peripheral tolerance or mucosal tolerance 
(Wells, 1911; Chase, 1946; Elson and Zivny, 1996). This represents an important 
physiological mechanism which is thought to provide protection against the 
development of food and other allergies (Mowat, 1987). Mucosal tolerance also allows 
the mucosal immune system to focus on antigens or pathogens which represent a threat 
to the host and is antigen-specific (Miller and Hanson, 1979), but is not particularly
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long-lasting (Melamed and Friedman, 1993b). Parameters such as the type of antigen, 
antigen dose and frequency of antigen delivery, mucosal route, delivery system and the 
genetic background of the individual may all affect the induction of mucosal tolerance 
(Friedman and Weiner, 1993; Strobel and Ferguson, 1984; Faria, 1993; Miller and 
Cook, 1994).
Mucosal tolerance was initially described following antigen feeding and was termed 
oral tolerance (Wells, 1911; Chase, 1946; Elson and Zivny, 1996). T cells appear to 
be the major targets of oral tolerance with delayed type hypersensitivity responses 
mediated by TH1 cells being the most susceptible to tolerization (Miller and Hanson, 
1979; Burstein et al., 1992), and there is little evidence to suggest that B cells are 
tolerized directly by the oral route (Titus and Chiller, 1981). Mechanisms involved in 
the induction of oral tolerance include clonal deletion (Chen et al., 1995), clonal anergy 
(Melamed and Friedman, 1993a) and immune deviation (Racked al, 1994), the latter 
through the generation of regulatory T cells secreting cytokines such as TGFß, IL-4 
and IL-10 (Weiner et al., 1994). These are not mutually exclusive mechanisms and 
may operate simultaneously. Perhaps the most important factor in determining which 
mechnism of tolerance induction is induced is the dose of antigen. High doses of 
antigen are thought to promote anergy-driven tolerance whereas low doses may favour 
the generation of suppression or immune deviation (Weiner et al., 1994).
The induction of tolerance via the respiratory and nasal mucosa was described 
comparatively recently (Holt et al., 1981; Holt, 1994; McMenamin et al., 1994). Like 
oral tolerance, respiratory tolerance may involve multiple mechanisms. It also appears 
that higher doses of antigen favour T cell anergy, whilst lower dosage favours immune 
deviation (Hoyne et al, 1993; 1996; 1997).
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The induction of mucosal tolerance has been used in attempts to treat autoimmune 
diseases both in animals and humans (Weiner et al., 1994). Some success has been 
reported in animal studies, including models of chronic experimental immune 
encephalomyelitis (EAE, Weiner, 1994), and in humans for the treatment of 
rheumatoid arthritis and multiple sclerosis (Weiner, 1994), although a greater 
understanding of the mechanisms underlying tolerance induction will be required for 
clinical application. In addition, mucosal administration of selected antigens, such as 
allergens, has also been used in attempts to prevent or reduce allergic reactions (as 
discussed in Section 1.8). In this respect, the respiratory route appears to be as 
efficient as the oral route in animal models (Weiner et al., 1994).
1.7 The neonatal immune system
The neonatal immune system is characterized by immunodeficiency, immaturity and the 
presence of maternal antibodies, and, as a result, neonatal tolerance to foreign antigens 
has been relatively easy to induce (Siegrist, 1997). However, recent studies have 
demonstrated that neonates are able to mount both humoral and cellular responses 
under certain conditions.
1.7.1 Neonatal tolerance
The concept of immunological tolerance was first proposed by Burnet and Fenner 
(1949) and soon after that Billingham and colleagues (1956) showed that newborn 
mice injected with allogeneic hematopoietic cells failed to reject the allograft, suggesting 
that these neonates had become "tolerant" to the alloantigen. Subsequently, neonatal B 
cell unresponsiveness (Fernandez and Möller, 1978; Lawton et al., 1972) and T cell 
tolerance (Yong and Atassi, 1983; Gammon et al., 1986; Qin et al., 1989) have been
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reported in several studies, whilst DNA immunization has also been shown to induce 
neonatal tolerance (Mor et a i, 1996; Cao et al., 1997).
A major factor in the development of neonatal tolerance appears to be the predominance 
of immature B cells in the young individuals (Osmond, 1986). Immature B cells lack 
surface (s) IgD which inhibits antigen-triggered signalling pathways (Yellen et al., 
1991). In addition, immature B and T cells do not express CD40 and CD40L surface 
molecules, respectively (Durandy et al., 1995). These factors may account for the 
relatively poor production of antibodies during early life. It has also been proposed 
that the predominance of immature T cells in the periphery contributes to neonatal 
tolerance, indeed the majority of neonatal CD4+CD8+ T cells display little 
responsiveness to antigen (Ramsdell et al., 1991). Neonatal T cells also exhibit poor 
helper function, due to their deficient cytokine production (Splawski and Lipsky, 
1991). These cells may need to undergo post-thymic maturation in the periphery of 
young animals in order to mediate physiological immune responses (Hosseinzadeh and 
Goldschneider, 1993). The high susceptibility of neonates to tolerance induction may 
also be related to the reduced numbers and function of their professional APC. For 
example, the numbers of macrophages bearing MHC class II molecules is lower in 
newborn lymphoid organs (Lu et al., 1979), whilst B cells (acting as APC) in 
newborns display decreased ability to induce IL-2 production compared to adults 
(Morris et a i,  1992).
1.7.2 Neonatal immune responsiveness
Although the administration of antigens to neonates has been shown to induce 
tolerance, several studies have also demonstrated that humoral and cell-mediated 
immune responses may develop following immunization. Howard and Hall (1976) 
first observed the induction of humoral responses, and a lack of tolerance induction,
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following injection of polysaccharide antigens into neonates, whilst oral administration 
of myelin basic protein primed neonates for immune responses and enhanced their 
development of EAE (Miller et al., 1993). In studies of infectious disease, Bacille 
Calmette-Guerin (BCG) vaccine, oral poliovirus vaccine and hepatitis B virus vaccine 
have all been used at or near birth and have provided effective preventive immunization 
against these diseases (reviewed in Ada and Ramsay, 1997). Furthermore, DNA 
immunization has provided a new approach for the induction of neonatal immune 
responses. Recent examples of immunogenic DNA vaccines include plasmids 
expressing the nucleoprotein of influenza virus, which primed neonates for CTL 
responses (Bot et al., 1996), and those expressing the murine leukemia virus genome, 
which induced virus-specific CTL and were protective against disease (Sarzotti et al., 
1996).
These studies have raised questions as to whether antigen exposure in neonatal life is 
primarily tolerogenic or immunogenic. Recent studies have shown that tolerance may 
not be an intrinsic property of the newborn immune system. However, the conditions 
under which antigen is introduced may be a critical determinant of tolerance or immune 
responsiveness (Ridge et a i, 1996; Sarzotti et al., 1996; Forsthuber et al., 1996). 
Firstly, the nature of antigen presentation may determine the immunological outcome of 
exposure to antigen. Antigen presentation by professional APC, such as dendritic 
cells, activated a CTL response, but tolerance was induced when the same antigen was 
processed by non-professional APC in both neonates and adults (Ridge et al., 1996). 
Secondly, antigen dose is also crucial. Neonatal and adult T cells both have a capacity 
either to be tolerized or activated, and higher doses of antigen are needed to tolerize 
adults compared to neonates (Ridge et al., 1996). In another study, Sarzotti et al. 
(1996) showed that whereas immunization of neonates with low doses of murine 
leukemia virus induced protective CTL responses, higher doses were not able to induce 
CTL. This failure to develop CTL responses was not due to immunological
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immaturity, rather it correlated with the induction of a non-protective TH2-type 
response (Sarzotti et al., 1996). In addition, the type of adjuvant that is used may 
determine the nature of immune response which is induced. Immunization of neonates 
with hen egg lysozyme (HEL) primed for both antigen-specific T cell and B cell 
memory. Delivery of HEL in incomplete Freund's adjuvant induced a TH2 cell 
response whilst complete Freund’s adjuvant generated a TH1 cell response both in 
neonates and adults (Forsthuber et al., 1996).
Taken together, these studies indicate that neonates have the potential for tolerization or 
immunization against antigens, as in adults. Clearly, conditions may be optimised 
either to immunize or tolerize the newborn in order to vaccinate against the development 
of disease.
1.8 The allergic immune response
1.8.1 Allergy and asthma
An allergic response occurs when an adaptive immune response is mounted against 
otherwise innocuous environmental antigens, such as pollens, house-dust mites or 
animal dander. These responses thus occur in an exaggerated or inappropriate way, 
causing inflammatory reactions and tissue damage, such as in asthma. Atopic allergy is 
characterised by increased production of allergen-specific IgE antibodies which bind to 
high-affinity Fee receptors (FceRI) on the surface of mast cells and basophils (Ogawa, 
1971). Cross linking of this antibody-receptor complex by allergens (Haydik and Ma, 
1988) triggers the release of histamine and other pharmacological mediators, such as 
chemotactic factors and cytokines. This IgE-mediated response is called the immediate- 
phase reaction (Sheard et al 1967), and occurs within seconds to minutes of exposure 
to allergen. The late-phase response is characterised by an inflammatory infiltrate at the
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site of allergen exposure, which occurs 4-24 hours later (Gleich, 1990), as discussed 
below.
Asthma is an allergic disorder clinically characterized by reversible airways obstruction, 
airways hyperreactivity and inflammation (McFadden and Gilbert, 1992; Bochner et 
al., 1994). Attempts to assign a single predisposing feature have not been successful 
and it is now realized that asthma is a complex disease process involving not only the 
immune system, but also the nervous system, the genetic background of the individual 
and environmental factors (Bochner et a l, 1994). Inflammation of the airways is the 
common pathological event in atopic asthma and there is an increasing body of 
evidence to suggest that the severity of disease correlates with the degree of airways 
inflammation (Azzawi et a l, 1990; Bousquet et a l, 1990; Bradley et al., 1991; Bentley 
et al., 1992). The composition of the inflammatory infiltrate in the asthmatic lung is 
characterized by increased numbers of eosinophils, neutrophils, mast cells and 
monocytes, each releasing mediators which cause tissue damage and dysfunction, as 
well as amplifying the inflammatory response (Bochner et al., 1994)
1.8.2 Cellular regulators and mediators of allergic airways responses
T and B lymphocytes, responsible for specific recognition of foreign antigens, and the 
factors which they secrete, are critically involved in the regulation of allergic reactions. 
Other leukocytes including mast cells, basophils and eosinophils act as effectors, each 
playing a characteristic role in the pathogenesis of allergic disease. Cellular interactions 
underlying the development of allergic airways disease are illustrated in Figure 1.1 and 
are discussed in detail below.
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1.8.2.1 T and B cell regulation of allergic responses
There is abundant evidence of a pivotal role for T lymphocytes in the induction of 
allergic disease (Corrigan et al., 1988; Bochner et al., 1994). CD4+ T cell activation is 
now considered a central event in the pathogenesis of asthma (Romagnani, 1997; Erb, 
1996). The degree of activation of CD4+ T cells correlates clearly with the numbers of 
eosinophils found in bronchoalveolar lavage fluid (BALF) and peripheral blood, as 
well as the severity of symptoms in human asthmatics (Robinson et al., 1992), whilst 
antibody-mediated depletion of CD4+ T cells has been shown to abrogate airways 
inflammation and hyperreactivity in mice (Kung et al., 1995). TH2-type CD4+ cells, 
and their secreted cytokines, IL-4 and IL-5, are the major T cell components of allergic 
responses (Leung et al., 1995; Robinson et al., 1992; Sanderson, 1992).
IL-4 is a critical factor in the regulation of CD4+ T cell commitment to the TH2 
phenotype and also regulates mast cell activity and, thus, the production of IgE 
antibodies (Swain et al., 1990; Geha, 1992). These antibodies may sensitize effector 
cells, such as mast cells and eosinophils, leading to their release of inflammatory 
substances, including histamine, cationic proteins and chemokines. IL-4 also has a 
role in the maintenance of the inflammatory response to recall antigens and in 
regulating production of the eosinophil-specific chemoattractant, eotaxin (Coyle et al., 
1995; Rothenberg et al., 1995). Eosinophilic inflammation in allergic airways was 
significantly reduced in aeroallergen-challenged IL-4 gene knockout mice (Brusselle et 
al., 1994), whilst neutralization of IL-4 using specific mAb reduced airways 
hyperreactivity and pulmonary eosinophilia in BALB/c mice (Corry et al., 1996). 
However, a conflicting report has recently shown that allergen-induced airways allergic 
disease may occur independently of IL-4 and allergen-specific antibody production in 
IL-4 deficient mice (Hogan et al., 1997). Contrasting mechanisms regulating induction 
of allergic airways dysfunction in the different strains of mice used in these studies may
account for the reported differences (Drazen et al., 1996). The molecular mechanism 
by which IL-4 delivers signals to T cells appears to be via activation of STAT 6 to 
induce TH2 phenotype development (Kaplan et al. 1996). Indeed, airways 
inflammation and hyperreactivity were abolished in STAT 6-deficent mice after allergen 
challenge (Akimoto, et al., 1998).
IL-5 regulates the growth, differentiation, activation and recruitment of eosinophils, 
which are the predominant inflammatory cells in allergic asthma (Sanderson, 1992). In 
the absence of IL-5, either following its depletion by anti-IL-5 antibodies (Kung et al., 
1995) or by gene knockout (Foster et al., 1996), allergen-induced airways eosinophilia 
and hyperreactivity is abolished, whilst reconstitution of IL-5 restores disease 
symptoms (Foster et al., 1996). As discussed above, in Section 1.5, IL-5 is clearly a 
critical regulator of atopic disease and has been identified as a key therapeutic target.
In addition to the activities of TH2 cytokines, CD28/B7 co-stimulation is also clearly 
important for the induction of allergic immune responses. Blockade of the interaction 
between this pair of co-stimulatory molecules by murine CTLA4-Hyl, a soluble form 
of murine CTLA-4 (a T cell surface molecule sharing identical ligands with CD28) 
results in inhibition of antigen-induced lung eosinophilia (Harris et al., 1997a). In 
particular, the interaction between CD28 and B7.1 (CD80), is important for the 
maintenance or amplification of allergic airways inflammation (Harris et al., 1997b).
There is now good evidence to suggest that CD8+ T cells also regulate allergic 
responses. Initial in vitro studies showed that activated mouse CD8+ T cells, when 
cultured in the presence of IL-4 and mitogens, developed into cells which included a 
CD8-CD4- population that did not produce IFNybut secreted TH2 cytokines, including 
IL-4 and IL-5 (Erard et al., 1993). An implication of these studies was that CD8+ T 
cells, normally a major component of TH1-driven antiviral immune responses, could
instead produce TH2 cytokines if induced in a microenvironment dominated by these 
cytokines. Subsequent experiments by these authors, using T cell receptor transgenic 
mice, showed that virus-specific CD8+ T cells could produce IL-5 and stimulate 
eosinophil recruitment into the lungs if stimulated by viral peptide in the context of a 
TH2-driven response to allergen (Coyle et al., 1995). Clinical studies, reported in the 
same year, found that CD8+ T cells from atopic individuals produced IL-4 and 
supported IgE production (Daser et al., 1995). Further evidence supporting an 
important role for CD8+ T cells in allergic responses came from murine studies, in 
which depletion of this subset prior to sensitization abrogated the subsequent 
development of eosinophilia and airways hyperreactivity, as well as IL-5 production in 
lymph nodes associated with airways (Hamelmann et al., 1996)
Earler studies in rats had shown that IFNy-producing CD8+ T cells were responsible 
for the induction of a "tolerant" state, as evidenced by suppression of IgE production, 
following repeated exposure to aeroallergen (McMenamin and Holt, 1993), and, 
furthermore, that small numbers of yö T cells could mediate this effect (McMenamin et 
al., 1994). More recent investigations into mechanisms underlying specific IgE 
unresponsiveness induced by inhaled allergen have led to somewhat different 
conclusions, demonstrating that the state of unresponsiveness of CD4+ T cells 
resulting in prolonged suppression of IgE production and eosinophil infiltration did not 
require the involvement of CD8+ T cells, yö T cells or IFNy production (Seymour et 
al., 1998). Indeed, the use of yÖ T cell deficient (yÖ-/-) mice in a model of pulmonary 
allergic inflammation has revealed significantly decreased IgE and IgGl production, 
IL-5 secretion and eosinophil infiltration in these animals, supportive of a role for yö T 
cells in the development of allergic airways disease. Further studies are clearly 
required in order to clarify the roles of CD8+ T cell populations in allergy.
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Elevated levels of allergen-specific IgE in both serum and BALF are commonly 
associated with bronchial asthma (Crimi et al., 1989; Burrows et al., 1989). B cells 
may thus play a vital role in allergic disease (Geha, 1992) by switching to IgE 
production to initiate early-stage allergic responses. These are generally characterized 
as IgE-dependent mast cell responses, inducing broncho-constriction through the 
production of histamine (Adams et al., 1979). IgE antibodies may also play a central 
role in TH2 responses and lung eosinophilia, since the administration of anti-IgE mAb 
inhibited both the recruitment of eosinophils into the lung and also the production of 
IL-4 and IL-5 following allergen treatment (Coyle et al., 1996). However, recent 
studies, using allergen-treated CD40-deficient mice, have demonstrated that airways 
inflammation and hyperreactivity were not attenuated in these animals, despite the 
abolition of allergen-specific IgG and IgE antibody production, suggesting that allergic 
airways disease can develop independently of allergen-specific immunoglobulins other 
than IgM (Hogan et al., 1997). These contradictory findings might, in some measure, 
be due to the different genetic backgrounds of the mice which were used in these 
studies.
1.8.2.2 Mast cells and basophils
which are now recognised as distinct lineages 
Mast cells and basophilsj^are derived from bone marrow stem cells. Basophils are
found in the blood stream whilst mast cells are found in body tissues (Helm et al
1988). Both tissue mast cells and circulating basophils express high affinity Fc
receptors for IgE and their cross-linking with IgE triggers the release of inflammatory
mediators, including histamine, by degranulation (Haydick and Ma, 1988). Besides
their effector activities, mast cells and basophils may secrete IL-4 when stimulated in
vitro with EL-3 or when their Fc receptors are cross-linked (Ben-Sasson, 1990; Smith
et al., 1994). This phenomenon has led to the hypothesis that IL-4 production by mast
cells or basophils, when stimulated by allergen, could produce a TH2 cytokine
microenvironment facilitating B cell switching to IgE production (Aebischer and 
Stadler, 1996).
1.8.2.3 Eosinophils
Eosinophils, like other granulocytes, are derived from bone marrow and comprise 1- 
3% of blood leucocytes in healthy, non-allergic individuals. Traditionally, eosinophils 
have been regarded as cytotoxic cells involved in host defence against parasitic 
infection (Gleich, 1990), but are also now widely accepted as the most important 
inflammatory cells mediating allergic disease (Desreumaux et al., 1992; Sanderson, 
1992). During an allergic response, eosinophils infiltrate inflammatory sites, mainly 
in the skin and mucosa, and contribute directly to tissue damage and chronic 
inflammation as end-stage effectors via their release of inflammatory mediators (Gleich 
et al., 1986; Weller, 1992; Desreumaux and Capron, 1996).
1.8.2.4 Eosinophil recruitment
Eosinophils develop within the bone marrow and are released into the circulation upon 
maturation. Their differentiation and maturation is driven by cytokines, particularly IL- 
5, which was originally termed eosinophil differentiation factor (Clutterbuck et al., 
1989). Upon exposure to antigen, eosinophil numbers appear to increase moderately 
in the bone marrow and in peripheral blood, a phase which is soon followed by a 
marked reduction of eosinophil numbers in bone marrow and their recruitment, via the 
blood, to inflammatory sites (Kung et al., 1994). There appear to be two major steps 
in this recruitment process. Firstly, eosinophils adhere to endothelia via adhesion 
molecules on endothelial cells. In particular, vascular cell adhesion molecule (VCAM)- 
1 interacts with the very late activation antigen (VLA)-4 expressed on eosinophils 
(Wardlaw et al., 1994; Nakajima et al., 1994). Exposure to cytokines such as IL-3 and
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IL-5 may enhance eosinophil adherence to endothelial cells (Walsh et al., 1991; Moser 
et al., 1992).
After binding to endothelia, eosinophils migrate to inflammatory sites in response to 
chemotactic factors (Weller, 1992). IL-5, IL-3, IL-2 and GM-CSF are all involved in 
eosinophil mobilization (Sullivan et al., 1996; Broide et al., 1992; Cruikshank et al., 
1991), IL-5, in particular, is a selective eosinophil chemoattractant (Walsh et al., 1990; 
Rand et al., 1991). Recently, C-C chemokines, including RANTES (regulated on 
activation, normal T cell expressed and secreted), monocyte chemotactic protein 
(MCP)-3, macrophage inflammatory protein (M lP )-la  and eotaxin have each been 
implicated in eosinophil recruitment to sites of inflammation (Weber and Dahinden, 
1995; Rothenberg et al., 1995). MICP-1 and M IP -la  have been found at high levels 
in the bronchoalveolar fluids of asthmatic patients, indicating their likely involvement in 
the recruitment of eosinophils to allergic airways (Lukacs et al., 1995; Alam et al., 
1996). Eotaxin is unique among the C-C chemokines because in vivo protein 
administration studies have demonstrated that this molecule is chemoattractive primarily 
for this cell type (Jose et al., 1994; Rothenberg et al., 1996). Additionally, the eotaxin 
receptor is predominantly expressed by the hematopoietic cells involved in allergic 
responses, i.e. eosinophils, basophils and TH2 cells. However, a combination of 
approaches, including eotaxin gene targeting, neutralization by antibodies and receptor 
antagonism, have uniformly shown only 2- to 3-fold reductions in eosinophil 
recruitment after antigen challenge (Gonzalo et al., 1996; Rotherberg et al., 1997), 
suggestive of further roles for this factor. Eotaxin also appears to play a critical role in 
regulating the levels of tissue-dwelling eosinophils at baseline (Matthews et al., 1998)
1.8.2.5. Eosinophil activation and function
There are significant differences between eosinophils obtained from patients with 
eosinophilia and those from normal individuals. Eosinophils may be "activated" in 
blood and tissues of eosinophil-associated allergic disease (Weller, 1992). Such 
activated cells express high levels of receptors for complement and IgG (Winqvist et 
al., 1982), are of lower density, and display prolonged survival (Gleich and 
Adolphson, 1986; Hodges et al., 1988), compared to eosinophils from normal 
individuals. Results from studies in animals indicate that IL-3, IL-5 and GM-CSF are 
the major activation factors for eosinophils (Fujisawa et al., 1990; Desreumaux and 
Capron, 1996), although this remains to be confirmed in human disease. Eosinophils 
may also be activated by immune complexes, particularly those involving IgA and IgE 
antibodies (Capron et al., 1994; Tomassini et al., 1991).
Following their activation and accumulation at sites of inflammation, eosinophils 
degranulate, releasing cytotoxic mediators such as basic proteins, cationic proteins, 
lipid mediators and neuropeptides, which cause local tissue damage and dysfunction 
(Gleich and Adolphson, 1986). Amongst these mediators, the most damaging appear 
to be the basic proteins (Gleich and Adolphson, 1986). In animal models, basic 
proteins have been shown to damage intestinal and respiratory epithelia and to alter 
smooth muscle function, inducing hyperreactivity (Gleich and Adolphson, 1986). In 
addition, these cells synthesise cytokines and chemokines which may contribute to 
allergic responses (Desreumaux and Capron, 1996). These include factors such as IL- 
3, IL-5 and GM-CSF, which have autocrine and paracrine activities, and also cytokines 
and chemokines involved in inflammatory responses, including TNFa, TGFa, 
TGFßl (Costa et al., 1993; Elovic et al., 1994), IL-8 (Yousefi et al., 1995) and MIP- 
l a  (Costa et al., 1993). Recently, it has also been shown that eosinophils may 
produce TH2 factors (IL-4 and IL-5) (Lamkhioued et al., 1995), as well as the TH1
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cytokine, IL-2 (Levi-Schaffer et al., 1996), suggestive of a broader role for eosinophils 
in immune regulation than has been previously thought.
1.8.2.6. NOS2 and allergic disease
Several recent studies have led to the suggestion that the development of allergic 
disease may be related to elevated production of NO. Asthmatic patients have increased 
levels of exhaled NO (Kharitinov et al., 1994; Gaston et al., 1993) and their peak NO 
concentrations are higher than in non-asthmatic controls (Kharitinov et al., 1994). In 
animal models, allergen-induced airways obstruction in guinea pigs was also associated 
with high levels of exhaled NO (Persson and Gustafsson, 1993). These increased 
levels of NO are thought to be catalysed by the enzyme NOS2 (Barnes and Liew, 
1995). In asthmatic patients, NOS2 is detected in bronchial biopsies of respiratory 
epithelium but cannot be seen in normal controls (Robbins et al., 1994b). 
Furthermore, in vitro studies have shown that human lung epithelial cells express 
NOS2 and produce large amounts of NO after exposure to pro-inflammatory cytokines 
(Robbins et al., 1994b). In animal models, murine T cells activated by antigen or 
mitogens have also been shown to express NOS2 and to produce substantial amounts 
of NO which may inhibit TH1 cell activity (Taylor-Robinson et al., 1994), although 
these data are somewhat controversial (Bauer et al., 1997). Thus, macrophages, 
epithelial cells, vascular smooth muscle, endothelial cells, and possibly T cells, all have 
the potential to express NOS2 (Robbins et al., 1994; Barnes, 1995).
Overall, these studies suggest that NOS2, and NO catalysed by this enzyme, may be 
important factors in the regulation of allergic responses. This has led to the hypothesis 
that NOS2, induced by pro-inflammatory cytokines, possibly secreted by macrophages 
and T cells, catalyses the production of large amounts of NO, which, in turn, 
suppresses the activity of TH1 cells whilst TH2 cell activity is up-regulated, leading to
amplified asthmatic inflammation (Barnes and Liew, 1995). Based on this hypothesis, 
specific NOS2 inhibitors may have the potential to suppress TH2-driven allergic 
responses and asthma.
1.9 Vaccination and immunotherapy in allergic disease
The science of immunology developed from the observation that those who survived a 
disease seldom suffered a second similar illness. Jenner is given credit for developing 
the procedure which has come to be known as vaccination, following his critical 
experiment which showed that smallpox disease could be prevented by prior infection 
with the related, but less virulent, cowpox virus. Since then, numerous vaccines have 
been developed and used successfully in the control of a variety of infectious diseases 
(reviewed in Ada and Ramsay, 1997). Vaccination is a concept which may also have 
applications for protection against non-infectious conditions, including allergic disease. 
In particular, early childhood is a stage when specific T cell responses to environmental 
antigens are usually initiated and the selection of the appropriate T cell population 
occurs (Holt, 1994). Active intervention with vaccines at this stage might conceivably 
result in the stimulation of "protective" TH1 immune responses against allergens and 
prevention of TH2-driven allergic responses upon subsequent exposure to allergen.
Alternative strategies used to treat established allergic disease include allergen 
avoidance, chemical therapy and, more recently, immunotherapy. Immunotherapy 
against allergy initially referred to the process of repeated subcutaneous injection of 
crude extracts of allergen in attempts to redirect allergic responses towards a long-term 
decline of the specific IgE response (Norman, 1993). The term immunotherapy now 
covers a variety of approaches which have been used to modulate the immune response 
for the control of disease (Baskar et ai, 1997). This concept was originally introduced 
by Noon for the treatment of hay fever. Since then, however, a number of
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immunotherapies have been developed for the treatment of allergic disorders, cancer 
and autoimmune disease (Schwartz, 1995). A promising recent example is the 
demonstration, in mice, that BCG, when administered to airways, can suppress 
allergen-induced airways inflammation through its ability to activate TH1 cells and 
IFNy production (Erb et al., 1998). The development of further approaches to 
vaccination and immunotherapy of allergic disease is discussed below.
1.9.1 The use of allergens in vaccination or therapy against allergic 
disease
Allergens have been administered both prior to allergic sensitization, in attempts to 
prevent the development of disease, or to sensitized individuals, in order to treat or 
reverse allergic reactions. Early studies used extracts from common allergens such as 
house dust mites, grass pollens and bee venom (Haugaard et al., 1991; Fennerty et al., 
1988; Jutel et al., 1995), with some successes reported in the down regulation of early 
phase IgE and mast cell responses (Norman, 1993; Creticos et al., 1989), late phase 
eosinophilia (Durham et al., 1995; Iliopoulos et al., 1991) and hyperreactivity (Majchel 
et al., 1992). The knowledge that allergic responses are mediated by T cells, especially 
by CD4+ TH2 cells, led to the development of techniques aimed at specific inactivation 
of this cell subset. In this context, several authors have reported the use of T cell 
epitopes, identified within allergens, as potential therapeutic modalities which might 
induce T cell tolerance (Hoyne et al., 1995) and, to date, a number of clinical trials 
employing this approach are in progress (Muller et al., 1997; Norman et al., 1993).
1.9.2 The use of recombinant cytokines for treatment of allergic 
airways disease
Although the events leading to the development of allergic airways disease are 
complex, as discussed above, TH2 cytokines, notably IL-4 and IL-5, produced by 
allergen-specific T cells, have emerged as important causative factors. In contrast, 
cytokines which promote the development of TH1 cells, or which are released by these 
cells, are known to inhibit TH2-driven immune responses (Snapper et al., 1987; 
Mosmann et al., 1989; Yssel et al., 1993), suggesting further ways of treating allergic 
disease. Thus, nebulised IFNy, given intranasally, has been used to decrease 
eosinophil infiltration and bronchial responsiveness in a murine model of allergic 
airways disease (Lack et al., 1993), whilst treatment of atopic individuals with IFNy or 
IFNa has resulted in transient clinical improvements, particularly in the case of asthma 
(Boguniewicz et al., 1990; Reinhold et al., 1993). Similarly, in animal models, IL-12 
administered as a recombinant protein, may also suppress TH2-driven allergic disease 
(Manetti et al., 1993; McKnight et al., 1994; Wang et al., 1994a; Marshall et al., 1995; 
Gavett et al., 1995; Kips et al., 1996; Sur et al., 1996). These effects were mediated, 
in most cases, via the activity of IFNy, although there is some evidence that IL-12 may 
down regulate IL-4 expression and TH2-driven immune responses independently of 
this factor (Wang et al., 1994b; Marshall et al., 1995; Gavett et al., 1995). It remains 
to be seen whether approaches based on these findings will be successful in the clinic.
1.9.3 Genetic approaches for vaccination and immunotherapy
Recombinant DNA technology has recently provided a range of new approaches for 
vaccination and immunotherapy of disease. These include live recombinant viral 
vectors (Cavanagh, 1985; Flexner et al., 1988) and naked DNA plasmids, now 
commonly termed DNA vaccines (Donnelly et al., 1997). The capacity of viral vectors
to express foreign genes was first demonstrated in 1982 (Nakano et al., 1982). Since 
then, recombinant viral vaccine technologies have developed rapidly and have proven 
effective for the control of infectious diseases in a wide range of animal models 
(reviewed in Ada and Ramsay, 1997). A wide variety of viruses have been used as 
vectors for the delivery of vaccine antigens, including adenoviruses, polioviruses and 
herpesviruses, however, the most widely studied and best characterized are the 
poxviruses.
1.9.3.1 Poxvirus vectors
Poxviruses are large double-stranded DNA viruses and replicate in the host cytoplasm 
(Fenner et al., 1989). Poxviruses possess several advantages over other viral vectors, 
including their ability to accommodate large amounts of foreign genetic material (Smith 
and Moss, 1983) and the susceptibility of many cell types to infection (Moss, 1990). 
The most commonly used poxvirus vectors are vaccinia virus (VV) and avipoxvirus, a 
poxvirus of birds. Vaccinia virus has been successfully used as an immunizing agent 
during the global eradication of smallpox (Fenner et al., 1988), and has a wide host 
range, including humans, primates, rodents and rabbits (Fenner et al., 1989). In 
contrast, the avipoxvirus, fowlpox virus (FPV), has a narrow host range, with the 
chicken as its only natural host (Tripathy et al., 1975). FPV infection of mammalian 
cells is non-productive (Taylor and Paoletti, 1988), although foreign genes under the 
control of early virus promoters are expressed (Cox et al., 1993a). Thus, FPV 
potentially represents a safer and more persistent gene delivery vector, compared to 
VV.
In addition to their potential as delivery vehicles for heterologous vaccine antigens, a 
large number of studies, particularly in this laboratory, have demonstrated that 
poxvirus vectors engineered to express genes encoding cytokines can profoundly and
selectively modulate specific immune responses (reviewed in Ramshaw et al., 1997). 
These include reports of vaccinia viruses encoding IL-2 (Flexner et al., 1988; 
Ramshaw et al., 1987) , IFNy (Kohonen-Corish et al., 1990), TNFa (Sambhi et al., 
1991), IL-12 (Hogan et al., 1998), IL-4 (Sharma et al., 1996), IL-5 (Ramsay et al., 
1993a) and IL-6 (Ramsay et al., 1994a), and FPV encoding IL-2 or IL-6 (Leong et al., 
1994).
1.9.3.2 DNA vaccines
It was first announced in 1990 that naked DNA plasmids, when injected into animal 
cells, induced the production of encoded foreign genes (Wolff et al., 1990). Since 
then, there have been enormous advances in the development of these constructs, with 
several DNA vaccines already in use in clinical trials against AIDS, influenza and 
cancer (Donnelly et al, 1997).
DNA vaccines consist of an antigen-encoding gene whose expression is normally 
regulated by a strong mammalian promoter located on a plasmid backbone of bacterial 
DNA (Ulmer et al., 1993; Wolff et al., 1990). DNA immunization has a number of 
advantages over both conventional approaches to vaccination and also most 
recombinant virus vaccines and is currently regarded as the most promising recent 
development in the field. Major potential advantages of DNA vaccines include a 
capacity to induce long-lasting humoral and cell-mediated responses (Ulmer et al., 
1996), the potential for repeated administration without problems of pre-existing 
vector-specific immunity, the expression of encoded antigens in their native antigenic 
form (Pardoll and Beckerleg, 1995), and their ease of production, stability and purity. 
To date, DNA immunization has been shown to be effective in various animal models 
of disease, including a wide range of infectious diseases (Ulmer et al., 1993; Xiang 
and Ertl, 1995; Davis et al., 1996; Geissler et al., 1997; Tascon et al., 1996; Lowrie et
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al., 1997; Ramsay et al., 1997), cancer (Condon et al., 1996; Syrengelas et al., 1996), 
autoimmune disease (Waisman et al., 1996) and recently, allergic disease (Hsu et al., 
1996a and 1996b; Raz et al., 1996; Raz et al., 1997; Roman et al., 1997b).
DNA immunization is effective not only in adults, but also for the induction of neonatal 
immunity, which is not always easily achieved by conventional vaccines. Sustained 
exposure to small amounts of antigen following DNA immunization may, in fact, 
overcome the tolerance often induced by conventional vaccines in neonates and 
accelerate clearance of maternal antibodies (Bot et al., 1997; Sarzotti et al., 1996; 
Martinez et al., 1997).
DNA vaccines have developed rapidly since 1990, from laboratory phenomena to the 
stage of clinical trials. The potential drawbacks of this approach, however, include the 
intrinsic immunostimulatory properties of DNA, which may contribute to the 
development of autoimmune disease (Klinman et al, 1997; Gilkeson et al., 1993) and 
the potential for integration of foreign DNA into host chromosomes (Siegrist, 1997). It 
should be noted, however, that neither of these phenomena have been reported to occur 
in the vast amount of literature that has now accumulated in this field.
1.9.3.3 Applications of recombinant vectors in vaccination or therapy 
of allergic disease
Recombinant vectors appear to have great potential as agents mediating protection 
against the development of allergic disease. In particular, DNA vaccines encoding 
allergen genes have been shown to induce specific TH1 -based immune responses, 
which appeared to inhibit the induction of secondary TH2-driven allergic responses 
upon re-exposure to the allergen in mice (Hsu et al., 1996; Raz et al., 1996). When 
this approach was used to treat ongoing disease, it apparently induced a switch from
primary TH2-driven allergic responses to secondary, protective TH1 responses (Raz et 
al., 1996) and inhibited pulmonary eosinophilia (Broide et al., 1997).
DNA vaccine plasmids have been shown to contain immunostimulatory sequences 
(ISS) which comprise unmethylated CpG DNA motifs possessing adjuvant properties 
which may non-specifically enhance T cell responses, particularly TH1 responses (Chu 
et al., 1997; Roman et al., 1997). Indeed, when administered intranasally as simple 
oligonucleotides along with allergen, these sequences prevented TH2 cytokine 
induction, IgE production, eosinophilic inflammation and airways hyperreactivity in a 
murine model of allergic airways disease (Kline et al., 1998). Clearly, ISS may 
represent a novel approach to immunotherapy of atopic disease.
Recombinant vectors have also been successfully used as vehicles for the delivery of 
cytokine genes to suppress allergic responses. DNA vaccines encoding IFNy inhibited 
pulmonary allergic disease when given intra-tracheally to sensitized mice (Li et al., 
1996). Studies in this laboratory have shown that intranasal delivery of IL-12 genes in 
rVV prior to aeroallergen treatment also prevented the development of eosinophilic 
inflammation, airways hyperreactivity and lung damage (Hogan et al., 1998). 
Together, these data underline the promise of genetic approaches for vaccination and 
immunotherapy against allergic disease and provide a basis for the rational development 
of effective treatments for use in humans.
1.10 Scope of This Thesis
Atopic allergy is caused, in part, by exaggerated or inappropriate adaptive immune 
responses against otherwise innocuous environmental antigens. These responses are 
mediated by a variety of immune cells and soluble molecules, including TH2 cells, their 
secreted products IL-4 and IL-5, and eosinophils. Active intervention to direct the
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activity of these cells and cytokines may represent an effective treatment for allergic 
disease. The work reported in this thesis was performed in order to study the potential 
of the type 1 cytokine, IL-12, when delivered in recombinant viral and DNA vectors, in 
the treatment of allergic airways disease and to examine mechanisms underlying its 
activity. The regulatory role of nitric oxide, synthesized by the enzyme nitric oxide 
synthase (NOS) 2, in allergic airways disease was also studied using mice deficient for 
this molecule.
In Chapter 2, a murine model of allergic airways disease was established in which the 
disease state was known to correlate with pulmonary eosinophilic inflammation. 
Sensitized mice were given DNA vaccines or fowlpoxvirus vectors engineered to 
express IL-12 and the protective efficacy of these constructs was assessed in the 
disease model.
In Chapter 3, DNA vaccines encoding the allergen, OVA, together with IL-12 were 
used as a preventive neonatal vaccination strategy, in contrast to the therapeutic 
treatments studied in Chapter 2. The capacity of this vaccine to protect against the 
development of allergic airways disease in adult life was tested in animals given 
systemic inocula of the vaccine as neonates.
Whilst IL-12 might conceivably suppress allergic airways disease by changing the 
polarity of the allergen-specific immune response towards TH1 activity, or selectively 
enhancing the recruitment of TH1 cells into sites of inflammation, it may also directly 
influence the activity of inflammatory cells, such as eosinophils. The influence of IL- 
12 on the development of inflammatory cells, particularly eosinophils, in vitro and in 
vivo, was studied in Chapter 4.
Finally, nitric oxide (NO) appears to regulate many physiological systems and has been 
implicated in the pathogenesis of allergic asthma. In Chapter 5, the role of inducible 
NO in the development of allergic airways disease was examined following the 
establishment of the disease model in mice rendered deficient for the enzyme nitric 
oxide synthase (NOS) 2.
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Chapter 2
Mucosal IL-12 gene delivery using novel DNA 
and fowlpoxvirus vectors for protection against 
allergic airways disease
2.1 Introduction
Allergic airways disease is clinically characterized by airways obstruction, 
inflammation and bronchial hyperresponsiveness (Bochner et al., 1994). The 
pathophysiology of the disease is mediated by networks of cells, inflammatory 
mediators and cytokines in which T cells, mast cells and eosinophils play a pivotal role 
(Bradding et al., 1994; Ying et al., 1997; Coyle et al., 1996). Disease severity 
correlates closely with the degree of local inflammation and T cell activity (Azzawi et 
al., 1990; Bentley et al, 1992). TH2 cells predominate in the allergic inflammatory 
infiltrate and their cytokine secretion profiles include IL-4 and IL-5, whose activities 
appear to be central to the local allergic inflammatory response. The molecular and 
cellular mechanisms underlying the predominance of TH2 cells in allergic airways 
remain to be resolved, however their products appear to have profound and specific 
effects in promoting allergic disease. IL-4 modulates the development of mast cells 
(Madden et al, 1991) and, through its influence on antibody class switching, regulates 
the production of IgE (Geha et al., 1992) which may specifically sensitize mast cells, 
eosinophils, basophils and macrophages, leading to the release of inflammatory 
substances, including histamine, leukotrienes, platelet-activating factor, cationic 
proteins and chemokines. These molecules may, in turn, augment the inflammatory 
process. IL-5 regulates the growth, differentiation and activation of eosinophils, 
which are consistently the predominant leukocyte population in the inflammatory 
infiltrate of asthmatics (Sanderson et al., 1992) and may be a key factor in their 
recruitment into the allergic lung. In addition, both IL-4 and IL-10 can suppress the 
development of alternative types of immune response which can inhibit TH2 cell- 
driven inflammatory responses (Mosmann and Coffman, 1989).
Recent in vivo studies in murine models of allergic airways inflammation have also 
strongly implicated TH2 cells and/or their products in the pathogenesis of allergic
asthma. Firstly, antibody-mediated depletion of TH cells or IL-5 abrogated the 
eosinophilia and airways hyperreactivity associated with disease (Kung et al, 1995). 
Secondly, IL-4-deficiency resulted in marked attenuation of inflammation, either by its 
inhibitory effects on TH2 cell-derived IL-5 production and eosinophil recruitment 
(Brusselle et al., 1994), or through modulation of IgE production and mast cell activity 
(Corry et al., 1996). Thirdly, allergen-induced eosinophilia, damage to airways 
epithelium and airways hyperreactivity were all abolished in IL-5-deficient mice but 
were restored following vector-directed reconstitution of IL-5 production (Foster et al., 
1996).
Although the chain of events leading to allergic airways disease is highly complex, the 
dysregulated production of type 2 cytokines, notably IL-4 and IL-5, by allergen- 
specific T cells, has clearly emerged as an important causative factor. Thus, increased 
understanding of the regulation of TH2-type inflammatory immune responses, and of 
how such responses may be specifically inhibited or ablated, may facilitate the 
development of preventive measures or effective therapies for allergic airways disease. 
Other cytokines, particularly those produced by the TH1 cell subset (including IFNy) 
are known to promote TH 1 cell development, to inhibit TH2 cell development and to 
suppress TH2-driven immune responses (Mosmann and Coffman, 1989; Yssel et al.,
1993) . Recent reports from large scale epidemiological studies have suggested that 
exposure in early childhood to infectious agents, such as Mycobacterium tuberculosis 
and measles virus, which promote type 1 immune responses, may inhibit the 
subsequent development of allergic disorders, including asthma, via immune deviation 
and suppression of type 2 responses (Shaheen et al., 1996; Shirakawa et al, 1997). 
Such results require careful interpretation, particularly in the face of evidence that 
severe bacterial or virus infections may, in fact, trigger atopic episodes (Lacour et al,
1994) and given the complexity of the environmental and immunological contribution 
to asthma (Bochner et al, 1994; Lynch et al, 1993). Nevertheless, the inhibition of 
allergen-specific TH2-mediated immune responses represents an attractive approach to
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the prevention and/or treatment of allergic asthma as evidenced by recent work from 
our laboratory (Hogan et al., 1998) and by others (Gavett et a l,  1995; Li et al., 1996; 
Erb et al., 1998).
Several factors, including IL-12, IFNy, and the type I interferons (e.g. IFNa), have 
been shown to promote the development of THl-type immune responses. IL-12 is a 
recently-described heterodimeric cytokine which has been shown to strongly promote 
the differentiation of naive T cells to the TH1 phenotype and to suppress the 
expression of TH2 cytokines (Manetti et al., 1993; Hsieh et al., 1993). IL-12 is 
produced primarily by antigen-presenting cells, particularly macrophages, and appears 
to be a critical regulator of TH1-driven immune responses, greatly enhancing T cell and 
natural killer (NK) cell production of IFNy and IL-2 (Trinchieri, 1995). Reports from 
an increasing number of studies have shown that IL-12 has adjuvant effects on both 
cell-mediated and humoral immune responses when administered as a recombinant 
protein in vaccines against a variety of infectious diseases (Afonso et al., 1994; Wynn 
et al., 1995) and may also suppress potentially deleterious TH2-driven responses 
against parasites and allergens (Manetti et al., 1993; Wang et al., 1994; Marshall et al., 
1995; Gavett et al., 1995; Kips et al., 1996; Sur et al., 1996). These effects were 
mediated, in the majority of cases, via the activity of IFNy, although there is also 
evidence that IL-12 may down regulate IL-4 expression and TH2-driven immune 
responses independently of IFNy (Wang et al., 1994a; Marshall et al., 1995; Gavett et 
al., 1995). Interestingly, recent in vitro evidence supports the contention that IL-12 
may not only stimulate the development of naive T cells into TH1 cells, but may also 
rapidly convert a TH2 cell population into one predominantly containing THl-type cells 
(thus down regulating IL-4 and IL-5 production and up regulating IFNy secretion) and 
enhance antigen-specific T lymphocyte proliferation (Marshall et al., 1995; Sornasse et 
al., 1996). When used to treat allergic disease in animal models however, including 
models of allergic lung disease, only transient down regulation of allergic inflammation
was recorded following the administration of either recombinant IL-12 or IFNy protein, 
and this usually required the delivery of multiple doses of protein over several days 
(Gavett et al., 1995; Kips et al., 1996; Sur et al., 1996; Lack et al., 1996). More stable 
and long-lasting suppression of TH2 cytokine secretion may conceivably be achieved 
by sustained expression of TH1 factors at appropriate sites and times.
Gene therapy has recently been used, both experimentally and clinically, as a tool for 
modifying the progression of a number of diseases (Mulligan, et al., 1993). Work in 
our laboratory has previously shown that localised, transient cytokine gene expression, 
which was achieved following immunization of mice with a single inoculum of 
replicating vaccinia virus (VV) vectors engineered to encode cytokine genes, 
profoundly and selectively modulated host immune responses (Ramsay et al., 1994a; 
Ramshaw et al., 1997). Following immunization, the encoded cytokines were secreted 
from infected cells for the duration of infection and in amounts determined by the extent 
of virus replication. Although VV is an attractive candidate for use as a vector for the 
expression of foreign genes, this approach also has some limitations. For example, the 
wide host range of VV raises concerns about its introduction as a vector-based vaccine 
(Tartaglia et al., 1990). In addition, expression of foreign genes in recombinant VV is 
relatively short-lived because the vims is normally cleared rapidly. VV may also cause 
vaccine-associated complications, particularly in immuno-compromised individuals 
(Behbehami, 1983).
More recently, alternative, non-replicating vectors, have been developed in our 
laboratory. These have the great potential advantages of (i) long-term persistence in the 
host, and (ii) a capacity to be used for repeated immunization in the same individual, 
due largely to the fact that they elicit little or no host immunity against vector 
components. These vectors include "naked" DNA plasmids (DNA vaccines) and 
fowlpox vims (FPV), a poxvims of avian species. Both are eminently suitable for the
delivery and sustained expression of genes of choice in mammalian tissues, including 
cytokine genes. DNA vectors appear to be taken up readily by cells following their 
delivery by a number of different routes and encoded antigens under the transcriptional 
control of suitable promoters may be expressed for long periods in vivo (Donnelly et 
al., 1997). These features have laid the foundations for several immediate applications 
of DNA technology, including preventive and therapeutic vaccination and gene therapy. 
Fowlpox virus, whose replication is blocked in mammalian cells, can nevertheless 
infect mammalian tissues and express encoded genes placed under the control of early 
promoters (Taylor and Paoletti, 1988). It has been recently shown that cytokine genes 
which are encoded in DNA vaccines or fowlpox virus vectors are expressed for 
prolonged periods following immunization of mice with these constructs and have 
profound and selective effects on host immunity (Leong et al., 1994 and Ramsay et al., 
1997). In addition, encoded vaccine antigens may be detected in several tissues 
(including lungs) for at least 12 weeks (in the case of fowlpox virus) and 15 weeks 
(DNA vaccines) after inoculation. These vectors appear, therefore, to represent ideal 
vehicles for the sustained delivery of immunomodulatory factors.
In this Chapter, a murine model of allergic airways disease was established and used to 
test the efficacy of recombinant DNA and FPV vectors encoding IL-12 in suppressing 
TH2-driven inflammation and disease. The aim of these studies was to provide an 
immunological basis for the development of novel therapeutic strategies for allergic 
airways disease.
2.2 Materials and Methods
2.2.1. Mice
Seven to eight week old C57BL/6 mice were used in these experiments. The mice 
were bred under specific pathogen-free conditions in the Animal Breeding 
Establishment, John Curtin School of Medical Research, Australian National 
University.
2.2.2. Establishment of a murine model of allergic airways disease
A murine model of allergic airways disease, based on those described by Foster et al 
(1996) and Li et al (1996), was established as shown in Figure 2.1. Initially, mice 
were sensitized by two i.p. injections with 50 pg OVA (Grade V, Sigma Chemical 
Co., St. Louis, MO) in 1 mg alhydrogel (CSL Ltd., Parkville, Australia) given on 
days 0 and 12. Non-sensitized controls received 1 mg of alhydrogel in normal saline. 
On day 24, mice were anesthetized with Saffan Anaesthetic Injection (Pitman-Moore 
Inc. NSW, Australia), 1: 6 dilution, 200 pl/mouse i.v., followed by intra-tracheal 
(i.t.) challenge twice (1 week apart) with 100 pg of OVA in 50 pi PBS. Mice were 
sacrificed on day 34. Bronchoalveolar lavage fluid (BALF), lung tissue, blood smears 
and lung and spleen T cells were collected at sacrifice, and airways hyperreactivity 
(AHR) was measured as described below.
2.2.3. Assessment of blood and lung eosinophilia and lung histology
Three days after the final treatment with OVA, bronchoalveolar lavage (BAL) was 
performed by tracheal cannulation and instillation of 1 ml of normal saline into the 
lungs. Each animal was lavaged twice, with approximately 0.8 ml of fluid recovered
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per wash. The BAL fluid (BALF) was centrifuged (1500 x g at 4° C for 5 minutes),
total cell counts were made using trypan blue and 1CP cells were taken for cytospin
formal saline-fixed
(Shandon Scientific Ltd., Cheshire, UK). Sections were cut fronj^paraffin-embedded 
lung tissues for histological analysis. Blood samples were drawn from the tail vein 3 
days after the last challenge. Blood, cytospin smears were stained with May- 
Grunwald-Giemsa solution and lung sections were stained with hematoxylin-eosin for 
studies of differential counting of cells in blood, cell populations in BALF and for 
histology. 200 leukocytes were counted on each slide for blood and cytospin smears.
2.2.4. Measurement of airways hyperreactivity
Airways hyperreactivity (AHR) was measured by barometric plethysmography (Jacky, 
1978) using a whole-body barometric plethysmograph (WBP) (Buxco Electronics Inc., 
Troy, NY, USA), interfaced with a Max II analysis station (Buxco) using differential 
pressure transducers. AHR was measured as airflow obstruction caused by the 
spasmogen, ß-methacholine. Briefly, unrestrained and conscious mice were placed 
into the main chamber of the WBP and were nebulized, first with PBS as baseline 
reading, then with increasing doses (0.75 to 50 mg/ml) of ß-methacholine for 3 min for 
each nebulization through an inlet of the main chamber. Readings were taken of 
respiratory rate, tidal volume, and plethysmography and enhanced pause (Penh). 
Airways resistance is expressed as: Penh = ((Te/0.3 Tr) - 1) x (2Pef/3Pif), where Te = 
expiratory time (seconds), Tr = relaxation time (seconds), Pef = peak expiratory flow 
(millilitres), and Pif = peak inspiratory flow (millilitres/second). Penh were calculated 
over a 3 min period following each nebulization. Airways hyperreactivity was 
expressed as a multiple of increase of Penh for each concentration of ß-methacholine 
compared with Penh values after challenge with PBS alone.
2.2.5 Construction of FPV and DNA vectors
Fowlpoxvirus vectors encoding the genes for murine IL-12 and the hemagglutinin 
(HA) glycoprotein of influenza virus (FPV-IL-12) and an appropriate control virus 
(FPV-HA-X) were available in this laboratory (JCSMR, ANU). Their construction 
was based on methods described elsewhere (Boyle and Coupar, 1988a; Boyle and 
Coupar, 1988b; Leong et al., 1996). Briefly, for FPV-IL-12, chicken embryo skin 
(CES) cells were infected with FPV-M3, a tissue culture passage strain derived from a 
mild vaccine strain, at a multiplicity of infection (moi) of 0.01 for 1 hour. The 
monolayers were then transfected with 10 jig of pAF09-mIL-12 (a fowipox virus 
plasmid encoding murine IL-12) in 0.2 mg/ml DEAE-dextran (mw of 2 x 106, 
Pharmacia, NJ, USA). After 16-24 hours transfection, the monolayers were washed 
and incubated for 6-7 days in Dulbecco's minimal essential medium (DMEM), 
containing 2.5 pg/ml mycophenolic acid, 250 pg/ml xanthine, 0.1 mM hypoxanthine, 
0.4 pM aminopterine and 30 pM thymidine. After 3 cycles of growth under these 
conditions, recombinant FPV were purified by plaquing under non-selective conditions 
with 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (0.3 mg/ml, BRL) in DMEM. 
Two to three cycles of purification of blue-plaque recombinant viruses were performed 
until the virus population was homogeneous. The recombinant viruses were analysed 
by PCR (Heine and Boyle, 1993) to confirm the absence of wild type FPV-M3. The 
expression of IL-12 protein in supernatants overlying cells infected with FPV-IL-12 
was confirmed by IL-12 bioassays (A.J. Ramsay, unpublished data).
DNA vaccines encoding both p35 and p40 of murine IL-12 were also available in this 
laboratory. Brief construction details are as follows. IL-12-p35 and IL-12-p40 (from 
pEDp35 and pEDp40 respectively and both obtained from Dr.S.Wolf, Genetics 
Institute, Cambridge, MA, USA) were subcloned into the plasmid vector pIRES neo 
(CLONTECH Laboratories, Inc., CA). pIRES contains the human cytomegalovirus
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(CMV) major immediate early promoter / enhancer followed by a multiple cloning site 
(MCS) and a synthetic intron known to enhance the stability of the mRNA. The vector 
also contains the internal ribosome entry site (IRES) of the encephalomyocarditis virus 
(ECMV), which permits the translation of two open reading frames from one 
messenger RNA. The IL-12-p40 gene was excised from pED-p40 with EcoRI, end- 
filled with the Klenow fragment of DNA polymerase I and ligated into the end-filled 
BamHI site of pIRES neo. The IL-12p35 EcoRI fragment of pED-p35 had been 
similarly subcloned between the Smal and Xbal sites of pIRES neo. The resulting 
plasmid was called pIRES-IL-12. In this plasmid, IL-12 p40 and p35 genes are 
transcribed as a bicistronic mRNA. Translation of the second cistron (p35) occurs by 
internal initiation via the IRES. pIRES-IL-12 was propagated in E. coli, strain DH5a, 
in the presence of ampicillin and DNA was extracted and purified by a standard CsCl 
density gradients (Sambrook et al, 1989). Endotoxin was removed with an endotoxin 
removal system (ICN Biomedicals, Inc. Costa Mesa, CA).
2.2.6. In vivo delivery of FPV and DNA vectors
FPV were delivered intranasally to mice anesthetized with avertin. Doses of 107 plaque 
forming units (pfu) of virus were given in 40 pi gelatine saline. Liposome-mediated 
mucosal delivery of DNA vaccine was performed as described by Li et al., (1996). 
Briefly, 20 jig of plasmid DNA in 5 pi PBS was mixed with 25 pi (2 mg/ml) 
lipofectAMINE (Life Technologies, Gaithersburg, MD., USA) at room temperature for 
40 min. 20 pi of PBS was added to the mixture and mixed well before gene transfer 
via the intra-tracheal route to mice anesthetized with Saffan (Pitman-More Inc., NSW, 
Australia).
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2.2.7. Analysis of DNA- and FPV-mediated IL-12 expression in vivo
Mice were immunized as above via the i.t. route at varying time points with pIRES-EL- 
12 or control pIRESneo prior to RT-PCR analysis of IL-12 expression in vivo. Lung 
tissues were collected on days 1, 2, 3, 7, 10, 14 and 33 after gene transfer and were 
stored at -70°C. Total RNA was extracted from these tissues by homogenizing 
samples with RNAzol™ B (2 ml per 100 mg tissue) (Biotecx Laboratories Inc. TX, 
USA) in a glass-Teflon homogenenizer. 0.2 ml chloroform per 2 ml homogenate was 
added and the samples were shaken vigorously for 30 sec and kept on ice for 15 
minutes. The samples were centrifuged at 14000 x g for 15 min and the upper aqueous 
phase, containing RNA, was transferred to fresh tubes and treated with DNase I at 20 
U/50 pi for 20 min at room temperature. An equal volume of isopropanol was added 
and samples were stored at -20°C for 60 min. Samples were then centrifuged at 13000 
x g for 20 minutes at 4°C to precipitate RNA. The RNA pellet was washed with 75% 
ethanol, dried and re-suspended in diethylpyrocarbonate (DEPC) treated RNase free 
water. The absence of plasmid DNA in the RNA was confirmed by PCR using IL-12- 
p35 and EL-12-p40 primers (see below) without the reverse transcriptase (RT) reaction.
Reverse transcription of RNA was carried out using lpg (in 15 pi) of denatured RNA
in a total volume of 25 pi containing M-MLV-RT-reverse transcriptase (200 U,
Promega Corporation, WL, USA), M-MLV-RT buffer (Promega), dNTPs (each at 2.5
mM), random primer (0.5 pg, Promega), and RNasin (20U, Promega). The mix was
incubated at 37°C for 60 min, then at 90° C for 5 min and 4° C for 5 min. The cDNA
was diluted by adding 175 pi DEPC treated water. Subsequent PCR amplification was
performed using 5 pi of the above cDNA in a total volume of 20 pi, containing Taq
DNA nolvmerase (1.25U, Advanced Biotechnologies Ltd, Surrey, UK) and primers 
picomoles
(10 see below), MgCl2 (1.25 pM), PCR buffer (Advanced Biotechnologies), and
A
dNTPs (2.5 mM). Amplifications were carried out in a capillary thermal cycler
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(Corbett Research, Sydney, Australia). An initial denaturation step at 95° C for 3 min 
was followed by 30 cycles of PCR. Cycling conditions were 95° C for 30 sec, 54° C 
for 30 sec, and 72° C for 60 sec, followed by a final extension at 72° C for 5 min. 
Primers used for IL-12-p35 were 5 '-GGCT ACT AG AG AG ACTTCTTCC-3' (sense) 
and 5'-GTGAAGCAGGATGCAGAGCTTC-3' (antisense). Primers used for IL-12- 
p40 were 5'-CGTGCTCATGGCTGGTGCAAAG-3' (sense) and 5’- 
GGGGTTGTGGCAAGCTTATC-3' (antisense). Primers used for the mouse 
"housekeeping gene", hypoxanthine-guanine phosphoribosyl transferase (HPRT) as a 
control, were 5'-GTTGGATACAGGCCAAGACTTTGTTG-3' (sense) and 5'- 
GATTCAACTTGCGCTCATCTTAGGC-3 ’ (antisense). 10 pg of pEL-12-p35 or pIL- 
12-p40 DNA (in the vector pJW4303, see Section 3.2.2) were used as positive 
controls, and DEPC-treated water was used as a negative control template in the PCR 
reaction. The primers used for PCR amplification of p40 mRNA were designed such 
that only plasmid-derived IL-12 mRNA was detected and not endogenous mRNA (the 
anti-sense primer is located in the plasmid vector). The p35 primers, however, 
amplified both plasmid-derived and endogenous transcripts.
Southern blot hybridization was carried out to detect and confirm the specificity of the 
PCR products. In brief, the PCR products were electrophoresed on a 2% agarose gel 
and transferred onto a nylon membrane (GeneScreen Plus, Dupont, MA.USA) by 
capillary blotting under alkaline conditions (0.4 M NaOH). The membrane was then 
blocked with 1.0% (w/v) skim milk in 5 ml of pre-hybridization buffer (5 x SSC, 
containing 0.03M Na3Citrate, 0.75 M NaCl and 0.1% SDS) at 42° C for 2 hours. 
FITC-labelled DNA probe (5 ng/ml, see below) was added to the pre-hybridization 
buffer and incubated at 42° C for 2 hours. The blot was washed twice with 5 x SSC, 
then twice with 1 x SSC, blocked, as above, at room temperature for 1 hour and then 
washed in 0.15M NaCl and 0.1 M Tris (pH 7.5). Anti-FITC-horse radish peroxidase 
(HRP) conjugate was added at 1: 1000 dilution in buffer A (0.5% BSA, 0.4 M NaCl
and 0.1 M Tris pH 7.5). The blot was washed 3 times with buffer A. Signal detection 
was carried out with the ECL DNA detection system (Amersham, UK). Briefly, the 
blot was incubated in detection solution for 1 minute and then exposed to Kodak 
autoradiography film for 3 min. The following probes were used:
I L - 12 -p35 , 5 ’-G C A G A T C A T T C T A G A C A A G G G C -3\ IL -1 2 -p 4 0 , 5 ’-
TCTGTCTGCAGAGAAGGTCACA-3', HPRT 5’-GTTGTTGGATTGCCCTTGAC- 
3 ’.
Sera from mice given DNA or FPV vectors encoding IL-12, or control vectors, were 
taken at different time points both prior to or following allergen challenge and analysed 
for the presence of IL-12 by ELISA (see Section 5.2.8)
2.2.8. Preparation of CD4+ T cell populations from lung and spleen
Mice were anesthetized with ketamine and Rompun and their lungs perfused with 1 ml 
of collagenase (0.1% in PBS) injected through the trachea. Tracheae were tied with 
surgical sutures and the lungs were removed immediately and incubated at 37°C in 
HBSS medium for 60 min. Spleens were also collected into HBSS. Organs were then 
gently homogenized, filtered through sterile surgical gauze, red blood cells were lysed 
by osmotic shock and the preparations were centrifuged (1500 x g for 10 min) and 
resuspended in DMEM containing 5% FCS (complete medium). The cell preparations 
were labelled with L3T4 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) 
and passed through MiniMACS Separation Columns (Miltenyi Biotec). Eluates were 
shown by flow cytometry to comprise >95% CD4+ T cells.
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2.2.9. Flow cytometry for CD4-enriched and CD4-depleted cells
1C)6 CD4-enriched and CD4-depleted cells from spleen or lung were resuspended in 50 
pi PBS. 10 pi biotinylated anti-CD4 antibodies (Biosource International, Camarillo, 
CA, USA) was added and the cells were incubated on ice for 20 min, washed and 
resuspended in 50 pi PBS. Biotinylated antibodies were detected by incubation with 
FITC-streptavidin (Amersham International Inc., UK) on ice for 20 min. Cells were 
washed and resuspended in 0.25 ml cold PBS for flow cytometry. Labelled samples 
were analysed on a FACS 440 Flow Cytometer (Becton Dickinson Immunocytometry 
System, CA, USA). Analyses of data were performed using PC-LYSYS software 
version 1.0 (Becton Dickinson).
2.2.10. Determination of cytokine production by CD4+ T cells
Purified CD4+ T cell populations were cultured at 5x10^ cells/well in complete medium 
on anti-CD3 mAb-coated 96-well microtiter plates (Nunc, Roskilde, Denmark) at 37°C 
in an atmosphere containing 5% CO2 for 72 hours (mAb 2C11 at 50 pg/ml, a gift from 
S. Hogan, JCSMR, ANU). Supernatants were then harvested for determination of 
IL-4, IL-5 and IFNy production by ELISA. The antibody pairs used for cytokine 
detection were as follows: EL-4, 11B11 (5 pg/ml for coating; ATCC, Rockville, MD, 
USA) and biotinylated BVD6-24G2 (625ng/ml; PharMingen, San Diego, CA, USA); 
IL-5, TRFK-5 (2 pg/m l for coating; a gift from S. Chin, JCSMR, ANU) and 
biotinylated TRFK-4 (1.2 pg/ml; PharMingen); and IFNy, R4-6A2 (5 pg/ml for 
coating; ATCC) and a polyclonal rabbit anti-mouse IFNy antibody (1/500 dilution; 
from A.J. Ramsay, JCSMR, ANU). Subsequently, for IL-4 and IL-5 detection, 
streptavidin-HRP (1/1000 dilution, SeroTec, Oxford, UK) was added for 1 hour 
followed by the addition of 50 pi per well of substrate solution (Kirkegaard & Perry 
Laboratories, MA). For IFNy detection, alkaline phosphatase-conjugated sheep anti-
rabbit lg (1/1000 dilution, Silenus, Hawthorn, Australia) was added for 1 hour and the 
colour reaction was developed by the addition of a solution prepared by dissolving 
phosphatase substrate tablets (Sigma Chemical Co., MO, USA) in alkaline phosphatase 
substrate buffer (Sigma). Optical density was measured at 405 nm after 20 min 
incubation. Purified murine IL-4 (400U/ml), IL-5 (200 U/ml) and IFNy (100 U/ml) 
(A.J. Ramsay, JCSMR, ANU) were used for the generation of standard curves.
2.2.11. Determination of OVA-specific immunoglobulins
Blood samples were taken 3 days after the final allergen challenge and serum anti-OVA 
IgGl, IgG2a and IgE antibody levels were determined by ELISA. Briefly, plates were 
coated with OVA protein at 1 mg/ml, 50 pl/well in bicarbonate buffer (PH9.6) at 4°C 
overnight. Unlabelled anti-IgGl (0.2ug/ml), anti-IgG2a (lug/ml) or anti-IgE (lug/ml) 
were also coated onto plates to capture immunoglobulin standards. All subsequent 
steps were performed at room temperature with 50 pi of reagent per well. The wells 
were washed 5 times with PBS-0.1% Tween (PBST) after each reaction. The plates 
were then blocked with PBST containing 3% bovine serum albumin (BSA) for 2 
hours. Serum samples were added for 1.5 hours. Purified murine isotype standards 
(Biosource International, Camarillo, CA, USA), i.e. IgGl (100ng/ml), or IgG2a 
(100ng/ml) or IgE (500ng/ml), were used in serial dilutions. Biotinylated goat anti­
mouse IgGl (0.5 pg/ml) or IgG2a (4 ug/ml) (Biosource International), or rat anti­
mouse IgE (5ug/ml) (PharMingen), were then added to appropriate wells and incubated 
for 1 hour followed by the addition of appropriate alkaline phosphatase-antibody 
conjugates (1:1000, Biosource International) for a further 1 hour. Assays were 
developed by using a solution prepared by dissolving phosphatase substrate tablets 
(Sigma) in alkaline phosphatase substrate buffer (Sigma). Optical density was 
measured at 405 nm after 20 min of incubation using a THERMOmax Reader 
(Molecular Devices, CA, USA).
2.2.12. Statistical Analyses
Data were expressed as mean ±  SEM and differences between experimental groups 
within each experiment were analyzed using the unpaired Student's t-test.
2.3. Results
2.3.1. A murine model of allergic airways disease
A murine model of allergic airways disease was established for use in these studies as 
described in Materials and Methods. Intra-tracheal challenge of mice which had been 
sensitized with OVA resulted in a massive increase in numbers of eosinophils in BALF 
in comparison to control mice given saline, in which no eosinophils were detected 
(Table 2.1). Numbers of neutrophils and lymphocytes were also increased in allergen- 
treated animals. The marked increases in eosinophil numbers in BALF prompted an 
examination of blood eosinophilia. In this model, however, numbers of eosinophils in 
the circulation were not significantly elevated over the baseline levels seen in mice 
treated with saline (Figure 2.2). Histological examination of lung tissues from mice 
given OVA showed extensive eosinophilic inflammation around the airways and 
correlated with gross alterations in the structural integrity of airway walls, epithelial cell 
shedding, microvascular leakage and mucosal edema (Figure 2.4) whilst those from 
control mice showed clear airways and normal lung tissue (Figure 2.3). Airways 
inflammation following allergen challenge was also associated with significant 
increases in AHR over that seen in control mice (Figure 2.5). Thus, the allergic 
airways disease generated in this mouse model is characterized by airways 
eosinophilia, airways hyperreactivity and extensive tissue damage in the lung.
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2.3.2. Mucosal delivery of FPV-IL-12 prior to allergen challenge 
suppresses the development of allergic airways disease
To study whether mucosal delivery of IL-12 by FPV could reverse the airways 
inflammation and disease observed following allergen treatment in this model, OVA- 
sensitized mice were given FPV-IL-12 or control virus (FPV-HA-X), on day 22, 2 
days prior to i.t. challenge as shown in Figure 2.6. Mice given the control FPV prior 
to challenge developed all of the symptoms of allergic airways disease as described 
above in sensitized mice which had been challenged with OVA but not given control 
virus. These symptoms included marked increases in eosinophil numbers in BALF 
(Figure 2.7), histopathological changes in the lung (gross alterations in the structural 
integrity of the airway walls, microvascular leakage, mucosal edema and particulate 
exudation in the lumina of airways) (Figure 2.8 A and B) and AHR to ß-methacholine 
(Figure 2.9). In sharp contrast, the mice given FPV-IL-12 had significantly lower 
levels of eosinophilia in BALF (Figure 2.7), whilst histologically, their lungs showed 
clear airways with no signs of disease (Figure 2.8 C and D), resembling those seen in 
saline-treated mice (Figure 2.3). Levels of AHR to ß-methacholine in FPV-IL-12- 
treated mice were similar to the baseline levels found in control mice treated with saline 
(Figure 2.9). Thus, administration of FPV-encoded IL-12 prior to allergen challenge 
in sensitized mice prevented the development of the major symptoms of allergic 
airways disease.
To address possible mechanisms of IL-12-mediated inhibition of allergic disease in this 
model, cytokine secretion profiles of CD4+ T cells from lung and spleen were 
analysed. Given the strong correlation between markedly increased local production of 
TH2 cytokines and disease, particularly IL-5 and eosinophilia, it was important to 
determine whether the secretion of these factors was altered following IL-12 gene 
delivery. Mice which had been given FPV-IL-12 produced significantly higher levels
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of EFNy in the lungs and spleen (Figure 2.10 A and D) compared to mice treated with 
control virus. In contrast, lung T cells from these mice produced lower levels of IL-5 
(Figure 2.10 C). IL-4 production in the lung was not altered following treatment with 
FPV-IL-12 (Figure 2.10 B). IL-4 and IL-5 production by splenic T cells was below 
the limits of detection (Figure 2.10 E and F).
Serum levels of OVA-specific antibodies were also measured in order to examine 
whether these changes in cytokine profiles were reflected in the antibody isotype 
profiles. As shown in Figure 2.11, IgGl production was significantly reduced in mice 
given FPV-IL-12, whereas IgG2a and IgE levels were similar to those measured in 
animals given FPV-HA-X.
Thus, mucosal delivery of EL-12 encoded by FPV two days prior to allergen challenge 
effectively suppressed allergic airways disease in sensitized mice. Prevention of 
disease development correlated with upregulated local and systemic EFNy secretion and 
suppression of IL-5 production in the lungs, although EL-4 levels were not apparently 
reduced.
2.3.3. Longer-term protective effects of FPV-IL-12
The demonstrated persistence of FPV following immunization prompted a further study 
of possible longer-term protection against allergic airways disease. In these 
experiments, sensitized mice were treated intranasally with FPV-IL-12 and challenged 
with OVA after an interval of 4 weeks (Figure 2.6). The results showed that mice 
given FPV-IL-12 had decreased levels of eosinophilia in BALF (Figure 2.12), whilst 
AHR to ß-methacholine was detected above baseline levels only in mice given the 
control virus (Figure 2.13). Analyses of cytokine secretion profiles revealed 
significant increases in IFNy production by both lung and splenic T cells from mice
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given FPV-IL-12, however, levels of EL-4 and IL-5 production were not significantly 
altered (Figure 2.14). Titres of OVA-specific IgG l, IgE and IgG2a serum antibodies 
in mice given FPV-IL-12 were not significantly different from those found in mice 
treated with control vector (Figure 2.15).
In summary, FPV-mediated delivery of IL-12 provided effective suppression of 
allergic airways disease for a prolonged period. Indeed, a single dose of the FPV-IL- 
12 construct to sensitized mice prior to allergen challenge markedly reduced 
eosinophilic inflammation in the lung and prevented the development both of the 
histopathological changes associated with disease and AHR. Interestingly, IFNy 
production by lung T cells taken at this stage was elevated in mice which had been 
given FPV-IL-12, although TH2 cytokine secretion did not appear to be suppressed.
2.3.4. Expression of pIRES-IL-12 mRNA
DNA vaccination is now widely thought to represent another promising approach for 
sustained in vivo delivery of molecules of biological importance. In light of the 
success of FPV-mediated IL-12 gene delivery in suppressing the development of 
allergic airways disease, it was decided to generate DNA vaccine plasmids encoding 
this factor and to test their protective capacity in the murine model. Initially, pERES-EL- 
12 was constructed (see Section 2.2.5) and the duration of IL-12 gene expression in 
murine lung tissues following intra-tracheal delivery was determined using RT-PCR. 
Expression of both genes was high on days 1, 2 and 3 after immunization and 
gradually decreased thereafter, although could still clearly be detected as late as 33 days 
after inoculation (Figure 2.16). HPRT gene expression levels remained constant, 
indicating that the observed decreases in IL-12-p35 and IL-12-p40 mRNA levels 
reflected decreased gene expression. The specificity of the assay was confirmed by 
Southern hybridization analysis using gene-specific internal primers. These results
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showed that mucosal delivery of pIRES-IL-12 resulted in relatively long-term 
expression of IL-12 mRNA in the lung.
2.3.5. Mucosal delivery of pIRES-IL-12 prior to allergen challenge 
suppresses the development of allergic airways disease
Next, to study whether DNA vaccine-mediated delivery of IL-12 could also effectively 
suppress airways inflammation and AHR following OVA treatment, sensitized mice 
were immunized with pIRES-DL-12 two days before challenge. As shown in Figure 
2.17, mice given the IL-12 DNA vaccine had significantly lower numbers of 
eosinophils in BALF compared to mice given control pIRES. Levels of AHR to ß- 
methacholine were also markedly inhibited, indeed, they were similar to the baseline 
levels observed in controls (Figure 2.18). Histological examination of lung tissues 
from mice treated with pIRES-IL-12 revealed minimal morphological changes, similar 
to those shown above in mice given FPV-IL-12 (data not shown).
Studies of cytokine secretion profiles showed that IFNy production by lung and splenic 
T cells was significantly increased in mice given pIRES-IL-12 (Figure 2.19 A and D). 
In contrast, levels of IL-5, but not of IL-4, in the lung were somewhat lower 
compared to mice treated with control vector (Figure 2.19 C and B), whilst neither of 
these factors was detected in the spleen (Figure 2.19 E and F). No significant changes 
in OVA-specific serum antibody isotype profiles were observed in mice given pIRES- 
EL-12 (Figure 2.20).
These results clearly demonstrate that mucosal delivery of a DNA vaccine encoding IL- 
12 was protective against the development of allergic airways disease in sensitized 
mice. This was associated with increased levels of IFNy production and some 
diminution of local IL-5 production.
2.3.6. Longer-term protective effects of pIRES-IL-12
RT-PCR analyses of lung tissues from mice which had been given pIRES-IL-12 i.t., 
but were otherwise untreated, had shown that IL-12 mRNA was expressed up to 33 
days after gene transfer, albeit at reduced levels (Figure 2.16). To determine whether 
this correlated with prolonged protection against the development of allergic airways 
disease, OVA-sensitized mice were given the EL-12 plasmid i.t., challenged with OVA 
four weeks later and sacrificed on day 33 after immunization. The results indicated 
that, unlike FPV-IL-12, pIRES-IL-12 failed to provide longer-term protection against 
the development of disease in this model. Similar levels of airways eosinophilia 
(Figure 2.21) AHR to ß-methacholine (Figure 2.22) and OVA-specific serum antibody 
isotypes (Figure 2.23) were seen in mice given the IL-12 or control plasmids, whilst 
there was no evidence for enhanced local or systemic TH1 cytokine secretion or 
suppressed TH2 cytokine production (Figure 2.24). It appears, therefore, that this 
DNA vaccine, whilst clearly effective when given two days prior to allergen challenge, 
may have been unable to sustain sufficient levels of production of IL-12 to provide the 
longer-term protective effects which were mediated by the FPV-IL-12 construct in this 
model.
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2.4. Discussion
In this Chapter, a murine model of allergic airways disease was established and used to 
test the protective efficacy of DNA vaccine- and fowlpoxvirus vector-mediated mucosal 
IL-12 gene transfer against the development of disease in sensitized individuals. It was 
shown that mucosal delivery of a single inoculum of either of these constructs to 
allergen-sensitized mice mediated protection against the development of eosinophilic 
airways inflammation, airways hyperreactivity and lung damage induced by challenge 
with allergen. Furthermore, the FPV-IL-12 construct provided protection against 
disease for at least four weeks after delivery. Inhibition of disease correlated with 
marked enhancement of TH1 immune responses (characterized by EFNy production), 
both locally and systemically, and significant decreases in the production of IL-5, but 
not of IL-4, in the lung.
Previous studies have shown that repeated instillation of recombinant IL-12 (Gavett et 
al., 1995; Kips et al., 1996; Sur et al., 1996a) or IFNy (Nakajima et al., 1993; Lack et 
al. , 1996), either intra-peritoneally or into the lung, inhibited airways inflammation 
and, in some instances, AHR. However, repeated doses over intervals ranging from 
5-13 days were required for these protective effects. Subsequent studies from this 
laboratory demonstrated that recombinant vaccinia virus-mediated delivery of IL-12 
was also highly effective for the suppression of allergic airways disease (Hogan et al., 
1998). In the present study, this work has been extended to show that the use of 
relatively persistent, non-replicating, and therefore potentially safer, recombinant 
vectors to deliver IL-12 is effective in protection against the development of disease for 
at least four weeks after immunization.
The effectiveness of FPV as a delivery vehicle for the sustained production of IL-12 
may be related to certain biological characteristics of the virus. FPV has a narrow host
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range (Tripathy et al., 1975) and infection in non-avian species is abortive, with no 
viral progeny being produced (Taylor et al., 1988). However, inserted foreign genes 
under the transcriptional control of early virus promoters are expressed soon after 
infection (Taylor et al., 1988; Cox et al., 1993). The abortive nature of FPV infection 
in mammalian species may also account for the sustained expression of encoded genes 
and the capacity for repeated use, in that little in the way of host immune responses 
against the virus itself are mounted due to the lack of production of virus structural 
proteins. It should be noted that whilst FPV-IL-12 produced high levels of IL-12 in 
vitro, levels in sera from mice given intranasal inocula of this construct were 
consistently undetectable in our ELISA. Previous studies in this laboratory have 
shown that recombinant poxvirus vectors engineered to express a variety of different 
cytokine genes often do not generate detectable levels of the encoded factors in sera, 
but nervertheless mediate a wide range of profound immunological effects due to 
localized production at or near sites of infection (Ramshaw et al., 1992; Ramsay et al., 
1994).
DNA plasmids are now regarded as having many advantages over conventional 
vaccines and most gene delivery vehicles (Liu et a i, 1997; Ulmer et al., 1996), 
particularly relating to their capacity, as with FPV, for sustained delivery of encoded 
genes and repeated use in the same individual. Indeed, recently published studies have 
already demonstrated some therapeutic efficacy of DNA vaccination in animal models 
of allergic disease (Hsu et al., 1996a and 1996b; Raz et al., 1996; Li et al., 1996). 
However, potential disadvantages, particularly for mucosal delivery, include 
difficulties associated with targeting and uptake of DNA vaccines in vivo. In the 
present study, DNA-mediated IL-12 gene transfer was highly effective in suppressing 
airways disease in the short-term when given intra-tracheally as a suspension in a 
cationic lipid solution (lipofectamine). A considerable body of work has now 
accumulated in which such compounds have been used in attempts to enhance cellular
uptake of DNA in the lung in a variety of animal disease models (Alton et a l ,  1993; 
Feigner, et al., 1995; Hyde et a l,  1993; Stribling et al., 1992; Li et a l ,  1996). The 
present data indicate that this also represents an effective strategy for enhancing EL-12 
gene transfer into lung tissues. However, despite sustained expression of vector- 
directed EL-12 mRNA for at least 33 days after delivery, it was apparent that pERES-EL- 
12 was unable to mediate longer-term protection against disease if allergen challenge 
was delayed for 4 weeks. It is likely that the diminished levels of IL-12 gene 
expression seen by this stage, possibly due to a gradual loss of the plasmid through 
attrition of transfected cells or to down-regulation of promoter activity in vivo 
(Wheeler et al., 1996), were insufficient to prevent the development of disease 
following the delayed challenge. This is supported by the similarities in levels of 
CD4+ T cell production of TH1 and TH2 cytokines found in treated and control mice 
by this stage.
The protective effects of vector-mediated EL-12 delivery against allergic airways disease 
correlated with local and systemic upregulation of IFNy production and local 
suppression of EL-5 production. It is likely that mucosal IL-12 gene transfer promoted 
the development or recruitment of THl-type lung T cells resulting in the down- 
regulation of IL-5, but not IL-4, expression. These factors have been strongly 
implicated in the pathogenesis of allergic airways disease through their influence on IgE 
production, mast cell activity and eosinophil development and function (Geha et al., 
1992; Sanderson et a l ,  1986; Foster et a l ,  1996). In particular, IL-5 regulates 
eosinophil differentiation (Sanderson et al., 1986) and these cells are critical mediators 
of allergic airways disease in this model (Foster et a l, 1996).
Down-regulation of the production of EL-5, but not IL-4, by vector-directed IL-12 is 
consistent with earlier work in a murine model of allergic disease, in which 
administration of recombinant IL-12 protein up-regulated IFNy, down-regulated IL-5,
but did not change IL-4 production (Sur et al., 1996). Indeed, IL-4 and IL-5 are not 
always co-ordinately produced (Sewell and Mu, 1996). For example, different 
adjuvants may selectively stimulate EL-4 or IL-5 production. Pertussis toxin plus OVA 
induces IL-5 but not EL-4 expression, whilst cyclophosphamide plus OVA induces EL- 
4 but not IL-5 (Mu and Sewell, 1993; Mu et a l, 1993). IL-4 is a key cytokine 
promoting the development of TH2 responses and the production of TH2 cytokines, 
but is not mandatory for EL-5 production. In a model of helminth infection, immuno- 
neutralization of IL-4 abolishes the IgE response but has no effect on eosinophilia 
(Coffman et a l, 1989), suggesting that IL-5 continued to induce eosinophilia in the 
absence of EL-4. In addition, there is ample evidence that the expression of different 
cytokines can be regulated independently in individual cells (Assenmacher et al., 1994; 
Bucy et al., 1994; Kelso, 1995).
The production of OVA-specific antibodies of the IgGl isotype was suppressed in mice 
treated with pIRES-IL-12 or FPV-IL-12. This could be due to increased IFNy 
production, as this factor has been shown to inhibit TH2 cytokine-driven antibody 
synthesis (Coyle et al., 1996b). However, IgE production in the sensitized animals 
was maintained in the face of treatment with either vector, despite the suppression of 
allergic disease. It has previously been shown, in a murine allergy model, that 
administration of IL-12 during sensitization inhibited IgE production, but had no such 
effects when given to sensitized mice (Kips et al., 1996). It is also known that EL-12 
may directly suppress IgE synthesis by IL-4-stimulated human lymphocytes through 
inhibition of the development of precursor B cells into IgE-producing cells, rather than 
blocking the expansion of committed IgE producers (Kiniwa et al., 1992).
The suppressive effects of IFNy on TH2 cell development in vitro and in vivo have 
been widely reported (Hogan et al., 1998; Gajewski and Fitch, 1988; Wang et al, 
1994), although the mechanisms underlying this activity remain to be clarified. A
possible mode of action might related to the capacity of IFNy to regulate the expression 
of co-stimulatory molecules on local antigen-presenting cell populations (Harris et al., 
1997a and 1997b). Notwithstanding this uncertainty, the central role of IFNy in 
mediating the protective effects of vector-directed IL-12 have recently been 
demonstrated in this laboratory by the establishment of our model in EFNy-receptor- 
deficient mice (Hogan et al., 1998). IL-12-mediated protection from disease was 
greatly diminished, although not ablated, in the mutant animals. Despite these 
findings, the use of EL-12 in our delivery vectors may represent a superior approach to 
IFNy delivery, due to the much greater half-life of the former in body fluids and the 
added potential for IFNy-independent inhibitory effects on TH2-driven immune 
responses and inflammatory cell populations (Wang et a l ,  1994; Marshall et al., 
1995), in addition to its capacity for upregulating TH1 cell development and IFNy 
production (Trinchieri, 1995)
In conclusion, the studies presented in this Chapter have shown that DNA vaccine- or 
FPV-mediated mucosal delivery of IL-12 effectively inhibits the development of 
allergic airways inflammation, AHR and lung damage in sensitized mice. Protection 
from disease correlated with upregulation of local and systemic IFNy secretion and 
down-regulation of IL-5 production. Further possible protective effects of IL-12, 
mediated either via IFNy upregulation or independently of this factor, particularly its 
influence on inflammatory cell development, will be addressed in Chapter 4. The 
vectors used in the present study clearly represent potentially safe and persistent 
vehicles for the delivery of immuno-modulatory genes and other genes of biological 
importance. In the next Chapter, the protective capacity of DNA vaccine plasmids as 
preventive vaccines against allergic airways disease in naive rather than sensitized
individuals will be studied.
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Figure 2.2 Eosinophils in blood after intra-tracheal challenge with OVA or 
saline
Mice were sensitized and challenged as described in Section 2.2.2. Blood smears 
were taken at 3 days after the last challenge and eosinophils enumerated 
following staining with May-Grunwald-Giemsa solution. Data represent the 
mean + SEM for groups of five mice and are representative of two experiments
Figure 2.3. Histological analysis of lung sections from control mice
Mice were sensitized and challenged with saline as described in Section 2.2.2 
and shown in Figure 2.1. Lungs were removed for histological analysis 3 days 
after the second challenge and stained with hematoxylin-eosin. A (x 50) and B 
(xl60): showing clear airways and normal lung tissue. Sections are 
representative of at least 4 mice per group.
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Figure 2.4. Histological analysis of lung sections from mice sensitized and 
challenged with OVA
Mice were sensitized and challenged with OVA as described in Section 2.2.2 and 
shown in Figure 2.1. Lungs were removed for histological analysis 3 days after the 
second challenge and stained with hematoxylin-eosin. A (x 50) shows inflammatory 
infiltration around airways (a) originating from pulmonary blood vessels (v), gross 
alterations in structural integrity of airway walls and parenchyma, epithelial cell 
shedding and mucus blockage of airways (b). B (x 250) shows more detail of 
breakdown of airways epithilium and mucus and cellular blockage of airways. C (x 
400) shows predominance of eosinophils (e) in the inflammatory infiltrate. Sections 
are representative of at least 4 mice per group.
ß-methacholine (mg/ml)
Figure 2.5 Airways hyperreactivity to ß-methacholine after intra-tracheal 
challenge with OVA or saline
Mice were sensitized and challenged as described in Section 2.2.2. Airways 
hyperreactivity was measured against ß-methacholine (0.75-25 mg/ml) using 
whole body plethysmography at 3 days after challenge. Penh is a calculated 
measure of bronchospasm (see Section 2.2.4). Data represent the mean ± SEM of 
Penh values in percentages over PBS baseline Penh values for groups of five 
mice and are representative of two experiments. *p<0.05 compared to mice 
treated with saline.
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Figure 2.7 Eosinophils in BALF from mice immunized i.n. with FPV-IL-12 
and challenged with OVA
Mice were sensitized and challenged as described in Section 2.2.2. FPV-IL-12 
or FPV-HA-X control virus were given i.n. 2 days before challenge. BAL was 
performed after sacrifice and eosinophils in BALF enumerated on cytospin 
smears stained with May-Grunwald-Giemsa solution. Data represent the mean ± 
SEM for groups of five mice and are representative of two experiments. *p<0.05 
compared to mice immunized with FPV-HA-X and challenged with OVA.
Figure 2.8 Histological analysis of lung sections from sensitized and 
allergen-challenged mice given FPV-HA-X or FPV-IL-12 (overleaf)
Mice were sensitized, immunized and challenged as described in Section 2.2.2 
and shown in Figure 2.6. Lungs were removed for histological analysis 3 days 
after the second challenge and stained with hematoxylin-eosin. A (x 50) and B 
(x 250): mice treated with FPV-HA-X showed diseased airways as described 
for Figures 2.4 A and B. C (x 100) and D (x 250): mice treated with FPV-IL- 
12 showed clear airways with no signs of disease. Sections are representative 
of at least 4 mice per group.
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Figure 2.9 Airways hyperreactivity to ß-methacholine in mice given FPV- 
IL-12
Mice were sensitized and challenged as described in Section 2.2.2. FPV-IL-12 
or FPV-HA-X were given i.n. 2 days before challenge. Control mice were 
treated with saline. Airways hyperreactivity was measured against ß- 
methacholine (0.75-25 mg/ml) using whole body plethysmography 3 days after 
challenge. Results represent the mean + SEM of Penh values in percentages 
over PBS baseline Penh values for groups of five mice and are representative of 
two experiments. *p<0.05 compared to mice immunised with FPV-IL-12 or 
saline-treated mice.
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Figure 2.12 Eosinophil numbers in BALF from mice immunized with FPV- 
IL-12 four weeks before OVA challenge
Mice were sensitized and challenged as described in Section 2.2.2 and Figure 2.6 
and were given FPV-IL-12 or FPV-HA-X i.n. at 10 days after the second 
sensitization. Mice were challenged i.t. with OVA at 4 weeks after 
immunization. BAL was performed 3 days after the second OVA challenge and 
eosinophils in BALF enumerated on cytospin smears stained with May- 
Grunwald-Giemsa solution. Data represent the mean ± SEM for groups of five 
mice and are representative of two experiments. * p<0.05 compared to mice 
immunized with FPV-HA-X and challenged with OVA.
ß-methacholine (mg/ml)
Figure 2.13 Airways hyperreactivity to ß-methacholine in mice immunized 
with FPV-IL-12 four weeks before OVA challenge
Mice were sensitized and challenged as described in Section 2.2.2 and Figure 2.6 
and were given FPV-IL-12 or FPV-HA-X i.n. at 10 days after the second 
sensitization. Mice were challenged i.t. with OVA at 4 weeks after 
immunization. Control mice were treated with saline. Airways hyperreactivity 
was measured against ß-methacholine (0.75-50 mg/ml) using whole body 
plethysmography 3 days after the challenge. Results represent the mean + SEM 
of Penh values in percentages over PBS baseline Penh values for groups of five 
mice and are representative of two experiments. *p<0.05 compared to mice 
immunized with FPV-IL-12 or saline-treated mice.
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Figure 2.16 RT-PCR/Southern blot analysis of IL-12 mRNA expression in 
lung tissues after intra-tracheal immunization with pIRES-IL-12
Lung tissues were collected at different time points after DNA immunization. 
Extraction of total RNAs and RT-PCR were carried out as described in Section 
2.2.7. The PCR products were electrophoresed, transferred to membrane and 
hybridized with FITC-labelled DNA probes. The signals were detected using 
ECL DNA detection systems. No expression was observed in mice immunized 
with control vector (pIRES) at each time point (data not s h o w n ) . 10 pg of 
pJW-IL-12p35 or pJW-IL-12p40 used as positive control. DEPC treated 
water used as negative control. The result at each time point is representative of 
groups of 3 mice.
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Figure 2.17 Eosinophils in BALF from mice immunized i.t. with 
pIRES-IL-12 and challenged with OVA
Mice were sensitized and challenged as described in Section 2.2.2. pIRES-IL-12 
or pIRES were given i.t. 2 days before challenge. BAL was performed after 
sacrifice and eosinophils in BALF enumerated on cytospin smears stained with 
May-Grunwald-Giemsa solution. Data represent the mean ± SEM for groups of 
five mice and are representative of two experiments. *p<0.05 compared to mice 
immunized with pIRES and challenged with OVA.
2000 1
1000 -
0.7 1.5 3 6 12 25 50
saline control
pIRES
plRES-IL-12
ß-methacholine (mg/ml)
Figure 2.18 Airways hyperreactivity to ß-methacholine in mice given 
pIRES-IL-12
Mice were sensitized and challenged as described in Section 2.2.2. pIRES-IL-12 
or pIRES were given i.t. 2 days before the first OVA challenge. Control mice 
were treated with saline. Airways hyperreactivity was measured against ß- 
methacholine (0.75-50 mg/ml) using whole body plethysmography 3 days after 
the challenge. Results represent the mean + SEM of Penh values in percentages 
over PBS baseline Penh values for groups of five mice and are representative of 
two experiments. *p<0.05 compared to mice immunised with pIRES-IL-12 or 
saline-treated mice.
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Figure 2.21 Eosinophil numbers in BALF from mice immunized with 
pIRES-IL-12 four weeks before OVA challenge
Mice were sensitized and challenged as described in Section 2.2.2 and Figure 2.6 
and were given pIRES-IL-12 or pIRES i.t. at 10 days after the second 
sensitization. Mice were challenged i.t. with OVA at 4 weeks after 
immunization. BAL was performed 3 days after the second OVA challenge and 
eosinophils in BALF enumerated on cytospin smears stained with May- 
Grunwald-Giemsa solution. Data represent the mean ± SEM for groups of five 
mice and are representative of two experiments.
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Figure 2.22 Airways hyperreactivity to ß-methacholine in mice immunized 
with pIRES-IL-12 four weeks before OVA challenge
Mice were sensitized and challenged as described in Section 2.2.2 and Figure 
2.6 and were given pIRES-IL-12 or pIRES i.t. at 10 days after the second 
sensitization. Mice were challenged i.t. with OVA at 4 weeks after 
immunization. Control mice were treated with saline. Airways hyperreactivity 
was measured against ß-methacholine (0.75-50 mg/ml) using whole body 
plethysmography 3 days after the last challenge. Results represent the mean ± 
SEM of Penh values in percentages over PBS baseline Penh values for groups of 
five mice and are representative of two experiments.
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Chapter 3
Neonatal DNA vaccination for protection against 
allergic airways disease in adult life
3.1. Introduction
Initial exposure to environmental allergens occurs during late intrauterine life or in 
infancy and it is generally agreed that high level allergen exposure during this time 
leads to sensitization (Holt et al., 1990). Specific T cell responses are initiated at this 
stage and may determine whether individuals become atopic. The selection of 
appropriate T cell expansion occurs during the early stages of an immune response and 
is driven by antigen. If antigen-specific T cell selection favours the development of 
TH1 cells, IL-2 and IFNy are induced. In contrast, if TH2 cells expand, IL-4 and EL- 
5 are produced, which can lead to IgE production, eosinophilia and allergic disease. 
Thus, early childhood is an important period in the development of allergic responses 
to environmental antigens. Active intervention by neonatal immunization to drive 
allergen-specific T cell selection towards allergen-specific THl-type immunity may, 
therefore, be an effective strategy to protect infants from allergic sensitization in early 
life and the later development of allergic diseases. Alternatively, neonatal delivery of 
allergen might prevent the development of allergic disease by inducing neonatal 
tolerance.
The concept of immunological tolerance was first proposed by Burnet and Fenner 
(1949) and soon after that Billingham and colleagues (1956) showed that newborn 
mice injected with allogeneic hematopoietic cells failed to reject allografts, suggesting 
that these neonates had become "tolerant" to the alloantigen. Subsequently, neonatal B 
cell unresponsiveness (Fernandez and Möller, 1978; Lawton et al, 1972) and neonatal 
T cell tolerance (Yong and Atassi, 1983; Gammon et al., 1986; Qin et al., 1989) have 
been demonstrated by several investigators. The induction of neonatal tolerance to 
foreign antigens is probably due to the distinctive neonatal immunological 
characteristics of immunodeficiency, immaturity and the presence of maternal 
antibodies (Siegrist, 1997). Nevertheless, many studies have demonstrated that
neonates are able to mount both humoral and cellular immune responses under certain 
conditions. Howard and Hale (1976) first observed the induction of humoral 
responses (i.e. a lack of tolerance) following injection of polysaccharide antigens into 
neonates, whilst the administration of myelin basic protein to immunologically primed 
neonates enhanced experimental autoimmune encephalomyelitis (EAE) (Miller et al., 
1994). In infectious disease models, Bacille Calmette-Guerin (BCG) vaccine, oral 
poliovirus vaccine and hepatitis B virus vaccine have all been used as immunogens at 
or near birth and have given protection against disease (reviewed in Ada and Ramsay, 
1997). Recent studies have suggested that tolerance may not be an intrinsic property 
of the newborn immune system, rather of the conditions under which an antigen is 
introduced, the antigen dose and the nature of the antigen-presenting cells (APCs) 
(Ridge et al., 1996; Sarzotti et al, 1996; Forsthuber et al., 1996). It is likely that these 
conditions can be optimized either to immunize or tolerize the newborn to protect them 
from allergic disease.
DNA vaccination in adults is usually characterized by the induction of effective and 
long-lasting immune responses following the sustained expression of small amounts 
of antigen. Several recent studies have demonstrated that DNA vaccination also 
induces immune responses in newborn mice (Sarzotti et al., 1996; Prince et al., 1997; 
Barrios et al, 1996; Bot et al., 1996; Hassett et al., 1997). Nevertheless, the protein 
encoded by a DNA vaccine is produced endogenously and expressed in the context of 
self MHC, so that the potential exists for the neonatal immune system to recognize it as 
"self" leading to the induction of tolerance. Indeed, tolerance has been induced 
following neonatal DNA immunization (Mor et al., 1996; Cao et al., 1997).
It may be possible, therefore, to tolerize neonates by exposure to allergen in the context 
of a DNA vaccine. Alternatively, co-expression of particular cytokine genes, along 
with an allergen gene, may establish specific immune responses which are protective
against allergic disease. In this context, it was shown in Chapter 2, that immunization 
of sensitized adult mice with DNA vaccines encoding IL-12 suppressed the 
development of allergic immune response and airways disease. The co-expression of 
allergen genes together with cytokine genes represents a specific vaccination strategy 
against allergic airways disease which contrasts with the therapeutic strategies 
developed in Chapter 2. Thus, in the present Chapter, a DNA vaccine encoding OVA 
was constructed and its immunogenicity confirmed in young adult mice. The vaccine 
was then given to neonates and its ability to induce both humoral and cell-mediated 
immunity was tested, either alone or following co-administration of plasmids encoding 
murine IL-12 genes. Finally, the protective capacity of this neonatal vaccination 
strategy was examined following sensitization and exposure to aeroallergen in adult 
life.
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3.2. Materials and methods
3.2.1. Mice
All pups were derived from either matings between 8-12 week-old C57BL/6 or 
BALB/c mice which were bred under specific pathogen-free conditions. Breeding 
cages were checked daily for new pups and the day of birth was recorded. Adult 
C57BL/6 mice (7 week-old) were used to test the immunogenicity of plasmid-encoded 
OVA. All animals were obtained from Animal Breeding Establishment, John Curtin 
School of Medical Research.
3.2.2. DNA vaccine construction
The DNA vector, pJW4303, was provided by Dr. James Arthos (Stanford University, 
CA, USA). This plasmid contains the human cytomegalovirus (CMV) promoter / 
enhancer with intron A and bovine growth hormone polyadenylation (poly A) signals. 
The OVA cDNA (in the plasimd pUG) was provided by Dr. F. R. Carbone (Monash 
Medical Centre, VIC, Australia). A 1350bp insert fragment was excised from pUG- 
OVA with EcoRI and Xbal and the ends were filled using the Klenow fragment of E. 
coli DNA polymerase I. The OVA cDNA fragment was then cloned into the blunted 
Hindlll site of pJW4303 and restriction digestion was used to confirm correct 
orientation of the insert. The resulting DNA vaccine was called pOVA (Figure 3.1). 
The DNA vaccines which together encode murine IL-12 were already available in this 
laboratory. Briefly, IL-12-p35 and IL-12-p40 (respectively from pEDp35 and 
pEDp40, both obtained from Dr. S. Wolf, Genetics Institute, Cambridge, MA, USA) 
were cloned into the Hindlll site of distinct pJW4303 plasmids. The resulting DNA 
vaccines were termed pIL-12-p35 and pIL-12-p40, respectively. The pEL-12 used in 
this Chapter refers to the combination of pLL-12-p35 and pLL-12-p40.
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3.2.3. Immunofluorescence assays
The expression of OVA protein by pOVA was confirmed in immunofluoresence 
assays. 143B cells (Rhim et al, 1975) were grown overnight on acid-washed glass 
coverslips in a 6-well tissue culture plate (Nunc, Roskilde, Denmark) at an initial 
inoculum of 10^ cells per well. The cells were then transfected with 10 pg of pOVA 
mixed with DOTAP transfection reagent (Boehringer Mannheim, Mannheim, 
Germany) according to the manufacturers instructions. After overnight incubation at 
37°C, the cells were rinsed in PBS and fixed in methanol at -20°C for 10 min. Rabbit 
anti-0VA monoclonal antibodies (provided by Nick Gordon, JCSMR, ANU) were 
added at 1/300 dilution and cells were incubated at room temperature for 1 hour. The 
cells were rinsed 3 times in PBS and stained for 1 hour at room temperature with 
FITC-conjugated sheep anti-rabbit polyclonal antibodies (Silenus, Melbourne, 
Australia). The cells were then rinsed 3 times and examined under a fluorescence 
microscope.
3.2.4. Preparation of DNA for delivery via gene gun and DNA 
immunization of neonates
The DNA vaccines, pOVA, pEL-12-p40, pIL-12-p35 and pJW4303 were propagated in 
E. coli, strain DH5a, in the presence of ampicillin and DNA was extracted and purified 
by standard CsCl density gradient centrifugation (Sambrook et al., 1989). Endotoxin 
was removed with an endotoxin removal system (ICN Biomedicals, Inc. Costa Mesa, 
CA, USA). In preparation for delivery via the gene gun, pOVA, pOVA + pEL-12, or 
the control vector, pJW4303 were coated onto 2.6 pm diameter gold particles (which 
were used as microprojectiles) at 2 pg DNA/mg gold. Briefly, 100 pi of 0.1 M 
spermidine was added to 50 mg gold particles and the mixture was sonicated for 3 sec 
using a Sonifier water bath sonicator (Branson Sonic Power Company, Danbury, CN,
USA). 100 jLig of DNA (in 50 (il) was added to the gold-spermidine mixture followed 
by vortexing. 200 pi of 2.5 mM CaC12 was then added to the gold-DNA mixture 
which was allowed to precipitate at room temperature for 10 min. The gold beads 
were centrifuged at 14000 x g for 3 min and the supernatant was removed. The pellet 
was washed three times with 70% ethanol (14000 x g for 3 min) and resuspended in 7 
ml 100% ethanol. The DNA-coated gold bead suspension was then loaded into Tefzal 
tubing (MacMaster-Carr Supply Co., CA, USA). Briefly, beads were allowed to 
settle for 3 min and the ethanol was drawn from the tubing at a rate of 3 inches per sec 
using a peristaltic pump. Gold beads were allowed to coat the internal surface of the 
tubing by rotation in a tube turner (Bamant Co. Barrington, EL, USA) at 20 RPM for 1 
min and were then dried with N2 at a flow rate of 350-400 ml/min for 3 min. Tubes 
were cut into 0.5 inch pieces for use as "bullets" and stored at 4°C.
For immunization, the bullets were loaded into the revolver apparatus of the gene gun 
(Agracetus Inc. WI, USA. Figure 3.2). 4 day-old neonatal mice were each given two 
shots (a total of 2.8 pg DN A), one on the back and one on the abdomen. 6-8 week-old 
adult mice were shaved and immunized with the same amount of DNA on the 
abdomen.
3.2.5. Determination of OVA-specific immunoglobulins
Blood samples were taken at seven weeks after neonatal DNA immunization, and also 
at 24 hours after the last aeroallergen treatment. Serum anti-OVA IgGl, IgG2a and IgE 
antibody titers were determined by ELISA (refer to Section 2.2.11).
3.2.6. Evaluation of secondary OVA-specific cytotoxic T lymphocytes 
(CTL) generated by DNA immunization of neonatal mice
Spleen cells were isolated at 7 weeks after neonatal DNA immunization for use in CTL 
assays. 2.5x107 spleen cells (effector cells) were re-stimulated in vitro with or 
without the peptide SIINFEKL (10pg/ml, Biomolecular Resource Facility, JCSMR) in 
0.2 ml Dulbecco's minimal essential medium (DMEM) supplemented with 10% FCS, 
50 pM  2-mercaptoethanol, 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM 
HEPES buffer (pH 7.6) and antibiotics (termed complete medium) at 37°C, in 
humidified air containing 5% CO2 for 1 hour. Cell cultures were then topped up with 
15 ml complete medium and incubated in upright 25 cm2 tissue culture flasks (Nunc) 
for 5 days as above. SIINFEKL is a peptide corresponding to the amino acid sequence 
257-264 of OVA and is the major CTL determinant recognized by mice of the H-2K^ 
haplotype. 5 x l0 6 syngeneic MC57G target cells were prepared for assay by pulsing 
with or without SIINFEKL (10pg/ml) in 0.3 ml complete medium for 2 hours, and 
were then incubated in the presence of 51 Cr (10 pCi/106 cells) at 37°C for 90 minutes.
The effector splenocytes were then added to labelled target cells at effector : target ratios 
of 60:1, 20:1, 6:1, 2:1 in a final volume of 200 pi of DMEM complete medium (in 
triplicate) in round-bottomed 96-well microtitre plates (Nunc), and were incubated for 6 
hours at 37°C in an atmosphere containing 5% CO2 . Cytotoxic activity was measured 
in 51Cr release assays (Karupiah et al., 1990). Spontaneous release of 51Cr was 
determined by incubation of targets in medium alone (without effector cells), and 
maximum release was determined by lysing labelled targets with 1% Triton-X100 
(Ajax Chemicals, NSW, Australia). 100 pi of supernatant was collected and 51Cr 
release was determined using a Packard microplate scintillation counter (Packard). 
Specific lysis was caculated using the following formula:
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experimental release - spontaneous release
% specific lysis = ------------------------------------------------------ x 100%
maximal release - spontaneous release
3.2.7. Sensitization and aeroallergen treatment of mice
For studies in this Chapter, a murine model of allergic airways disease described by 
Foster et al., 1996) was used as shown diagramatically in Figure 3.3. In this model, 
measurements of blood eosinophilia following allergen treatment could be made, in 
addition to the manifestations of disease described in the preceding Chapter. Briefly, 
mice (7-8 weeks of age) were sensitized by two i.p. injections of 50 jig OVA (Grade 
V, Sigma) in 1 mg alhydrogel (CSL Ltd., Parkville, Australia) given on days 0 and 12. 
Non-sensitized controls received 1 mg of alhydrogel in normal saline. On day 24, 
sensitized mice were exposed to aerosolized OVA (10 mg/ml in normal saline) for three 
30 min periods at intervals of 30 min and the process was repeated every second day 
for 8 days. Non-sensitized mice received aerosolized saline only. The aerosol was 
generated at 6 1/mm by a nebulizer producing particles of approximately 3.9 pm 
diameter into a closed chamber of 800 cm3. Mice were sacrificed on day 31, 24 h after 
the last aerosol.
3.2.8. Assessment of blood and lung eosinophilia
Twenty-four hours after the final treatment with aeroallergen, bronchoalveolar lavage 
(BAL) was performed as described in Section 2.2.3. Blood samples were drawn from 
the tail vein immediately prior to each course of aeroallergen treatment and on day 31 
before sacrifice. Cytospin smears and blood smears were stained with May-Grunwald- 
Giemsa solution and 200 leukocytes were counted on each slide for differential 
leukocyte counts.
3.2.9. Measurement of airways hyperreactivity
Refer to Section 2.2.4
3.2.10. Preparation of CD4+ T cell populations from lung and spleen
Refer to Section 2.2.8
3.2.11. Flow cytometry for CD4-enriched and CD4-depleted cells
Refer to Section 2.2.9
3.2.12. Determination of cytokine production by CD4+ T cells
Refer to Section 2.2.10
3.3. Results
3.3.1. Tests of antigen expression and immunogenicity of pOVA
The DNA vaccine, pOVA, was constructed as described in Section 3.2.2. To test its 
capacity to express OVA, 143B cells were transfected with pOVA and examined by 
fluorescence microscopy after staining with anti-OVA antibodies. In cells transfected 
with pOVA, strong, specific cytoplasmic staining was observed (Figure 3.4 B), 
whereas no such staining was found in cells transfected with the control plasmid, 
pJW4303 (Figure 3.4 A).
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To confirm its immunogenicity, 7 week-old C57BL/6 mice were immunized with 
pOVA by gene gun and sera were collected 7 weeks later for assay of OVA-specific 
antibodies. Mice immunized with pOVA mounted specific humoral responses, 
predominantly of the IgGl isotype, with little IgG2a detected, indicative of a TH2- 
driven immune response (Figure 3.5).
3.3.2. Neonatal DNA vaccination with pOVA induces antigen-specific 
humoral immune responses which are modulated by the co-delivery of 
IL-12 genes
Having established the immunogenicity of pOVA in adult mice, this plasmid was used 
to study the outcome of DNA vaccination in neonates. Both C57BL/6 and BALB/c 
mice were immunized with pOVA, pOVA + pEL-12 or pJW4303 on the fourth day after 
birth, and 7 weeks later, sera were collected for specific IgG l and IgG2a subclass 
analyses by ELISA (Figures 3.6 and 3.7). Immunization with pOVA induced anti- 
OVA antibody responses dominated by the IgGl isotype in both strains of mice. 
However, major differences were recorded between strains following pIL-12 co­
administration. A dramatic reduction was seen in anti-OVA antibody production in 
C57BL/6 mice given pOVA + pIL-12, due to an 85-fold decrease in IgGl levels, with 
no significant differences detected in the much smaller IgG2a subclass response 
(Figure 3.6). In contrast, IgGl levels in BALB/c mice following pIL-12 co-delivery 
were similar to those induced by pOVA alone, whilst IgG2a levels increased 5-fold 
(Figure 3.7). By 7 months after neonatal DNA immunization, levels of both OVA- 
specific IgGl and IgG2a antibodies in C57BL/6 mice given pOVA had increased about 
7-fold over those seen at 7 weeks, whereas approximately 70-fold increases were 
recorded in animals given pOVA + pIL-12 (Figure 3.8). Sera could not be collected 
from the BALB/c mice at the 7 month time point due to their death from causes 
unrelated to the experiment.
Overall, these results demonstrate that neonatal immunization with a DNA vaccine 
encoding OVA does not induce tolerance, rather generating a humoral immune 
response dominated by antibodies of the IgGl isotype. Co-delivery of a DNA vaccine 
encoding IL-12 had the effect of dramatically suppressing specific IgGl antibody 
production in C57BL/6 mice, or significantly enhancing the IgG2a response without 
diminising IgGl levels in BALB/c mice. Furthermore, the antibody responses 
generated following a single neonatal DNA immunization were sustained, at elevated 
levels, for at least 7 months after immunization.
DNA immunization has been shown to induce specific CTL activity in addition to 
humoral immune responses. To ascertain whether neonatal DNA immunization could 
generate CTL responses, spleen cells from mice immunized with pJW4303, pOVA, or 
pOVA + pIL-12 were isolated at 7 weeks after immunization for use in OVA-specific 
CTL assays. Specific CTL responses were detected in re-stimulated spleen cells from 
C57BL/6 mice immunized with either pOVA or pOVA + pIL-12 (Figure 3.9). These 
results demonstrate priming for specific CTL activity following a single neonatal DNA 
immunization, however, co-delivery of pIL-12 at this stage did not appear to enhance 
these responses.
To further characterize the nature of the immune responses induced by neonatal DNA 
immunization, lung and spleen T cell isolates were analysed for cytokine production 
following in vitro stimulation with anti-CD3 antibodies. Strong proliferative responses 
were observed in stimulated cultures from all groups (data not shown). Similar 
profiles of T cell cytokine production were seen in both C57BL/6 and BALB/c mice in 
response to immunization with each of the DNA vaccines (Figures 3.10 and Figure 
3.11). Immunization with pOVA induced the production of IFNy by spienocytes and 
lung cells from both strains of mice, whilst IL-5 was also detected in spleen cell 
supernatants. Co-delivery of pIL-12 led to significantly increased IFNy production by
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cells from both lungs and spleens, whereas IL-5 secretion was suppressed to levels 
near (BALB/c mice), or below (C57BL/6 mice), the limits of detection. IL-4 
production could not be measured in any of the cultures. This was not unexpected, in 
light of the established low-level of secretion of this factor normally found in stimulated 
bulk lymphocyte cultures. Mice given the control vaccine, pJW4303, displayed a weak 
"baseline" production of IFNy, which may reflect the activity of immunostimulatory 
motifs present in bacterial DNA plasmids as discussed below.
In summary, neonatal immunization with a DNA vaccine encoding OVA generated 
substantial humoral and cell-mediated immune responses in both C57BL/6 and BALB/c 
mice. Co-immunization with plasmids encoding IL-12 enhanced THl-type cytokine 
secretion in both strains. However, EL-12 had somewhat different effects on antibody 
production in BALB/c mice (IgG2a levels but not IgGl levels enhanced) and C57BL/6 
mice (enhanced IgG2a levels with time, but markedly suppressed IgGl production), 
suggesting that C57BL/6 mice are more sensitive to the inhibitory effects of this factor 
on TH2-driven immune responses.
3.3.3. Neonatal DNA vaccination inhibits allergic airways inflammation 
following aeroallergen challenge in adult life
It was clear that a single neonatal immunization with pIL-12 along with pOVA 
enhanced OVA-specific TH l-type immune responses whilst inhibiting TH2-type 
cytokine production, and antibody responses (at least in C57BL/6 mice), in the adult 
animals. These findings prompted a study of the capacity of this strategy to protect 
against the manifestations of allergic airways disease, initially in terms of airways 
inflammation following sensitization and aeroallergen challenge. The results 
demonstrated that neonatal vaccination with pOVA + pIL-12 afforded significant 
protection against eosinophilic airways inflammation in both C57BL/6 and BALB/c
mice following sensitization and aerosol challenge with OVA in adult life. Numbers of 
circulating eosinophils were markedly reduced in both C57BL/6 (Figure 3.12) and 
BALB/c mice (Figure 3.13) given pOVA + pEL-12 compared to those given pOVA or 
pJW4303, particularly at that stage corresponding to the peak of the allergic response 
(day 31). In addition, airways eosinophilic inflammation was dramatically suppressed 
in mice co-immunized with pIL-12 (Figures 3.14 and 3.15).
It is noteworthy that both blood and airways eosinophilic inflammation were also 
suppressed in OVA-sensitized and challenged adult mice which had been vaccinated, as 
neonates, with pOVA, i.e., without pIL-12 co-delivery (Figures 3.12-3.15). However, 
the levels of inhibition of allergic inflammation seen in these animals were, in most 
cases, significantly less than those detected in mice given both pOVA and pIL-12.
In summary, vaccination of neonates with pOVA and pIL-12 gave them marked 
protection, as adults, against the eosinophilic inflammation which normally mediates 
allergic disease following sensitization and challenge with allergen. Neonatal 
immunization with pOVA alone also inhibited allergic airways responses, although to a 
lesser extent.
3.3.4. Neonatal DNA vaccination inhibits airways hyperreactivity in 
C57BL/6 mice
Airways hyperreactivity is another major symptom of chronic allergic airways disease 
manifest in our model. Therefore, experiments were designed to determine whether 
neonatal vaccination with pOVA + pIL-12 could suppress AHR following sensitization 
and exposure to aeroallergen as adults, in addition to its capacity to inhibit eosinophilic 
inflammation. As shown in Figure 3.16, AHR in C57BL/6 mice given pOVA + pIL- 
12 as neonates was greatly reduced compared to mice immunized with pOVA or
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pJW4303. Indeed, AHR in the former was indistinguishable from that seen in non- 
allergic control mice. AHR was also inhibited in C57BL/6 mice treated with pOVA 
alone, although this was far less marked than in those given pEL-12. In contrast, no 
such inhibition of AHR was found in B ALB/c mice treated with pOVA with or without 
pIL-12 (Figure 3.17). Thus, neonatal DNA vaccination with pOVA and pIL-12 gave 
clear protection against allergic AHR in adult C57BL/6 mice, but not in BALB/c mice. 
The failure of this treatment to inhibit AHR in the latter, despite suppression of 
eosinophilic inflammation, points to differences in the mechanisms regulating 
inflammation and AHR in these strains of mice.
3.3.5. CD4+ T cell cytokine profiles after allergen challenge in mice 
vaccinated as neonates
Next, the cytokine profiles of CD4+ T cells from mice sensitized and challenged with 
allergen were examined in order to clarify possible mechanisms underlying the 
protection from allergic inflammation and AHR mediated by neonatal DNA vaccination.
Given the established links between allergic airways disease and dysregulated 
production of TH2-type cytokines, particularly EL-5, which drives eosinophilia, it was 
of interest to determine whether these factors were downregulated in mice given pOVA 
with or without pIL-12. As shown in Figure 3.18, CD4+ T cell production of IFNy 
was markedly enhanced in both lungs and spleens of C57BL/6 mice given pOVA + 
pIL-12 as neonates compared to those given pOVA or pJW4303. In contrast, IL-5 
production by T cells from the lungs of these mice was greatly inhibited (Figure 3.18 
C), although levels of IL-4 were not significantly altered, by co-delivery of pIL-12 
(Figure 3.18 B). Neither IL-4 nor IL-5 production was detected in splenic T cell 
cultures. Similar profiles were seen in BALB/c mice (Figure 3.19). Thus, it was 
clear that neonatal vaccination with pOVA and pIL-12 led to marked inhibition of IL-5
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production in the lungs and enhanced IFNy production in both lungs and spleens 
following sensitization and aeroallergen challenge in adult life.
It is noteworthy that neonatal vaccination with pOVA alone had similar, although 
significantly less marked, effects in the lungs of both C57BL/6 (Figure 3.18) and 
BALB/c mice (Figure 3.19), with enhancement of T cell production of IFNy and 
inhibition of IL-5 secretion, compared to animals given control DNA vaccine.
In summary, neonatal DNA vaccination with pOVA + pEL-12, or to a lesser extent with 
pOVA alone, enhanced TH1 cytokine secretion and suppressed IL-5 production, 
particularly in the lungs, following allergen challenge in adult life. These local changes 
in cytokine profiles are consistent with the protection from allergic inflammation that 
was afforded by neonatal vaccination.
3.3.6. Antibody profiles after allergen challenge in mice vaccinated as 
neonates
To ascertain whether the CD4+ T cell cytokine profiles had functional correlates in 
terms of antibody production, OVA-specific antibody isotype profiles were examined 
in these animals. In both C57BL/6 and BALB/c mice given control vaccine, pJW4303, 
as neonates, humoral responses against OVA following aeroallergen challenge as adults 
were dominated by antibodies of the IgGl isotype (Figures 3.20 and 3.21). In 
C57BL/6 mice given pOVA + pIL-12, IgGl production was greatly inhibited after 
allergen challenge compared to those given pOVA or pJW4303 (Figure. 3.20). Some 
inhibition of specific IgGl levels was also observed in BALB/c mice given pOVA + 
pEL-12, although this was much less marked and was comparable to that seen in mice 
given pOVA without pIL-12 (Figure 3.21). Strain differences were also observed in 
the effects of neonatal vaccination on the much smaller OVA-specific IgG2a response,
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with significant enhancement following pIL-12 vaccination most pronounced in 
B ALB/c mice. OVA-specific IgE production in response to aeroallergen challenge in 
mice given control vaccine was detected at levels 3-4 orders of magnitude lower than 
those of IgGl. Nevertheless, neonatal vaccination, particularly with pOVA + pIL-12, 
markedly suppressed IgE production in both strains of mice.
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3.4. Discussion
Early vaccination is thought to be an effective means of protecting infants from 
infectious disease and this concept may also apply to conditions such as allergic 
asthma. Effective vaccination in early life could lead to the induction of immune 
responses which are protective upon subsequent exposure to allergen. In this Chapter, 
a DNA vaccine encoding the allergen, OVA, was constructed and was used, along with 
similar constructs encoding murine EL-12, in order to study the protective capacity of a 
DNA-based neonatal vaccination strategy against sensitization and exposure to 
aeroallergen in adult life.
Initially, the immunogenicity of pOVA was tested in neonatal mice. It was found that 
intradermal vaccination, via gene gun, induced substantial OVA-specific cell-mediated 
and humoral responses at 7 weeks of age, the latter dominated by antibodies of the 
IgGl subclass. Co-immunization with pIL-12 markedly suppressed antibody 
production, particularly IgGl production, in C57BL/6 mice, but enhanced the levels of 
IgG2a, without suppressing IgGl levels, in BALB/c mice. Neonatal co-delivery of 
pIL-12 did not appear to enhance specific CTL responses. Cytokine assays 
demonstrated that pOVA had induced IFNy production by lung and spleen T cells 
which was enhanced following co-delivery of pIL-12 in both strains of mice. In 
addition, pOVA-induced EL-5 production was inhibited in mice also given pEL-12. It 
appears, therefore, that pOVA was strongly immunogenic following neonatal 
vaccination via the gene gun. Co-expression of IL-12 enhanced THl-type cytokine 
secretion and resultant antibody production, although BALB/c and C57BL/6 mice 
displayed differential sensitivities to the inhibitory effects of this factor on TH2-driven 
immune responses.
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The induction of immunity to pOVA is consistent with previous studies showing that 
neonatal DNA immunization can generate cell-mediated immunity (Sarzotti et a l , 1996; 
Prince et a l, 1996; Barrios et al, 1996; Bot et al., 1996; Hassett et al., 1997) and 
humoral immune responses (Wang et al, 1993; Martinez et al., 1997). These studies, 
and our present data, conflict with those of Mor et a l (1996), who reported that 
neonatal DNA immunization favoured tolerance induction. In explanation, it is likely 
that the nature and dosage of encoded antigen affects the induction of tolerance 
(Friedman and Weiner, 1994; Miller and Cook, 1994). It is also possible that the 
plasmid construct used by Mor and colleagues was not sufficiently immunogenic to 
induce immune responses in neonates.
The induction of cell-mediated immune responses, IFNy production and humoral 
responses in mice given pOVA demonstrates the capacity of DNA vaccination to elicit 
both TH1- and TH2-driven immune responses. Conventional vaccines 
characteristically induce TH2-biased immune responses in neonates (Barrios et al., 
1996; Sarzotti et al., 1996), most likely due to immaturity of their antigen presenting 
cells, impairment of IL-12 production by microbial antigens or poor responses to 
signals required for full activation of APCs (Martinez et al., 1997; Ridge et al., 1996). 
Others have shown that DNA vaccines may circumvent the deficient induction of TH1- 
driven responses in neonates (Martinez et a l, 1997). Mice given a plasmid-encoding 
measles virus hemagglutinin within the first week of life mounted responses 
characterized by IgG2a antibodies and IFNy production, whilst a plasmid-encoding the 
C fragment of tetanus toxin induced mixed TH1/TH2 responses, but with TH1-driven 
responses apparently dominant (Martinez et a l, 1997). Our DNA vaccine, pOVA, 
induced both cell-mediated and humoral immune responses, although the latter were 
dominated by antibodies of the IgGl subclass. In general, OVA induces TH2- 
dominant antibody responses, even when encoded in recombinant vaccinia virus 
vectors, although OVA-specific CTL are also generated (A. Ramsay, unpublished
data). In the case of DNA vaccine-encoded antigens, the route of administration may 
also influence the nature of the immune response. Gene gun delivery of DNA has been 
shown to elicit both TH1 and TH2-type cells, whereas intramuscular immunization 
appears to favour TH1 cell development (Feltquate et al., 1997). Nevertheless, the co­
delivery of pLL-12 by gene gun primed for THl-type cells in lungs and spleen.
Whether the neonatal immune system responds immediately following vaccination or 
only after further maturation of T and/or B cells is unclear. DNA vaccines are known 
to induce sustained, low level expression of encoded antigens (Wolff et al., 1992; 
W olff et al., 1990) and would, therefore, have the capacity for protracted stimulation of 
the immune system. In adult mice immunized with pOVA, antibodies were first 
detected by 3 weeks after vaccination in most individuals (data not shown), and all 
mice had responded by 6 weeks. A similar pattern of responsiveness was observed 
following neonatal vaccination, in that most mice had developed some antibody 
responses by 4 weeks and all had responded by 7 weeks. These findings suggest that 
the neonatal immune system is probably activated shortly after immunization.
The immunogenicity of pOVA in neonates, and the capacity of co-expressed IL-12 to 
deviate the OVA-specific immune response, prompted an examination of the capacity of 
this strategy to protect mice against the development of allergic airways disease. As 
shown in Chapter 2, the ability of IL-12 to suppress ongoing disease demonstrated the 
therapeutic capacity of this molecule, however, the suppression of allergen-specific 
TH2-mediated responses obviously also represents an attractive aim of preventive 
vaccination against allergic disease. Neonatal vaccination with pOVA + pEL-12 via 
gene gun resulted in marked inhibition of airways inflammation and airways 
hyperreactivity and suppression of OVA-specific antibody production following 
sensitization and aeroallergen challenge in adult life. Analyses of the cytokine secretion 
profiles of lung and spleen CD4+ T cells from these animals suggested that the
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mechanism of IL-12 activity underlying disease suppression was a marked up- 
regulation of IFNy production with a concomitant inhibition of IL-5 secretion. Thus, 
IL-12, probably acting, at least in part, through the induction of IFNy (Hogan et al., 
1998), appears to prime for the development of THl-type cells. This is supported by 
the predominance of IFNy-secreting CD4+ T cells in the spleens of OVA-challenged 
adult mice which had been given pEL-12 as neonates. Co-delivery of pEL-12 also led to 
marked increases in IFNy secretion by lung T cells following sensitization and aerosol 
challenge with OVA, and a significant shift in the ratio of IFNy: IL-4 secretion in 
favour of TH1 responsiveness. More dramatic effects were seen in the down- 
regulation of EL-5 production by lung T cells in both the B ALB/c and C57BL/6 strains. 
IL-5 is the major regulator of eosinophil differentiation and also has chemotactic 
activity for these cells (Sanderson et a l,  1986; Clutterbuck, 1989; Schweizer et al., 
1994), and its down-regulation correlated with the marked reduction in local 
eosinophilic inflammation observed in allergen-challenged mice which had been 
vaccinated with pOVA + pEL-12 as neonates. Eosinophils are the critical mediators of 
allergic airways disease in our model (Foster et al., 1996). The inhibition of 
eosinophilia in adult mice vaccinated as neonates is clearly a major correlate of the 
protective efficacy of this approach.
The production of OVA-specific IgE antibodies in both strains of mice given pOVA + 
pIL-12 was also markedly suppressed. It is possible that enhanced IFNy production in 
vaccinated animals was sufficient to down regulate IgE antibody production over the 7- 
8 week period between vaccination and aeroallergen challenge despite continued IL-4 
production. Our results support those of a similar study in which immunization of 
mice with a DNA vaccine encoding the ß-galactosidase gene inhibited specific IgE 
production without concomitant suppression of EL-4 secretion (Raz et al., 1996). The 
suppression of IgE synthesis could also be due to direct suppressive effects of vaccine- 
encoded IL-12 (Kiniwa et al., 1992; Morris et al., 1994). Moreover, the decreased
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production of EL-5 observed in our study might also contribute to the inhibition of IgE
secretion, since it has been shown that EL-5 may enhance IL-4-induced IgE synthesis
and CD23 expression on B cells (Coffman et al., 1988; Pene et al., 1988).
It is noteworthy that neonatal vaccination protected C57BL/6 but not BALB/c mice
from the development of AHR following aeroallergen challenge. Two different
pathways have been proposed as contributing to allergen-induced AHR. One is driven
by EL-5 production and eosinophilia (Foster et al., 1996), whilst the other is regulated
by EL-4 and IgE-mediated activation of mast cells (Corry et al., 1996). C57BL/6 mice
are genetically deficient in certain mast cell-derived inflammatory mediators, and are
(Drazen et al., 1996)
thereby resistant to mast cell-mediated AHR. There is now clear evidence that AHR in 
these mice is largely regulated by EL-5-mediated eosinophilic inflammation (Foster et 
al., 1996). In our studies, therefore, vaccine-induced suppression of IL-5 production 
and eosinophilia may account for the observed inhibition of AHR in C57BL/6 mice. 
The failure of co-immunization with pIL-12 to reduce AHR in BALB/c mice may 
reflect the continued production of IL-4 and specific IgE antibodies, albeit at low titres 
in this strain. Furthermore, recent studies have shown that allergen-induced AHR in 
BALB/c mice can be regulated by a novel CD4+ T cell pathway independently of either 
IL-4 or EL-5 production (Hogan et a l ,  1998b).
Whilst neonatal DNA vaccination with genes encoding OVA and IL-12 was clearly 
protective against the development of allergic airways disease in adult life, it was also 
evident that mice immunized with pOVA alone were afforded some degree of protection 
against eosinophilia and AHR. Previous studies using DNA-encoded allergens have 
also reported varying degrees of protection against allergic responses (Hsu et a l ,  
1996a; Raz et al., 1996; Broide et al., 1997). In the present study, suppression of 
allergic disease in mice given pOVA correlated with reduced levels of EL-5 production 
and increased IFNy production, the lower magnitude of these changes compared to 
those seen in mice given pIL-12 notwithstanding. It was recently reported that DNA
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sequences containing CpG motifs are present in the ampicillin resistance gene of some 
DNA plasmid vectors (Krieg et al, 1995; Sato et al., 1996; Roman et al., 1997a). 
These "immunostimulatory" DNA sequences (ISSs) have the capacity to stimulate TH1 
responses in vaccinated individuals by inducing the production of IFNa, IFNß and IL- 
12. In the presence of an antigen, the resultant increased production of IFNy may 
promote the differentiation of naive CD4+ T cells towards TH1 development. It is, 
therefore, possible that ISSs in pJW4303 are responsible for the suppression of TH2- 
driven allergic responses observed in mice vaccinated with pOVA in the present study. 
The role of ISSs in immune deviation and their potential for immunotherapeutic and 
vaccination strategies against a variety of diseases is an area of active research (Krieg et 
al., 1995; Sato et al., 1996; Roman et al., 1997a).
The results presented in this Chapter clearly demonstrate the efficacy of a neonatal 
DNA-based preventive vaccination strategy against allergic airways disease. The 
administration, by gene gun, of pOVA + pIL-12 was protective against the 
development of TH2 cytokine-driven disease following sensitization and exposure to 
aeroallergen in early adult life, even in BALB/c mice regarded as "TH2 high 
responders". This study has thus provided "proof of concept" for genetic vaccination 
strategies as a basis for the development of sensible prophylaxis of atopic diseases, 
including asthma.
95
1. Hindill
2. Klenow
3. Dephosphorylation
CMVinA
6550 bp
lindin/EcoRI] 1647T4 DNA ligase
EcoRV 2697 
^Hindül/Xbal] 2997
1. EcoRI+Xbal
2. Klenow
Eco RI 1
pUG OVA
4450 bp
Figure 3.1 Construction of pOVA
pJW4303 was cut with Hindlll and end-filled with Klenow fragment of E. coli 
DNA polymerase I. The OVA coding sequence was excised from pUG OVA 
with EcoRI and Xbal, end-filled using Klenow fragment and then cloned into 
the blunted Hindlll site of pJW4303, giving rise to pJW OVA, or pOVA (see 
Section 3.2.2). CMVinA, human cytomegalovims promoter/enhancer with 
intron A. [Hindlll/EcoRI] and [Hindlll/Xbal], blunted sites.
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Figure 3.4 In vitro expression of OVA by transfected 143B cells
143B cell monolayers were transfected with pJW4303 (A) or pOVA (B) 
(Section 3.2.3), and were stained with rabbit anti-OVA monoclonal antibodies. 
Antibodies bound to OVA were detected using sheep anti-rabbit 
immunoglobulin-FITC conjugates. The monolayers were then mounted on 
microscope slides and examined under a fluorescence microscope 
(magnification x 1000).
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Figure 3.5 Antibody responses in adult mice 7 weeks after immunization 
with pOVA
7 week-old C57BL/6 mice were immunized by gene gun with pJW4303 or 
pOVA. Sera were collected 7 weeks later f a  ELISA. Data represent the mean ± 
SEM for groups of eight mice and are representative of two experiments.
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Figure 3.6 Antibody responses in C57BL/6 mice 7 weeks after neonatal 
DNA vaccination
C57BL/6 mice were immunized by gene gun withpJW4303, pOVA or pOVA + 
pIL-12 on the fourth day after birth. Sera were collected 7 weeks later for 
ELISA. Data represent the mean ± SEM for groups of eight mice and are 
representative of two experiments. * p< 0.0005 compared to levels of IgGl 
isotype in mice immunized with pOVA.
Figure 3.7 Antibody responses in BALB/c mice 7 weeks after neonatal DNA 
vaccination
BALB/c mice were immunized by gene gun with pJW4303, pOVAorpOVA + 
pIL-12 on the fourth day after birth. Sera were collected 7 weeks later for 
ELISA. Data represent the mean ± SEM for groups of eight mice and are 
representative of three experiments. * p< 0.005 compared to levels of IgG2a 
isotype in mice immunized with pOVA.
Figure 3.8 Antibody responses in C57BL/6 mice 7 months after neonatal 
DNA vaccination
C57BL/6 mice were immunized by gene gun with pJW4303, pOVA or pOVA + 
pIL-12 on the fourth day after birth. Sera were collected 7 months later for 
ELISA. Data represent the mean ± SEM for groups of 4 mice and are 
representative of two experiments. * p<0.05 compared to the corresponding 
levels of IgGl and IgG2a isotype in mice immunized with pOVA.
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Figure 3.10 CD4+ T cell cytokine profiles in C57BL/6 mice 7 weeks after 
neonatal DNA vaccination
C57BL/6 mice were immunized by gene gun with pJW4303, pOVA or 
pOVA+pIL-12 on the fourth day after birth. Seven weeks later, lung and 
spleen CD4+ T cells were isolated and stimulated in vitro with anti-CD3 
antibodies for 72 hours. Culture supernatants were harvested and analysed for 
IFNy and IL-5 production by ELISA. A and B, cytokine production by lung T 
cells, C and D, by spleen T cells. Data represent the mean ± SEM for two 
experiments. * p<0.05 compared to mice immunized with pOVA + pIL-12 or 
pJW4303. ** p<0.01 compared to mice given pOVA + IL-12.
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Figure 3.11 CD4+ T cell cytokine profiles in BALB/c mice 7 weeks after 
neonatal DNA vaccination
BALB/c mice were immunized by gene gun with pJW4303, pOVA or 
pOVA+pIL-12 on the fourth day after birth. Seven weeks later, lung and spleen 
CD4+ T cells were isolated and stimulated in vitro with anti-CD3 antibodies 
for 72 hours. Culture supernatants were harvested and analysed for IFNy and
IL-5 production by ELISA. A and B, cytokine production by lung T cells, C 
and D, by spleen T cells. Data represent the mean ± SEM for two experiments. 
* p<0.05 compared to mice immunized with pOVA + pIL-12 or pJW4303. 
**p<0.01 compared to mice given pOVA + pIL-12.
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Figure 3.12 Eosinophils in blood from C57BL/6 mice after OVA challenge
C57BL/6 mice were immunized with pJW4303, pOVA or pOVA + pIL-12 four 
days after birth. Seven weeks later mice were sensitized and treated with 
aeroallergen as described in Section 3.2.7. Blood smears were collected 2 
hours before each aerosol and 24 hours after the last challenge and stained with 
May-Grunwald-Giemsa solution. 400 cells were counted per smear. Data 
represent the mean ± SEM for groups of five mice and are representative of two 
experiments. *p<0.05 compared to mice immunized with pJW4303. +p<0.05 
compared to mice immunized with pJW4303 or pOVA + IL-12.
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Figure 3.13 Eosinophils in blood from BALB/c mice after OVA challenge
BALB/c mice were immunized with pJW4303, pOVA or pOVA + pIL-12 four 
days after birth. Seven weeks later mice were sensitized and treated with 
aeroallergen as described in Section 3.2.7. Blood smears were collected 2 
hpurs before, each aerosol and 24 frours after ,the last challenge and stained with 
May-Grunwald-Giemsa solution. 400 cells were counted per smear. Data 
represent the mean ± SEM for groups of five mice and are representative of two 
experiments. *p<0.05 compared to mice immunised with pJW4303. +p<0.05 
compared to mice immunized with pJW4303 or pOVA + IL-12.
Figure 3.14 Eosinophils in BALF from C57BL/6 mice after OVA challenge
C57BL/6 mice were immunized with pJW4303, pOVA or pOVA + pIL-12 four 
days after birth. Seven weeks later mice were sensitized and treated with 
aeroallergen as described in Section 3.2.7. BAL was performed after sacrifice on 
day 31 and eosinophils in BALF enumerated on cytospin smears stained with 
May-Grunwald-Giemsa solution. Data represent the mean ± SEM for groups of 
five mice and are representative of two experiments. *p<0.05 compared to mice 
immunized with pJW4303 or pOVA + pIL-12. **p<0.01 compared to mice 
immunized with pJW4303.
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Figure 3.15 Eosinophils in BALF from BALB/c mice after OVA challenge
BALB/c mice were immunized with pJW4303, pOVA or pOVA + pIL-12 four 
days after birth. Seven weeks later mice were sensitized and treated with 
aeroallergen as described in Section 3.2.7. BAL was performed after sacrifice cn 
day 31 and eosinophils in BALF enumerated on cytospin smears stained with 
May-Grunwald-Giemsa solution. Data represent the mean + SEM for groups of 
five mice and are representative of two experiments. *p<0.05 compared to mice 
immunised with pJW4303 or pOVA + pIL-12. **p<0.01 compared to mice
immunized with pJW4303.
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Figure 3.16 Airways hyperreactivity to ß-methacoline in C57BL/6 mice
C57BL/6 mice were immunized with pJW4303, pOVA or pOVA + pIL-12 
four days after birth. Seven weeks later mice were sensitized and treated with 
aeroallergen as described in Section 3.2.7. Mice in the control (saline) group 
were sensitized and aerosol challenged with saline but not given DNA 
vaccine. AHR was measured on day 31 and data are shown for the dose of ß- 
methacoline (12 mg/ml) that induced a maximal response in mice treated with 
pJW4303. Results represent the mean ± SEM of the Penh values in 
percentages of Penh values after PBS nebulization for groups of five mice 
and are representative of two experiments. *p<0.05 compared to mice 
immunised with pJW4303 or pOVA. +p<0.05 compared to mice immunized 
with pJW4303. Penh, enhanced pause (see Section 2.2.4).
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Figure 3.17 Airways hyperreactivity to ß-methacoline in BALB/c mice
BALB/c mice were immunised with pJW4303, pOVA or pOVA + pIL-12 
four days afterbirth. Seven weeks later mice were sensitized and treated with 
aeroallergen as described in Section 3.2.7. Mice in control (saline) group 
were sensitized and aerosol challenged with saline but were not given DNA 
vaccine. AHR was measured on day 31 and data are shown for the dose of ß- 
methacoline (12 mg/ml) that induced a maximal response in mice treated 
with pJW4303. Results represent the mean ± SEM of the Penh values in 
percentages of Penh values after PBS nebulization for groups of five mice 
and are representative of two experiments (see Section 2.2.4).
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Chapter 4
IL-12 selectively inhibits eosinophil 
hematopoiesis
4.1. Introduction
In Chapters 2 and 3, it was shown that DNA or fowlpoxvirus-mediated delivery of 
genes encoding murine IL-12 inhibited the development of allergic airways disease in 
sensitized adult mice, whilst neonatal vaccination with DNA vaccines encoding IL-12 
together with an allergen were protective against the development of disease in adult 
life. In each case, enhanced production of IFNy with concomitant suppression of LL-5 
production and, thereby, eosinophilic inflammation, suggested that an important 
mechanism underlying the inhibition of disease development was a phenotypic shift 
from TH2 towards TH 1 cell development. As discussed in Chapters 1 and 2, there is 
now ample evidence that IL-12 is a key cytokine involved in TH1 cell development 
which may also suppress TH2-driven immune responses (Manetti et a l ,  1993; Hsieh et 
a l , 1993; Afonso et a l,  1994; Wynn et a l ,  1995; Marshall et al., 1995; Gavett et al., 
1995; Kips et a l ,  1995; Sur et a l, 1995; Hogan et a l ,  1998). However, in addition to 
its role in TH cell differentiation, E L -12 has been shown to exert hematopoietic activity, 
as discussed below, and it was of interest to determine whether vector-directed IL-12 
was able to influence the early development of allergic inflammatory precursor cells in 
the present study.
Hematopoiesis is thought to be regulated by two, interacting, control systems. Firstly, 
specialized stromal cells in the bone marrow appear to be important in maintaining stem 
cell numbers and the production of progenitor cells. Secondly, through co-ordinated 
interactions, a number of hematopoietic growth factors and cytokines stimulate the 
proliferation and maturation of progenitor cells into mature cells of particular lineages 
(Spangrude et a l ,  1988; Metcalf, 1991; Moore, 1991; Ogawa, 1993). Four factors, 
known collectively as the colony-stimulating factors (CSFs), appear to be crucial for 
regulation of these processes. These include granulocyte-macrophage CSF (GM- 
CSF), granulocyte-CSF (G-CSF), macrophage CSF (M-CSF) and IL-3. IL-3 and
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GM-CSF are multi-potential growth factors, supporting the survival, proliferation and 
differentiation of multi-potent hematopoietic progenitor cells in vitro (Egeland et al., 
1991; McNiece et al., 1989), including eosinophilic progenitors (Sonoda et al, 1989). 
In addition, IL-5, produced largely by TH2 cells (Mosmann and Coffman, 1989) but 
also by eosinophils themselves (Desreumaux et al., 1992), and originally termed 
eosinophil differentiation factor, specifically promotes the clonal proliferation and 
differentiation of murine and human eosinophil precursors (Clutterbuck et al., 1989; 
Sonoda et al., 1989; Yamaguchi and Suda, 1988).
A number of studies have also demonstrated that IL-12 may influence the development 
of hematopoietic progenitor cells. In combination with hematopoietic growth factors or 
cytokines, including steel factor (SF) (Hirayama et al., 1994), IL-3 + SF, EL-3 + EL-11 
(Ploemacher et al., 1993; Fardoun-Joalland et al., 1995), G-CSF or CSF-1 (Ikebuchi 
and Clark, 1988), IL-12 synergistically enhances the proliferation of bone marrow 
progenitors and peripheral hematopoiesis in vitro (Jackson et al., 1995). In particular, 
IL-12, in synergy with IL-3, has been reported to increase the formation of both CSF- 
GEMM (granulocyte, erythrocyte, monocyte and megakaryocyte) and CSF-GM 
(granulocyte and monocyte) multi-lineage colonies in vitro, whilst EL-3 alone supports 
mainly CSF-G colony formation (Hirayama et al., 1994; Jocobsen et al., 1993). In 
contrast, in vivo, IL-12 has been shown to exert inhibitory effects on bone marrow 
hematopoiesis through the induction of EFNy (Eng et al., 1995; Quesniaux and Ryffel, 
1996). There are however, as yet, no detailed reports of the effects of IL-12 on the 
development of allergic inflammatory precursor cells, particularly eosinophils, which 
are critical mediators of disease in the models used in the present study.
To date, both liquid cell culture systems and colony formation assays have been used to 
study the effects of different cytokines and growth factors on hematopoiesis (Stanley et 
al., 1972; Begley et al., 1986; Ploemacher et al., 1993; Bertolini et al., 1995). In the
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latter, a semi-solid matrix is used to physically localize the progeny of individual 
precursor cells during the process of colony formation (Metcalf, 1993). In this 
Chapter, semi-solid agar colony formation assays were used to investigate the effects 
of IL-12 on clonal differentiation and proliferation of eosinophils from bone marrow 
progenitors. As a starting point, optimal conditions were established for eosinophil 
differentiation and proliferation in order to study the influence of IL-12 in vitro. Next, 
cells from a variety of cytokine gene knockout mice were cultured to examine the 
involvement of other factors on hematopoietic activity mediated by IL-12. Finally, 
bone marrow cells from animals which had been sensitized and challenged with 
allergen were cultured in order to study the influence of IL-12 on eosinophil precursor 
cell development in vivo .
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4.2. Materials and Methods
4.2.1 Mice
Six to eight week old female mice of the C57BL/6, BALB/c and 129/Sv strains, 
129/Sv mice bearing disrupted IFNy receptor genes (EFNyR-/-) (Huang et al., 1993), 
or EFNa/ß receptor genes (IFNa/ßR-/-) (Muller et al., 1994) were bred in the Animal 
Breeding Establishment of Australian National University under specific pathogen-free 
conditions. Mice were treated according to ANU Animal Welfare guidelines and age- 
matched animals were used throughout the experiments.
4.2.2. Growth factors and cytokines
Recombinant murine (rm) cytokines IL-3 and IL-5 were kindly provided by Dr. 
Andrew Hapel (JCSMR, ANU). IL-12 was a gift of Genetics Institutes, Cambridge, 
MA., USA. IFNy was kindly provided by Ms. S. Fordham (JCSMR, ANU).
4.2.3. In vivo treatment of mice
In some experiments, mice were immunized i.n. with vaccinia virus encoding EL-12 
(VV-HA-IL-12) or an appropriate control virus, VV-HA-X constructed as described 
elsewhere (Coupar et al., 1988; Hogan et al., 1998). Bone marrow cells were 
collected from these mice at 1 or 2 weeks after immunization for colony formation 
assays. In further experiments, where indicated, mice were sensitized and challenged 
with aeroallergen as described in Section 3.2.7, immunized i.n. with VV on the day 
before the first OVA aerosol challenge and bone marrow cells were collected 24 hours 
after the final challenge for use in colony formation assays.
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4.2.4. Colony formation assays
A modification of the method of Stanley (1972) was used to assess eosinophil colony 
formation from bone marrow progenitor cells in vitro. Briefly, bone marrow cells 
were collected from femurs by gentle flushing with lx  HBSS containing 15mM 
HEPES, 2% FCS and 50ug/ml gentamycin through a 26G hypodermic needle. Cells 
from mice within each group were pooled and cultured in 12-well Luc migration plates 
(Bacto Laboratories, New South Wales, Australia) in volumes of 400}il of 0.33% agar 
(Unipath Ltd., Basingstoke, England) in RPMI-1640 medium (JRH Biosciences, 
Lenexa, KS) containing 10% FCS, 4mM glutamine, 60ug/ml gentamycin per well. 
The cytokines, EL-3, EL-5, EL-12 and IFNy were added at appropriate concentrations as 
indicated in the Results section. Cultures were incubated at 37°C in a humidified 
atmosphere of 5% CO2 in air for 7 days and the semi-solid agar was lifted onto 
microscope slides, air-dried and stained with M ay-Grunwald-Giemsa solution. 
Numbers of colonies (> 50 cells per aggregate, Lu et al., 1990) containing eosinophils 
and other cell types were scored under light microscopy using morphological criteria.
4.3. Results
4.3.1. Optimization of colony formation assays for eosinophil clonal 
differentiation
Bone marrow cells from naive mice were used to establish colony formation assays in 
order to establish optimal conditions for the differentiation and proliferation of murine 
hematopoietic precursors. IL-3 was added to cultures at various concentrations to 
determine optimal levels for colony formation and to study whether this cytokine alone 
could stimulate the development of eosinophilic colonies. Different numbers of bone 
marrow cells were also used in these assays to determine optimal cell concentrations.
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The results presented in Table 4.1 showed a dose-dependent effect of IL-3 in 
stimulating colony formation, with a low dose (5 U/ml) stimulating only a few colonies 
at different starting cell concentrations, whilst a high concentration (500 U/ml) 
stimulated much larger numbers of colonies. The colony numbers stimulated by higher 
concentrations of IL-3 were not significantly greater than those produced by IL-3 at 
500 U/ml, therefore, this concentration was chosen as optimal. Similarly, 4 x 105 
cells/ml was chosen as the optimal cell number for all further experiments. It should 
also be noted that no eosinophil colony formation was detected in any of the cultures 
incubated in the presence of EL-3 alone.
Next, the effects of IL-5 in stimulating eosinophil hematopoiesis were examined. Bone 
marrow cells were isolated from three different strains of mice, C57BL/6, 129/Sv and 
BALB/c, in order to investigate whether strain differences influenced eosinophil 
development in vitro. In the presence of EL-5 at a concentration of 250 U/ml (with IL-3 
at 500 U/ml), eosinophil colonies formed in bone marrow cell cultures from all strains 
tested /Figure 4.1 A and B), with the percentage of eosinophilic colonies being scored 
at 11.2%, 4.0% and 3.8% in C57BL/6, 129/Sv and BALB/c mice respectively (Table 
4.2). These data confirmed a requirement for EL-5 in eosinophil differentiation in vitro 
and established the optimal assay conditions for use in subsequent experiments.
4.3.2. The effects of IL-12 on eosinophil colony formation in vitro
Having established the optimal conditions for eosinophil differentiation and 
proliferation in vitro, experiments were performed to study effects of IL-12 on 
eosinophil development using bone marrow progenitor cells from naive C57BL/6 mice. 
Colony formation assays were therefore established in the presence of different 
concentrations of EL-12 (0-70 ng/ml) and eosinophil development was assessed. As 
shown in Figure 4.2, IL-12 markedly suppressed eosinophil hematopoiesis in a dose-
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dependent manner. IL-12 clearly inhibited eosinophil colony formation at 
concentrations as low as 0.7 ng/ml (p<0.05), whilst maximum suppression occurred at 
7 ng/ml (the concentration selected for use in subsequent experiments). This is similar 
to the biologically active concentrations of IL-12 (10ng/ml) which were previously 
obtained in vivo in this laboratory by the use of VV encoding IL-12 (Hogan et al., 
1998). The total numbers of colonies which formed in the assay were apparently 
unaffected by the addition of IL-12 (Table 4.3), although numbers of eosinophil 
colonies were markedly suppressed. These data indicate that IL-12-mediated inhibition 
of eosinophil hematopoiesis was not likely to be due to a general suppressive effect of 
this factor on the development of all murine hematopoietic progenitors.
4.3.3. The suppressive effects of IL-12 are selective for eosinophil 
colony formation
It was important to determine whether the inhibitory effects of IL-12 were specific for 
eosinophil hematopoiesis or whether this factor also inhibited the development of any 
other major cell types. Differential colony counts confirmed that whereas IL-12 
suppressed the formation of eosinophil colonies by about 10-fold, it had no such 
effects on numbers of the other types of colonies typically seen in this assay (Figure 
4.3). The latter included monocyte colonies, basophil colonies, neutrophil colonies, 
blast cell colonies or colonies containing neutrophil/monocyte mixtures. It appeared, 
therefore, that the suppressive effects of EL-12 were highly selective for eosinophils.
4.3.4. IL-12-mediated suppression of eosinophil development may be a 
direct effect of this factor
It was of interest to determine whether IL-12-mediated inhibition of eosinophil 
development was a direct effect of this molecule or was mediated by secondary factors.
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Some functions of IL-12 are mediated by other cytokines, particularly IFNy, whose 
production is stimulated by this factor (Schmitt et al., 1994; Hogan et al., 1998). In 
order to address this issue, bone marrow cells from IFNyR-/- and IFNaßR-/- mice 
were used in colony formation assays to study the possible involvement of IFNy and 
the type I interferons (IFNaß) in IL-12-mediated suppression of eosinophil 
hematopoiesis. As shown in Table 4.4, cultures of cells from wild-type 129/Sv mice 
(the control strain for IFNyR-/- and IFNaßR-/- mice) in the presence of IL-12 led to a 
6-fold decrease in numbers of eosinophil colonies. Moreover, significant decreases of 
2-3-fold were seen in cultures of cells from IFNyR-/- and IFNaßR-/- mice, 
respectively. Thus, eosinophil colony formation was markedly inhibited by IL-12 in 
cultures from IFNyR-/- and IFNaßR-/- mice, indicating that this factor can specifically 
inhibit eosinophil hematopoiesis in a manner that is independent of EFN activity.
4.3.5. No synergistic effects of IL-12 and IFNy in the inhibition of 
eosinophil development
Next, experiments were designed to investigate the possibility of synergistic 
interactions between IL-12 and IFNy in the suppression of eosinophil development. 
Colony formation assays were established in which concentrations of IL-12 shown to 
be sub-optimal for the suppression of eosinophil hematopoiesis were used in 
combination with several different concentrations of IFNy. Initially, it was established 
that IFNy could significantly inhibit eosinophil colony formation at 1 U/ml, but not 
below this level (Figure 4.4). However, no clear suppression of eosinophil 
hematopoiesis was observed at sub-optimal concentrations of IFNy and IL-12 (Figure 
4.4). These data suggest that IL-12 does not act in synergy with IFNy in suppressing 
eosinophil development.
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4.3.6. Mucosal delivery of VV-encoding IL-12 suppresses eosinophil 
hematopoiesis in vivo
Preceding experiments in this Chapter clearly showed that IL-12 inhibits eosinophil 
hematopoiesis in vitro. In order to study whether this factor could also inhibit 
eosinophil development in vivo , C57BL/6 mice were immunized i.n. with VV-HA-IL- 
12 and bone marrow cells were collected for use in colony formation assays. As 
shown in Figure 4.5, eosinophil hematopoiesis was markedly suppressed in mice 
given the IL-12 virus either 1 or 2 weeks earlier. It has previously been shown, in our 
laboratory, that elevated levels of IL-12 may be detected in lungs and in sera of mice 
given VV-HA-IL-12 for up to 6 days after immunization (Hogan et al., 1998). 
Nevertheless, the present experiment has shown that the suppressive effects of IL-12 
are apparent, after 7 days in culture under optimal conditions for eosinophil 
development, using cells isolated from animals immunized at least 2 weeks earlier. 
These data suggest a protracted effect of vector-delivered IL-12 on eosinophil 
development in vivo.
4.3.7. IL-12 suppresses eosinophil hematopoiesis in allergen-treated 
mice
Eosinophilic inflammation is critical for the development of allergic airways disease in 
our model. Its suppression by DNA vaccine- or poxvirus vector-delivered IL-12 was 
shown to be an important determinant of the protective efficacy of this factor in the 
preceding Chapters. The present demonstration of a selective suppression of 
eosinophil hematopoiesis by IL-12 under conditions favouring eosinophil 
differentiation and proliferation prompted us to study the effects of this factor on 
eosinophil hematopoiesis in the mouse model of allergic airways disease. Mice were 
sensitized with OVA on days 0 and 12, immunized with VV on day 23 and challenged
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with aerosolized OVA prior to collection of bone marrow cells for use in colony 
formation assays 24 hours after the final challenge. As shown in Table 4.5, eosinophil 
colony formation was ablated in cultures established using cells taken from mice given 
VV-HA-IL-12, unlike those given control virus. It is likely, therefore, that IL-12- 
mediated inhibition of eosinophil colony formation was a major determinant of the 
protective efficacy of this factor in suppressing the development of allergic airways 
disease in our model. It should also be noted, that total colony numbers were 
significantly reduced in mice treated with VV-HA-IL-12 (p<0.01). This may be due to 
the activity of IFNy induced by virus-directed IL-12, indeed previous studies have 
demonstrated a generalized inhibition of proliferation of hematopoietic precursor cells 
by this factor (Snoeck and Bockstaele, 1994; Eng et al., 1995).
4 .3 .8 . IL -12 m ediated  suppression  of bone m arrow  stem  cell
developm ent in allergen-treated mice is selective for eosinophils and 
may occur independently o f IFNy
Experiments described earlier in this Chapter demonstrated that IL-12-mediated 
suppression of eosinophil development in vitro was highly selective and could occur 
independently of IFNy. In order to determine whether IL-12 mediated similarly 
selective inhibitory effects in vivo, differential cell counts were performed on colonies 
established from allergen-sensitized and challenged mice which had been given the IL- 
12 virus. Whilst ablation of eosinophil colony formation was recorded in these 
animals, the development of colonies containing inflammatory cells of the monocyte, 
basophil and neutrophil lineages was unaffected (Figure 4.6).
To investigate the role of endogenous IFNy activity in IL-12-mediated suppression of 
eosinophil development, bone marrow cells from sensitized IFNyR-/- mice given VV 
prior to aeroallergen challenge were cultured in colony formation assays. Whereas the
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total numbers of colonies per culture were significantly reduced in wild-type mice given 
VV-HA-IL-12 compared to those given control virus, this was not the case in IFNyR-/- 
animals (Table 4.6). These findings support the contention that IL-12-directed EFNy 
activity may exert a generalized inhibition of hematopoietic colony formation. 
Strikingly, however, virus-directed IL-12 markedly inhibited eosinophil colony 
formation in both wild-type and IFNyR-/- mice (Table 4.6), clearly demonstrating the 
capacity of this factor to suppress eosinophilopoiesis in vivo independently of IFNy 
activity.
Taken together, these results extended the in vitro findings, described earlier in this 
Chapter, to show that IL-12 selectively inhibits eosinophil development in vivo in a 
manner that is largely independent of endogenous IFNy activity. This previously 
undescribed effect represents an important mechanism by which EL-12, produced in the 
periphery, may suppress allergic airways disease, through direct inhibtion of 
eosinophilopoiesis in the bone marrow.
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4.4. Discussion
Regulation of hematopoiesis is achieved by the co-ordinated expression of a group of 
molecules collectively termed colony-stimulating factors (CSF) and by cytokines that 
synergistically act with CSF to stimulate the development of bone marrow progenitors 
into mature cells (Spangrude et a i,  1988; Metcalf, 1991; Moore, 1991; Ogawa, 1993). 
The committment of multi-potential cells to different lineages is therefore determined by 
a complex cascade of regulatory signals induced by both CSF and cytokines. 
Eosinophilopoiesis is regulated by granulocyte-macrophage colony stimulating factor 
(GM-CSF) and EL-3, as well as IL-5, which is specifically involved in the development 
and terminal differentiation of eosinophils (Clutterbuck et a l ,  1989; Sonoda et al., 
1989; Yamaguchi and Suda, 1988). IL-5 is a product largely of the TH2 subset of 
lymphocytes and is thought to drive the eosinophilia that develops in a variety of 
disease situations, including helminthic infections and allergic lung disease (Gleich and 
Adolphson, 1986; Weller, 1991)
IL-12 is a key cytokine driving the development of TH1 cells (Trinchieri, 1995), and 
may also suppress TH2-driven immune responses (Manetti et al., 1993; Hsieh et al., 
1993; Afonso et al., 1994; Wynn et al., 1995; Marshall et al., 1995; Gavett et al., 
1995; Kips et al., 1995; Sur et al., 1995; Hogan et al., 1998). Indeed, results 
presented in Chapters 2 and 3 showed that vector-directed IL-12 inhibited the 
development of allergic airways disease and that this correlated with enhanced T cell 
production of IFNy, but suppressed production of IL-5. In addition to its immuno- 
regulatory properties, IL-12 may exert hematopoietic activity. In vitro, IL-12, in 
synergy with factors such as IL-3, IL-11, steel factor and certain colony-stimualting 
factors, may enhance the proliferation of bone marrow progenitors as well as peripheral 
hematopoiesis (Hirayama et a l,  1994; Ploemacher et al., 1993; Fardoun-Joalland et 
al., 1995; Jackson et al., 1995; Hirayama et al., 1994; Ikebuchi and Clark, 1988).
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However, in vivo, IL-12 apparently inhibits hematopoiesis, ostensibly through the 
induction of IFNy (Eng et al., 1995; Quesniaux and Ryffel, 1996). The studies 
presented in this Chapter were designed to examine the role of IL-12 in the 
development of inflammatory precursor cells, particularly eosinophils, which are 
critical mediators of allergic airways disease, both in our murine model and in atopic 
individuals (Gleich and Adolphson, 1986).
Having first established the optimal in vitro conditions for differentiation and 
proliferation of murine eosinophilic precursor cells in colony formation assays, it was 
next shown that EL-12 markedly and selectively inhibited eosinophilopoiesis in a dose- 
dependent manner. The subsequent use of bone marrow progenitors from DFNyR-/- or 
IFNocßR-/- mice demonstrated that this effect could be mediated independently of 
endogenous EFN activity. Delivery via rVV vectors, to otherwise untreated animals, 
showed that IL-12 also inhibited eosinophilopoiesis in vivo and that its effects on bone 
marrow progenitors were sustained for at least 2 weeks. Finally, eosinophil 
development was ablated in sensitized mice given these constructs prior to aeroallergen 
challenge, again in a highly selective manner which could occur independently of host 
IFNy activity. These experiments clearly demonstrate that the production of a 
regulatory factor in the periphery may influence the development of precursor cells in 
hematopoietic tissues. The selective inhibition of eosinophil development from bone 
marrow progenitor cells, both in vitro and in vivo, is a previously undescribed activity 
of IL-12 and may represent an important mechanism by which this factor may suppress 
the development of allergic airways disease, and, perhaps other TH2-driven 
conditions.
The use of mice with dysfunctional receptors for IFNy and IFNocß in these studies 
revealed that a significant degree of inhibition of eosinophil development was mediated 
by IL-12 in the absence of host IFN activity. In particular, IFNy, the production of
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which is markedly upregulated by IL-12, is thought to mediate many of the functions 
of this factor (reviewed in Trinchieri, 1995). These findings raised the possibility that 
IL-12 was acting directly on bone marrow progenitors to inhibit development of cells 
of the eosinophil lineage. Further studies, in a variety of factor-deficient mouse 
strains, may help to clarify the possible involvement of other molecules in mediating 
IL-12 activity in this model. However, it may be more instructive, in future studies, to 
establish the degree to which primitive stem cells, or immature hematopoietic cells of 
different lineages, express functional receptors for this molecule. Bone marrow 
progenitor cells, despite being unable to produce IL-12, may express one, but not both 
transmembrane chains of the IL-12 receptor (Trinchieri, 1995). However, the IL-12 
p40 chain shows significant sequence homology with the extracellular domain of the 
IL-6 receptor (Gearing and Cosman, 1991), the soluble form of which may bind to its 
ligand in solution and form a complex which may, in turn, bind to cells expressing the 
additional chain of the receptor - a dimer of the gpl30 transmenbrane protein (Chua et 
al., 1994). Such complexes may induce biological functions in cells which do not 
express the complete receptor molecule, although it remains to be determined whether 
IL-12 signalling may occur in this manner in primitive stem cells. There is, however, 
some evidence for direct IL-12-mediated enhancement of the proliferation of highly 
primitive Lin- Sca-1+ progenitors in murine bone marrow (Jacobsen et al., 1993).
The apparent selectivity of IL-12 inhibition of eosinophil development in the present 
study invites speculation as to the mechanism of its activity on hematopoietic progenitor 
cells. It is interesting to note that, in the case of the CSFs, occupation of one type of 
receptor by its ligand may down regulate the expression of other CSF receptors, 
perhaps via mRNA instability (reviewed in Metcalf, 1991). There are reports of 
several other examples in which cytokine receptors may be down regulated by non­
ligand factors which elicit similar physiological responses. These include down 
regulation of IL-2 receptors by EL-4 in murine T and B cell lines (Femandez-Botran et
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al., 1989), IL-6 receptor down regulation by leukemia inhibitory factor in mouse 
leukemia cells (Yamaguchi et al., 1992) and M-CSF receptor down regulation by DL-3 
in mouse bone marrow cells (Nicola, 1987). It is tempting to speculate that IL-12 
might, in a similar way, down regulate the expression of receptors critical for 
eosinophil development on bone marrow progenitors. A likely candidate, in this 
respect, would be EL-5, the most potent differentiation factor for cells of the eosinophil 
lineage. Expression of the high affinity receptor for IL-5 (IL-5Ra) is highly restricted, 
and, in humans, IL-5Ra gene transcription and mRNA metabolism may be regulated 
by mechanisms which are distinct even from those used for the closely-related EL-3Ra 
and GM -CSFRa (Wang et al., 1998). Future studies in the laboratory are directed 
towards an examination of the effects of IL-12 on IL-5 receptor expression in 
hematopoietic cells at different stages of development.
In conclusion, the results presented in this Chapter have shown that IL-12 mediates a 
selective suppression of eosinophilopoiesis. These findings represent a novel function 
of IL-12 and provide a rational basis for the development of strategies for the 
prevention and/or treatment of atopic disease.
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Table 4.1. Colony formation in the presence of IL-3
cells/ml
IL-3 concentration
5 U/ml 50 U/ml 500 U/ml 1000 U/ml
2x  104 2.1 ±0.2 3.0 ±0.4 8.2 ± 2 10.2 ±3.2
105 4.1 ± 1.2 8.1 ±2.4 15.1 ±3.4 18.1 ± 1.7
4 x 105 5.1 ±2.1 10.0 ± 1.9 33.1 ±4.8 38.0 ±5.2
106 6.0 ± 1.8 16.2 ±2.6 38.3 ±4.5 39.2 ±6.8
Bone marrow progenitor cells were cultured in the presence of different
concentrations of IL-3 as described in Section 4.2.4. Cells were stained with 
May-Grunwald-Giemsa solution for differential counting. Data represent the 
mean ± SEM for 6-10 cultures per experiment and are representative of 2 
experiments.
Figure 4.1. The appearance of eosinophil colonies
Eosinophil colonies formed 7 days after the establishment of bone marrow 
progenitor cell colony formation assays as described in Section 4.2.4. (A), a 
typical eosinophil colony (> 90% of cells in the colony are eosinophils, x 
400). (B). a single eosinophil from a colony (note red granules, x 1000).

Table 4.2. Eosinophil colony formation in the presence of IL-3 and IL-5 
in three strains of mice
strain total colonies % of colonies containing eosinophils
C57BL/6 50.6 ±2.5 11.2 ± 1.4
129/Sv 40.4 ±1.2 4.0 ±0.7
BALB/c 74.3 ±6.3 A 8 ± i .3
Bone marrow progenitor cells were cultured in the presence of IL-3 (500 U/ml) 
and IL-5 (250 U/ml) as described in Section 4.2.4. Cells were stained with 
May-Grunwald-Giemsa solution for differential counting. Data represent the 
mean ± SEM for 6-10 cultures per experiment and are representative of 2 
experiments.
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Figure 4.2 Dose-dependent effects of IL-12 on suppression of eosinophil 
development
Bone marrow progenitor cells were cultured in the presence of IL-3, IL-5 and 
different concentrations of IL-12 as described in Section 4.2.4. Cells were 
stained with May-Grunwald-Giemsa solution for differential counting. Data 
represent the mean + SEM of 6-10 cultures per experiment and are 
representative of 2 experiments. *p<0.05, **p<0.01 compared to cultures 
without IL-12.
Table 4.3. IL-12 suppresses eosinophil colony formation
IL-3 + IL-5 IL-3 + IL-5 + IL-12
total numbers of colonies 50.6 ±2.5 54.2 ±2.4
numbers of colonies containing 5.7 ±0.9 0.6 ± 0.2*
eosinophils
Bone marrow progenitor cells were cultured in the presence of IL-3 and IL-5, 
with or without IL-12 (7 ng/ml), as described in Section 4.2.4. Cells were 
stained with May-Grunwald-Giemsa solution for differential counting. Data 
represent the mean ± SEM for 6-10 cultures per experiment and are 
representative of 2 experiments. *p<0.01 compared to cultures without IL-12.
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Figure 4.3 Selective suppression of eosinophil colony formation by IL-12 in 
vitro
Bone marrow progenitor cells were cultured in the presence of IL-3 and IL-5 
with or without IL-12 (7 ng/ml) as described in Section 4.2.4. Cells were stained 
with May-Grunwald-Giemsa solution for differential counting. Data represent 
the mean + SEM for 6-10 cultures per experiment and are representative of 2 
experiments. *p<0.01 compared to eosinophil colonies in cultures without IL-12.
Table 4.4. Direct suppression of eosinophil development by IL-12
strain % of colonies containing eosinophils
wild type (129/Sv) + IL-3, IL-5 4.0 ±0.8
wild type (129/Sv)+ IL-3, IL-5, IL-12 0.7 ±0.7**
IFNyR-/- + IL-3, IL-5 3.1 ±0.7
IFNyR-/- + IL-3, IL-5, IL-12 1.1 ±0.2*
IFNocßR-/- + IL-3, IL-5 5.2 ±0.6
IFNaßR-/- + IL-3, IL-5, IL-12 3.1 ±0.2*
Bone marrow progenitor cells were collected from IFNyR-/- and IFNaßR-/- 
mice and their wild-type controls and cultured as described in Section 4.2.4. IL- 
3 (500 U/ml), IL-5 (250 U/ml) and IL-12 (7 ng/ml) were added to the cultures 
as indicated. Cells were stained with May-Grunwald-Giemsa solution for 
differential counting. Data represent the mean + SEM for 6-10 cultures per 
experiment and are representative of 2 experiments. *p<0.05 and ** p< 0.005 
compared to cultures without IL-12.
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Figure 4.5. In vivo effects of vector-directed IL-12 on eosinophil 
hematopoiesis
C57BL/6 mice were immunized i.n. with VV at 1 or 2 weeks before sacrifice 
and bone marrow cells were cultured in the presence of IL-3 and IL-5 as 
described in Section 4.2.4 followed by staining with May-Grunwald-Giemsa 
solution. Results represent the mean + SEM for groups of 4 mice and are 
representative of 2 experiments. *p<0.05 compared to mice immunized with 
VV-HA-X.
Table 4.5. Mice protected from allergic airways disease following IL-12 
gene delivery do not develop eosinophil colonies in bone marrow cell 
cultures
VV-HA-X VV-HA-IL-12
total colonies 41.2 ± 2.1 25.0 ± 1.3
colonies containing eosinophils 1.9 ±0.3 <1
percentage of colonies
containing eosinophils 4.8 ±0.8 <1
C57BL/6 mice were sensitized, immunized i.n. with VV and challenged with 
aeroallergen as described in Section 4.2.3. Bone marrow progenitor cells were 
collected 24 hours after the last challenge and cultured in the presence of IL-3 
and IL-5 as described in Section 4.2.4, followed by staining with May- 
Grunwald-Giemsa solution. Data represent the mean ± SEM for 6-10 cultures 
per experiment and are representative of 2 experiments.
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Figure 4.6 Selective suppression of eosinophil colony formation by IL-12 in 
mice sensitized and challenged with allergen
C57BL/6 mice were sensitized, immunized with VV and challenged with 
aeroallergen as described in Section 4.2.3. Bone marrow progenitor cells were
collected 24 hours after the final challenge and cultured in the presence of IL-3 
and IL-5 (but without IL-12) as described in Section 4.2.4, followed by staining 
with May-Grunwald-Giemsa solution. Data represent the mean + SEM for 6-10 
cultures per experiment and are representative of 2 experiments. *p<0.01 
compared to eosinophil colonies in mice immunized with VV-HA-X.
Table 4.6. IL-12 mediates direct suppression of eosinophil development 
in allergen-treated mice
strain total colonies % of colonies containing 
eosinophils
wild type 80.4 ±6.7 9.3 ±0.9
wild type + VV-HA-X 91.5 ± 10.6 10.7 ±2.6
wild type + VV-HA-IL-12 34.3 ±4.6* 1.35 ±0.6*
IFNyR-/- 107 ±7.2 12.7 ±0.6
IFNyR-/- + VV-HA-X 99.3 ±7.8 14.5 ±0.9
IFNyR-/- + VV-HA-IL-12 106.0 ±5.9 4.9 ±0.7**
IFNyR-/- mice and wild-type controls (129/Sv) were sensitized, immunized with 
VV and challenged with aeroallergen as described in Section 4.2.3. Bone 
marrow progenitor cells were collected 24 hours after the final challenge and 
cultured in the presence of IL-3 and IL-5 as described in Section 4.2.4, followed 
by staining with May-Grunwald-Giemsa solution. Data represent the mean ± 
SEM for 6-10 cultures per experiment and are representative of 2 experiments. 
*p<0.01, ** p< 0.005 compared to mice treated with VV-HA-X.
Chapter 5
Inhibition of allergic airways inflammation 
mice lacking nitric oxide synthase 2
5.1. Introduction
Nitric oxide (NO) is involved in the regulation of many physiological processes 
(Moncada et al., 1991; Nathan and Xie, 1994). It is sythesized from L-arginine by the 
enzyme NO synthase (NOS), which exists either in constitutive or inducible forms 
(Gaston et al, 1993). Constitutive isoforms, following their activation by increased 
levels of intracellular calcium ions, appear to form picomolar amounts of locally acting 
NO which may act as a signalling molecule in a number of processes (Gaston et al., 
1993), including neural responses and vasodilation (Kuo et al., 1992). Inducible NOS 
(now termed NOS2), which is not dependent on elevated calcium ion concentrations, is 
induced in a wide variety of cell types by cytokines, including IL-lb, TNFa and IFNy, 
or microbial products such as lipopolysaccharides (Xie et al., 1992). in which it 
catalyses the production of much higher levels of NO mediating widespread 
antimicrobial effects (Nathan and Xie, 1994). Normally, resting cells do not express 
NOS2 unless triggered by appropriate stimuli (Dugas et al., 1995), however cells such 
as macrophages, epithelial cells, vascular smooth muscle, endothelial cells, T cells and 
eosinophils have the potential to express NOS2 when stimulated in this manner 
(Moncada and Higgs, 1995; Nussler and Billiar, 1993; Del Pozo et al., 1997).
There is increasing evidence that NO also plays a role in the regulation of airways 
function in both health and disease. As in other tissues, both constitutive and inducible 
isoforms of NOS have been identified in lungs, with the latter implicated mainly in 
defence against infection and during airways inflammation (Barnes, 1995). NO is 
produced by a variety of cell types in the respiratory tract (Kobzik et al., 1993; Tracey 
et al., 1994). It has been reported that asthmatic patients have increased expression of 
NOS2 in epithelial cells lining their airways (Hamid et al., 1993; Robbins et al., 1994) 
and elevated levels of exhaled NO (Kharitonov et a l, 1994), whilst allergen-induced 
airways obstruction in a guinea pig model of allergic airways disease was also
associated with high levels of exhaled NO (Persson and Gustafsson, 1993). In 
addition, chemical inhibition of NO activity has recently been shown to suppress 
pulmonary eosinophilic inflammation in mice, although this was apparently not due to 
inhibition of NOS2 function (Feder et ai, 1997).
Asthma is characterized by inflammation, airways hyperreactivity and reversible 
airways obstruction (Bochner et al., 1994) and it is likely that NO influences these 
pathophysiological events. Pulmonary inflammation is thought to play a critical role in 
the pathogenesis of asthma (Bochner et al., 1994), with strong correlations between 
disease, the local expression of TH2-type cytokines (including EL-4 and EL-5) by lung 
T cells and the presence of inflammatory cells, particularly eosinophils, in blood and 
airways (Robinson et al., 1992; Leung et al, 1995). It has recently been proposed that 
NO from airways epithelial cells, and possibly macrophages and TH1 cells, promotes 
asthmatic inflammation via down regulation of TH1 cell-derived IFNy with 
concomitant up regulation of TH2 cell numbers and resultant increased local expression 
of IL-4 and IL-5 (Barnes and Liew, 1995). In addition, NO is a bronchodilator 
(Dupuy et al., 1992) and a potent bronchial vasodilator (Kuo et al., 1992), and may 
also mediate cytotoxic effects on airways epithelia (Heiss et al., 1994). In this 
Chapter, we have used mice rendered deficient for NOS2 production in a model of 
allergic airways disease in order to more clearly define the activity of this molecule in 
disease pathogenesis.
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5.2. Materials and Methods
5.2.1 Mice
The NOS2-deficient mice and wild-type controls used in these studies were derived as 
described elsewhere (MacMicking et al., 1995). Cells from the NOS2 mutants were 
deficient for NO production in response to inductive regimens which included LPS 
and/or interferons. The mice were bred in the Animal Breeding Establishment of the 
Australian National University, and were treated according to ANU Animal Welfare 
guidelines and age- and sex-matched animals were used in these studies.
5.2.2. Sensitization and aeroallergen treatment of mice
A murine model of allergic airways disease was established as described in Chapter 3 
(Foster et al., 1996). In this model, exposure to aeroallergen induces airways 
inflammation and AHR which are closely associated with eosinophilia and localized 
expression of TH2-type cytokines, particularly EL-4 and IL-5. In some experiments, 
groups of mice were given an i.p. dose of 0.8mg/mouse of either mAb against murine 
EFNy (R4-6A2, ATCC, Rockville, MD) or mAb GL113 (a kind gift of Dr. J. Abrams, 
DNAX Research Institute of Molecular and Cellular Biology, Palo Alto, CA) as a rat 
IgGl isotype control one day prior to each course of aeroallergen treatment (ie. on days 
23, 25, 27 and 29). Sections were cut from paraffin-embedded lung tissues and 
stained with May-Grunwald-Giemsa solution for histological studies.
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5.2.3. Assessment of bone marrow, blood and lung inflammatory cell 
populations
Twenty-four hours after the final treatment with aeroallergen on the day of sacrifice 
(day 31), bronchoalveolar lavage was performed by tracheal cannulation and instillation 
of 1 ml of normal saline into the lungs. Each animal was lavaged twice, with 
approximately 0.8 ml of fluid being recovered per wash. BALF was centrifuged (1500 
x G at 4° C for 5 minutes), total cell counts were made using trypan blue and 106 cells 
were taken for cytospin (Shandon Scientific Ltd., Cheshire, UK). Blood smears were 
made from samples drawn from the tail vein immediately prior to each course of 
aeroallergen treatment and on the day of sacrifice. Numbers of eosinophilic cells in 
bone marrow were assessed using aspirates collected during the course of aeroallergen 
treatment. Cytospin smears of cells from BALF, blood and bone marrow were stained 
with May-Grunwald-Giemsa solution and 200 leukocytes were counted on each slide.
5.2.4. Measurement of eosinophil hematopoiesis in bone marrow
Twenty-four hours after the final treatment with aeroallergen, bone marrow cells were 
collected, colony-forming assays established and numbers of colonies containing 
eosinophils scored all as described in Section 4.2.4.
5.2.5. Measurement of airways hyperreactivity
Mice were anesthetized with a mixture of ketamine (Troy Laboratories, Smithfield, 
Australia) at 60mg/kg body mass and Rompun (Bayer Australia, Pymble, Australia) at 
8mg/kg given by i.p. injection and their tracheae were cannulated and connected to a 
bronchospasm transducer (Ugo Basil 7020) coupled to a Lab Mac/8 computer analysis 
station (Adlnstruments, Sydney, Australia). Analyses were performed during
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cumulative i.v. administration of the spasmogen b-methacholine as detailed elsewhere 
(Foster et al., 1996). The increase in respiratory overflow volume provoked by b- 
methacholine is represented as a percentage of maximal overflow volume (100%) 
obtained by totally occluding the tracheal cannula.
5.2.6. Determination of OVA-specific immunoglobulins
Refer to Section 2.2.11.
5.2.7. Preparation of CD4+ T cell populations from lung and spleen
Refer to Section 2.2.8.
5.2.8. Determination of cytokine production
Cytokine levels were assayed in BALF taken on the day of sacrifice and in supernatants 
overlying cultures of CD4+ T cells from lung and spleen. Purified CD4+ T cell 
populations were cultured at 5xl05 cells/well in complete medium on anti-CD3 mAb 
(2C11, 50 ug/ml)-coated 96-well microtiter plates (Nunc, Roskilde, Denmark) at 37°C 
for 72 h. Supernatants were then harvested for determination of cytokine production 
by standard ELISA (see Section 2.2.10). The Ab pairs used for cytokine detection 
were as follows: IL-4, 11B11 (ATCC) and BVD6-24G2 (PharMingen); EL-5, TRFK-5 
(2 mg/ml for coating; a gift from S. Chin, JCSMR, ANU) and TRFK-4 (PharMingen); 
EFNy, R4-6A2 (ATCC) and a polyclonal rabbit anti-mouse EFNy antibody made in our 
laboratory; TNF-a, TN3-19.12 (a kind gift of Dr. R. Schreiber, W ashington 
University, St. Louis, MO) and a polyclonal rabbit anti-mouse TNF antibody (a kind 
gift of Mrs. S. Fordham, John Curtin School of Medical Research); EL-12, C17.8 and 
C15.6 (kind gifts of Dr. G. Trinchieri, Wistar Institute, Philadelphia, PA).
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5.2.9. Measurement of reactive nitrogen intermediates (RNI)
Sera were collected 24 h after the final treatment with aeroallergen and tested for the 
presence of RNI (nitrites or nitrates) according to established methods (Rockett et al., 
1994). Briefly, nitrite was measured by addition of 100jr\ of Griess reagent to 30yjd of 
test sample. Protein was removed by the addition of 100ml of trichloroacetic acid 
followed by centrifugation and the optical density of each sample was read at 540 nm 
with a reference at 650 nm using a microplate reader. For nitrate measurements, the 
nitrate was first converted to nitrite by incubation with nitrate reductase and NADPH 
(Boehringer Mannheim, Mannheim, Germany) for 20 min. Results were quantified by 
reading against appropriate standard curves.
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5.3 Results
5.3.1. RNI are detected at background levels in allergic NOS2-/- mice
Levels of RNI were measured in sera to confirm that NOS2 gene-deficiency resulted in 
reduced levels of NO induced during the course of allergic inflammation. The 
concentrations of nitrates in sera from OVA-treated wild-type (NOS2+/+) mice were 
significantly greater than those from control (saline-treated) wild-type or NOS2- 
deficient mice (Figure 5.1). In contrast, RNI were detected in OVA-treated NOS 2- 
deficient mice only at backgound levels (Figure 5.1). These results indicate that 
increased production of NO is not induced during allergic lung inflammation in the 
mutant mice.
5.3.2. Allergic eosinophilia in peripheral blood and BALF and airways 
disease are down regulated in mice lacking NOS2.
Aerosol challenge of wild-type mice sensitized with OVA normally leads to widespread 
eosinophilic inflammation, primarily in the peribronchial and perivascular regions as 
we have previously reported (Foster et al., 1996). We therefore initially examined 
blood smears taken from aerosol-treated wild-type mice and found markedly elevated 
numbers of eosinophils in the bloodstream of those given OVA (Figure 5.2). A 
significant blood eosinophilia was first detected on day 28, after the second day of 
exposure to aeroallergen, with peak counts recorded on day 31, after the full course of 
treatment. Although blood eosinophil numbers had also increased in OVA-treated 
NOS2-/- mice by day 28, they remained relatively constant thereafter until sacrifice and 
were significantly lower than the rising counts recorded in wild-type mice after both the 
third (p<0.05) and fourth (p<0.01) aeroallergen treatments.
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In addition to blood eosinophil levels, differential counts of lung leukocyte populations 
were made in BALF samples taken after aeroalllergen treatment (Table 5.1). 
Eosinophils, whilst rarely detected in saline-treated wild-type or NOS2-/- mice, were 
the predominant leukocyte type in BALF from aeroaillergen-treated mice. However, 
their numbers in NOS2-/- mice were consistently less than half of those found in wild- 
type animals. Other leukocyte populations, particularly lymphocytes and macrophages, 
were present in BALF in much smaller numbers, all though these were significantly 
elevated in the NOS2 mutant mice. In the case of 1 ymphocytes, a 20-fold increase 
over saline-treated mutants was recorded compared to a 5-fold increase in the wild-type 
mice, indicating that these non-eosinophilic components of the allergic inflammatory 
response are somewhat enhanced in the NOS2-deficie)nt animals.
The degree of airways disease in NOS2-/- and wild-type mice was assessed following 
histological examination of lung tissues. A system of grading of several parameters 
was used, where 1 represented mild pathology and 5 represented the most severe 
disease. These parameters included the degree of leukocyte inflammation adjacent to 
the airways, particularly eosinophilic infiltration, the development of gross alterations 
in the structural integrity of the airway walls, microvascular leakage, mucosal edema 
and particulate exudation and mucous occlusion in the lumina of the airways. Based on 
this system, disease severity was invariably graded .at 5 in aeroallergen-treated wild- 
type mice but consistently only at either 2 or 3 in the NOS2 mutants.
5.3.3. Eosinophil development is not suppressed in NOS2-deficient 
mice
The development of eosinophils in the bone marrow was studied in NOS2-deficient 
mice in light of the marked decreases in numbers of these cells in their blood and 
airways following aeroallergen treatment. Analyses of bone marrow cells taken from
OVA-treated NOS2-/- and wild-type mice in colony-forming assays revealed no 
significant differences in the percentages of colonies containing eosinophils after 7 days 
in culture (Table 5.2). In addition, similar numbers of mature eosinophilic cells were 
found in the bone marrow of sensitized NOS2 mutants and wild-type mice during and 
after aerosol treatment with OVA (Table 5.3). These findings suggest that the 
reduction in circulatory and pulmonary eosinophil numbers observed in NOS2- 
deficient mice are due neither to suppression of eosinophil colony formation nor of 
eosinophil maturation in the bone marrow in response to aeroallergen challenge.
5.3.4. Airways hyperreactivity is not inhibited in mice lacking NOS2
In this disease model, airways eosinophilic inflammation following aeroallergen 
challenge is directly associated with AHR to the spasmogen, b-methacholine (Foster et 
a i ,  1996). The markedly decreased eosinophilic inflammation and airways disease 
observed in sensitized NOS2-deficient mice treated with aerosolized OVA prompted a 
study of the development of AHR in these animals. As shown in Figure 5.3, AHR in 
allergic wild-type mice increased with dosage of ß-methacholine to a maximum of 60% 
airways occlusion over the baseline levels seen in controls. Similar high levels of AHR 
were found in OVA-treated NOS2 mutants, although these were recorded over baseline 
levels which were markedly higher than those found in the wild-type mice. These 
elevated basal readings may reflect removal of the known bronchodilatory influence of 
inducible NO in the mutants. Nevertheless, it appeared that the diminished airways 
allergic inflammatory infiltrate following OVA treatment of these mice was still 
sufficient to provoke substantial AHR.
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5.3.5. Elevated IFNy production does not greatly modify the TH2 
cytokine-driven immune response in allergic NOS2-/- mice
Next, cytokine profiles of CD4+ T cells and specific antibody responses were 
compared in aeroallergen-treated NOS2-/- and wild-type mice. Given the correlation 
between allergic airways disease and expression of type 2 cytokines by lung T cells, 
together with the proposition that local NO production promotes airways inflammation 
through down regulation of T cell-derived IFNy, it was of interest to determine whether 
the marked decrease in blood and airways eosinophilia seen in the aeroallergen-treated 
NOS2 mutants might reflect a shift in the characteristics of the immune response in 
these animals. As shown in Figure 5.4, activated lung and spleen CD4+ T cells from 
control, non-allergic NOS2-/- and wild-type mice secreted similar levels of IFNy, 
however neither IL-4 nor IL-5 was detected. In contrast, whilst CD4+ T cells from 
OVA-treated wild-type animals produced significantly less IFNy than those from 
saline-treated controls, there was pronounced expression of both IL-4 and IL-5, 
particularly among cells from the lungs. Similar patterns of TH2 cytokine expression 
were found in cells from OVA-treated NOS2 mutants, however both lung and splenic T 
cells from these animals also secreted very high levels of IFNy. In addition, EL-12 and 
TNFa were detected at similar levels only marginally above background in BALF from 
both wild-type and mutant mice treated with OVA (data not shown).
The majority of the specific antibody response in mice sensitized with OVA (measured 
on day 24) and treated with aeroallergen (day 31) was of the IgGl subclass and titers 
recorded in NOS2-/- and wild-type animals did not differ significantly at either time 
point (Figure 5.5). Whilst significantly lower levels of OVA-specific IgE were found 
in sensitized NOS2 mutants compared to wild-type mice, titers were also similar after 
aerosolization. However, NOS2-deficiency increased levels of specific IgG2a, albeit at 
comparatively low titers, particularly after OVA aerosol challenge.
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Together, these observations suggest that NOS2-deficiency leads to marked increases 
in both local and systemic T cell-derived IFNy production and in levels of serum IgG2a 
against the allergen. However, neither the characteristic TH2 cytokine-driven specific 
IgGl and IgE responses nor the production of IL-4 and IL-5 by lung T cells were 
modified in allergic NOS2-/- mice.
5.3.6. Depletion of IFNy reverses inhibition of airways inflammation in 
NOS2-/-mice
These pronounced increases in IFNy production might account for the decreased 
eosinophilic inflammation and, therefore, airways disease, seen in aeroallergen-treated 
NOS2-deficient mice. To test this hypothesis, NOS2 mutants were treated with mAbs 
against IFNy during their course of treatment with OVA. As shown in Figure 5.6, the 
inhibition of blood eosinophilia from day 28 (after the second treatment with 
aerosolized OVA) recorded in NOS2-/- mice was abolished in mice given mAb against 
IFNy. Similarly, the marked reduction in eosinophil numbers in BALF seen in allergic 
mutants was reversed in mice depleted of this factor (Figure 5.7). In addition, the 
symptoms of severe disease as described above in wild-type mice were evident in the 
mAb-treated mutants (data not shown). Thus, it appears that IFNy was responsible for 
the suppression of eosinophilic inflammation and allergic pathology in NOS2-/- mice 
despite their capacity for continued production of IL-5.
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5.4. Discussion
Nitric oxide, which has been implicated in many physiological processes (Moncada et 
al., 1991; Nathan and Xie, 1994), may play an important role in airways function both 
in health and disease (Barnes, 1995). During asthma, the expression of inducible nitric 
oxide synthase (NOS2) by cells of the respiratory tract, particularly epithelial cells, 
increases markedly, while levels of exhaled NO are also elevated (Barnes, 1995; 
Hamid et al., 1993; Robbins et al., 1994; Kharitonov et al., 1994). In this Chapter, 
mice rendered deficient for the production of NOS2 were used in a model of allergic 
airways disease. The results clearly showed that the manifestations of disease, 
including infiltration of leukocytes, particularly eosinophils, around the airways, gross 
alterations in the structural integrity of the airway walls, microvascular leakage, 
mucosal edema and particulate exudation and mucous occlusion of the airways lumina 
were markedly less severe in NOS2-/- mice than in wild-type animals. NOS2- 
deficiency resulted in a 55-60% reduction in both circulatory and pulmonary eosinophil 
numbers following edler gen treatment although no suppression of eosinophil precursor 
development, nor of maturation in the bone marrow following aeroallergen treatment, 
was apparent. Although representing a relatively small percentage of the inflammatory 
cell population of the lung, both macrophages and lymphocytes were recorded in 
significantly higher numbers in the mutant mice. These changes were accompanied by 
pronounced increases in the capacity of cultured T cells to secrete IFNy upon 
restimulation in vitro, but not by any obvious changes in local production of IL-4, IL- 
5, IL-12 or TNFa, nor by major changes in the largely IgGl and IgE OVA-specific 
serum immunoglobulin profiles in the mutants. The markedly enhanced production of 
IFNy in the NOS2-/- mice was apparently responsible for the suppression of both 
eosinophilia and disease, as in vivo depletion of this factor restored allergic 
inflammation and pathology in these animals.
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These findings are in partial agreement with those of Feder and colleagues, who 
recently showed that chemical inhibition of NO activity suppressed pulmonary 
eosinophilic inflammation in a murine model of allergic airways disease (Feder et a l,
1997) . However, these authors attributed the reduction in inflammation to NO 
catalysed by enzymes other than NOS2 and speculated that localized NO production 
enhances extravasation of circulating eosinophils into the lung. In contrast, the present 
study, using mice with a specific mutation, has clearly shown that NOS2-deficiency 
leads to a IFNy-mediated suppression of both pulmonary and circulating eosinophilia 
and allergic airways disease following aeroallergen challenge.
The severity of clinical asthma appears to correlate with the degree of airways 
inflammation and, therefore, the level of local TH2 cell activity (Azzawi et a l ,  1990). 
In murine models of allergic airways inflammation, aeroallergen challenge of sensitized 
mice normally leads to widespread eosinophilia which correlates directly with disease 
(Foster et al., 1996; Nakajima et al., 1992; Brusselle et a l,  1994; Gavett et a l ,  1995). 
In addition, eosinophilia is, in turn, critically dependent on IL-5 in vivo (Foster et a l ,  
1996) and TH1 cytokine-mediated suppression of eosinophilia and disease is 
accompanied by a marked down regulation of local IL-5 production (Hogan et a l ,
1998) . It was therefore somewhat surprising to find that T cell isolates from both the 
lungs and spleens of aeroallergen-treated NOS2-/- mutants retained the capacity to 
secrete high levels of both IL-4 and IL-5, as in wild-type animals, in the face of their 
ability to produce large amounts of IFNy upon restimulation in vitro, particularly given 
the established role of EFNy as a potent suppressor of TH2 cell activity (Hogan et a l ,  
1998; Gajewski and Fitch, 1988; Wang et a l ,  1994). It is possible that the 
suppressive effects of IFNy may be countered by the generation of strong TH2 
responses with IL-4 and EL-5 secretion, such as in the model used in these studies, and 
that high local levels of IL-4 promote TH2 cell development despite significant local 
IFNy production. In this context, studies from this laboratory, and those of other
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investigators, have shown that local virus infections which normally induce IFNy 
production did not suppress eosinophilic airways inflammation in similar models of 
allergic airways disease (Hogan et a l, 1998; Schwarze et al., 1997). Other organisms, 
however, such as Bacille Calmette-Guerin, have been reported to inhibit TH2-driven 
responses through their capacity to stimulate IFNy production (Erb et al., 1998).
The enhanced T cell production of IFNy observed in the allergen-treated NOS2 mutants 
is in accordance with the finding that treatment of mice with inhibitors of NO 
production leads to marked increases in IFNy levels during Staphylococcal infection 
(Florquin et al., 1994). Similar enhancement of IFNy production has recently been 
reported in studies using NOS2-/- mutants infected with the protozoan, Leishmania 
major (Wei et al., 1995; Diefenbach et al., 1998), Mycobacterium tuberculosis 
(MacMicking et a l, 1997) or viruses, including ectromelia virus and influenza virus, 
contributing to rapid viral clearance in the latter (Karupiah et al., 1998a and 1998b). 
How NO influences IFNy gene expression is unclear at this stage. However, recent 
evidence indicates that NO may regulate the activity of NF-kB transcription factors and 
protein tyrosine kinases belonging to the src kinase, mitogen-activated protein (MAP) 
kinase and Janus kinase (JAK) families (Lander et al., 1993; Kong et a l, 1996; Lander 
et a l, 1996; Duhe et a l, 1998), the latter with major implications for IFNy signaling 
(Schindler and Darnell, 1995). It has also been suggested that NO may down regulate 
THl-type immune responses and, in this way, diminish IFNy production (Wei et a l, 
1995). The delineation of mechanisms which regulate the development of different T 
cell subsets is of obvious importance for increased understanding of the pathogenesis 
of a number of diseases including allergy. In this regard, recent in vitro studies have 
indicated that NO may act differentially on activated murine and human T helper cell 
populations by inhibiting TH1 cytokine production but promoting the expression of 
TH2-type cytokines (Taylor-Robinson et a l, 1994; Benbemou et a l, 1997), although 
these data remain controversial (Bauer et a l, 1997). Nevertheless, it has been
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proposed that inducible NO, produced in asthmatic airways by epithelial cells, 
macrophages, and possibly THl-type cells, has an inhibitory effect on THl-type cells 
and their expression of IFNy, facilitating the activation of TH2-type cells and the 
development of allergic inflammation (Barnes and Liew, 1995). The greatly increased 
local expression of IFNy recorded in allergen-treated NOS2-/- mutants in the present 
study lends partial support to this hypothesis. However, it was clear from those data 
that the IFNy-mediated protection from airways inflammation in these animals was not 
due to suppression of T cell production of IL-4 and IL-5 by this factor.
These findings in NOS2-/- mutant mice indicate that inhibitors of NOS2 may be 
effective in suppressing allergic inflammation, particularly in the airways. They also 
suggest that the effects of such compounds would largely be mediated through IFNy 
activity in the face of continued production of TH2-type cytokines. These data suggest 
several potential mechanisms whereby allergic inflammation may be suppressed. The 
inhibition of eosinophilia recorded not only in BALF but also in the circulation of 
aeroallergen-treated NOS2 mutants, and its reversal by mAbs directed against IFNy, 
raised the possibility that this factor may down regulate inflammatory cell 
hematopoiesis, either directly or via intermediate molecules, possibly including NOS2 
itself. However, our studies using bone marrow cells indicate that eosinophil colony 
formation and maturation in the bone marrow following aeroallergen challenge is 
unaffected by NOS2 deficiency and suggest that the inhibitory effects of IFNy may 
occur at a later stage in eosinophilic inflammation, such as the subsequent maturation of 
these cells in the circulation. In addition, IFNy may directly influence the activity of 
mature inflammatory cells and, in this respect, has been shown to inhibit degranulation 
and release of inflammatory mediators from both eosinophils (Fujisawa et al., 1990) 
and mast cells (Coleman et al., 1991). In the latter case at least, this suppression may 
be mediated by IFNy-induced NO (Eastmond et a l, 1997). Selective inhibition of NO 
production might also protect against allergic pulmonary inflammation independently of
125
increased IFNy activity, our present data notwithstanding. It has recently been shown 
that NO specifically disrupts Fas receptor-mediated apoptosis of eosinophils 
(Hebestreit et a l ,  1998), whilst its vasodilatory properties (Kuo et a l ,  1992) and 
chemotactic activity for a variety of cell types, including eosinophils (Robbins et al., 
1995), may enhance their recruitment into allergic airways (Feder et a l ,  1997).
The lack of obvious differences between AHR measured in aeroallergen-treated wild- 
type and NOS2-/- mice, despite suppressed pulmonary eosinophilic inflammation in the 
latter, probably reflects the continued production of levels of eosinophil inflammatory 
mediators sufficient to provoke hyperreactivity. Previous work in this model has 
clearly demonstrated a close association between local eosinophilic inflammation and 
AHR (Foster et a l ,  1996). It should be noted, however, that the elevated A,HR 
readings in OVA-challenged mice in the present study were recorded over baseline 
levels in control (saline-treated) animals which were significantly greater in the NOS2 
mutants. Deficient NO production in these mice may have been responsible for this 
spontaneous AHR, given the reported, albeit variable, bronchodilatory activity of this 
molecule (Dupuy et a l ,  1992).
In conclusion, the results presented in this Chapter have shown that eosinophilic 
inflammation and related manifestations of allergic airways disease are markedly 
suppressed in mice deficient for NOS2 production, apparently due to pronounced IFNy 
expression in these animals. These data support the hypothesis that NO promotes 
allergic inflammation and indicate that specific inhibitors of NOS2 may be worthwhile 
components of therapeutic strategies against allergic diseases, including asthma.
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□  NOS2 - /-sal
□  NOS2 +/+ sal
H  NOS2 -/- OVA 
■  NOS2+/+OVA
Nitrate production in serum
Figure 5.1. Nitrate production in serum
Levels of reactive nitrogen intermediates was measured (as described in Section 5.2.9) 
in sera taken on day 31 from NOS2-/- and wild-type mice treated with OVA or saline 
(as described in Section 5.2.2). Data represent the mean ± SEM for groups of 5 mice 
and are representative of 2 experiments in each case. *P<0.01 compared with OVA- 
treated NOS2-/- mice.
15-,
□  NOS2 - /-sal
□  NOS2 +/+ sal 
H  NOS2-/-OVA 
■  NOS2+/+OVA
days post-sensitization
Figure 5. 2. Eosinophil numbers in peripheral blood
NOS2-/- and wild-type mice were sensitized and treated with aeroallergen as 
described in Section 5.2.2. Blood smears were prepared as described in Section 
5.2.3. Data represent the mean ± SEM for groups of 5 mice and are representative of 
3 such experiments. *P<0.05 and **P<0.01 compared with OVA-treated wild-type 
mice at the same time point.
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Table 5.3. Eosinophilic cells in bone marrow smears
eosinophilic cells (x 106)
day NOS2+/+ NOS2-/-
28 2.8 ±0.3 3.3 ±0.7
31 4.0 ± 1.5 5.8 ±0.6
Mice were sensitized and treated with aeroallergen as described in Section 5.2.2 
Bone marrow cell aspirates were collected on days 28 and 31 and cytospin 
smears stained with May-Grunwald-Giemsa solution. 200 cells per smear were 
scored by light microscopy using morphological criteria. Results represent mean 
counts ± SEM per mouse (n=3) and are representative of 2 experiments.
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Figure 5.3. Airways hyperreactivity to ß-methacholine in NOS2-/- and 
wild-type mice
Mice were sensitized and treated with aeroallergen as described in Section 
5.2.2. AHR was measured as described in Section 5.2.5 and data are shown 
for the dose of ß-methacoline (400 ug/kg) that induced a maximal response in 
wild-type mice treated with OVA. Data represent the mean + SEM for 
groups of 5 mice and are representative of 2 such experiments. *P<0.01 
compared with saline-treated wild-type mice, **P<0.05 compared with 
saline-treated NOS2-/- mice, +P<0.05 compared with saline-treated wild- 
type mice, each at the corresponding dose of ß-methacholine.
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Chapter 6
General Discussion
Several aspects of the regulation of immune responses in allergic disease were 
investigated in this thesis. In Chapter 2, the effects of gene delivery of IL-12 on the 
development of allergic airways disease was examined. It was shown that DNA or 
fowlpoxvirus vector-mediated mucosal delivery of this factor could dramatically inhibit 
the development of eosinophilic airways inflammation, airways hyperreactivity and 
lung damage normally induced by challenge with allergen in sensitized animals. The 
protective effects of IL-12 delivered in this way correlated with the local production and 
systemic up regulation of IFNy and concomitant down regulation of EL-5 production. 
Interestingly, however, IL-4 expression was not affected by IL-12 delivery in this 
model, indicating the discordant regulation of these factors. Overall, these data provide 
an immunological basis for the development of novel strategies for the treatment of 
atopic diseases, including asthma.
The vectors used in these studies represent safe and persistent vehicles for the delivery 
of biologically important molecules in vivo. Indeed, both vectors are currently being 
used in prophylactic and therapeutic clinical trials against a range of diseases including 
influenza, cancer and HIV infection (Donnelly et al., 1997). At least one of these 
clinical trials, involving our research group, utilises FPV engineered to express an HIV 
antigenic protein along with human DFNy. Whilst it may be feasible to deliver IL-12 in 
this manner for the treatment of diseases such as asthma, other treatment modalities 
which stimulate endogenous production of this factor may represent an alternative 
therapeutic strategy. Indeed, recently, mucosal delivery of one such agent, BCG, has 
been shown to inhibit allergic lung disease in mice (Erb et al., 1998). The authors 
attributed the protective effects of this approach to the activity of EFNy stimulated by the 
infection. It is also conceivable, however, that high levels of IL-12 were produced by 
this potent macrophage activiting organism and contributed to the efficacy of this 
treatment.
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Although EL-12 is a key cytokine driving the development of TH1 cells, and, as shown 
in Chapter 2, may suppress TH2-driven immune responses, this factor also exhibits 
hematopoietic activity. In Chapter 4, a novel activity of IL-12 is reported, i.e. the 
selective inhibition of eosinophilopoiesis in bone marrow cells. Previous studies on 
the hematopoietic activity of IL-12 have demonstrated its ability to synergise with EL-3, 
EL-11 and steel factor in enhancing the proliferation of bone marrow progenitor cells in 
vitro. However, in vivo, IL-12 appears to exert a generalized inhibitory effect on 
hematopoiesis, probably through the induction of EFNy. The addition of IL-12 to bone 
marrow cultures, at concentrations previously shown in this laboratory to suppress 
allergic lung disease (Hogan et al., 1998), selectively inhibited the development of 
eosinophil colonies. The ability of EL-12 to inhibit eosinophilopoeisis was confirmed 
in vivo, using mice given rVV encoding EL-12. Although many activities of EL-12 are 
mediated through the activity of IFNy, inhibition of eosinophil development in this 
study appeared to occur largely independent of IFNs, a finding revealed through the 
use of EFNyR-/- and EFNaßR-/- GKO mice. At this stage, there is limited information 
as to the mechanism of IL-12 inhibition of eosinophil development. One possibility is 
that IL-12 may down regulate the expression of receptors critical for eosinophil 
development on progenitor cells, a likely candidate being the receptor for EL-5. In this 
respect, studies are currently underway to examine the EL-5 receptor profile of bone 
marrow cells treated with IL-12 using flow cytometry and RT-PCR. There are several 
reported precedents for CSFs and cytokines down regulating the receptor molecules of 
other factors with similar biological properties, perhaps through mechanisms involving 
mRNA stability as discussed in Chapter 4.
These results also indicate that the systemic production of regulatory factors during 
immune stimulation may influence the nature of precursor cell development in the bone 
marrow. This may represent an important mechanism to ensure that specific
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populations of effector cells are appropriately stimulated or, indeed, suppressed during 
the development of different classes of immune response.
Clearly, however, these results demonstrate the potential of IL-12 to modify the 
development of allergic airways disease, not only through the inhibition of TH2 
responses but also through the selective suppression of eosinophilopoiesis.
Early childhood is an important period in the development of allergic responses to 
environmental antigens. In Chapter 3, novel vaccination strategies were investigated to 
determine whether active intervention by neonatal immunisation could drive allergen- 
specific T cell selection towards TH l-type immunity, thereby preventing allergic 
disease in later life. A DNA vaccine encoding the allergen, OVA, was constructed and 
co-administered to neonates with DNA encoding IL-12. This vaccine markedly 
suppressed antibody production, particularly of the IgGl isotype, in C57BL/6 mice, 
but enhanced the levels of IgG2a, without suppressing IgGl production, in BALB/c 
mice. Cytokine profile assays showed that co-delivery of IL-12 augmented IFNy 
production by lung and spleen T cells whilst suppressing IL-5 production. Thus, the 
OVA/IL-12 vaccine enhanced TH1 cytokine secretion and resulting antibody 
production. When neonates immunized with this vaccine were sensitised and 
challenged with aeroallergen in adult life, a marked suppresion of airways 
inflammation, airways hyperreactivity and TH2-type OVA-specific antibody production 
was observed. Analysis of the cytokine secretion profiles of spleen and lung T cells 
indicated that IL-12 delivery had markedly up regulated IFNy production with a 
concomitant suppression of IL-5. In particular, eosinophilia was markedly inhibited, 
indicating the protective efficacy of this approach.
These experimental results thus demonstrate the potential of genetic vaccination to 
prevent atopic diseases, including asthma, and provide proof of concept that neonatal
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vaccination strategies that promote TH1 responses can protect against the development 
of allergic airways disease in adult life.
Finally, in Chapter 5, the involvement of nitric oxide in the pathogenic sequelae of 
allergic airways disease was investigated using mice rendered genetically deficient for 
NOS2 production. The results clearly showed that the pathological processes 
associated with allergic lung disease were markedly less severe in NOS2-/- mice than in 
wild-type animals. NOS2 deficiency resulted in greater than 50% reduction in levels of 
both circulatory and pulmonary eosinophilia following allergen treatment, however 
there was no apparent inhibition of eosinophil precursor development in the bone 
marrow. The pronounced inhibition of allergic airways disease in NOS2-/- mice was 
associated with dramatically increased production of IFNy compared to wild type 
animals, although T cell isolates from spleens and lungs of NOS2-/- mice retained the 
capacity to produce high levels of IL-4 and IL-5. Overall, these findings further 
implicate nitric oxide in the development of allergic pathology and suggest that specific 
inhibitors of NOS2 activity may represent a useful therapeutic strategy for allergic 
diseases, including asthma.
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